Version Date: May 18, 2016 Amendment Letter: T
PROTOCOL NUMBER: 09-C-0096
PROTOCOL TITLE: Pilot and Feasibility Study of Redu ced-Intensity Hematopoietic Stem 
Cell Transplant for Patients with GATA2 Mutations
Abbreviated Title: HSCT for GATA2 Mutation
Principal Investigator: Dennis D. Hickstein M.D.1 
Telephone:  301-594-1718
Email:  hicksted@mail.nih.gov
Lead Associate Investigator: Mark Parta, M.D.9
Telephone: 301-451-4955Email: mark.parta@nih.gov
Medical Advisory  Investigator: Juan Gea-Banacloche, M.D.1
Telephone: 301-675-9512Email: banacloj@mail.nih.gov
Associate Investigators:
Terry Fry, M.D.7Steve Holland, M.D.2
Ronald Gress, M.D.1#Brenna Hansen, R.N.10
Steven Pavletic, M.D.1#Constance Yuan, MD, PhD9
Daniel Fowler, M.D.1James Kochenderfer, M.D.1
#Charles Bolan, M.D.6#Jennifer Wilder, R.N.8
#Daniele Avila, C.R.N.P.1#Seth Steinberg, Ph.D. 4
#Fran Hakim, Ph.D.1#Cynthia Delbrook, R.N.10
#Bazetta Blacklock-Schuver, R.N.10#Thomas Hughes, Pharm.D.3
#Maryalice Stetler-Stevenson, MD, PhD9#Hanh Khuu, M.D.5
#David Stroncek, M.D.5#Jennifer Mann, C.R.N.P.1
#Sharon Adams, M.T.5#Stephanie Cotton, R.N.10
#Kristen Cole, R.N.10
1Experimental Transplantation and Immunology Branch, CCR, NCI, NIH
2Clinical Infectious Diseases, NIAID, NIH
3Pharmacy Department, Clinical Center, NIH
4Biostatistics and Data Management Section, Na tional Cancer Institute
5Department of Transfusion Me dicine, Clinical Center, NIH
6Hematology Branch, NHLBI, NIH 
7 Pediatric Oncology Branch, CCR, NCI, NIH
8 Leidos Biomedical Research, Inc. (NCI ETIB Contractor)
9 Laboratory of Pathology, CCR, NCI, NIH
10Office of Clinical Director, CCR, NCI, NIH
Referral contact: Dennis D. Hickstein M.D
#Denotes individuals who will not make any clinical protocol decisionsStudy coordinator: Kristen Cole, R.N
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Email: colekr@mail.nih.gov
Telephone: 301-827-0374
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Précis
Background
xMutations in GATA2 lead to an immunodefi ciency disease that transforms into 
myelodysplastic syndrome (MDS) and acute  myelogenous leukemia (AML).  This 
syndrome, previously known as MonoMAC, has 4 clinical features: 1) infections with 
Mycobacterium Avium Complex (MAC) and othe r opportunistic infections as a teenager 
or young adult, 2) a peripheral blood leukocyte flow cytometry profile with T-lymphocytes, but a severe deficiency of monocytes, B-lymphocytes, and Natural Killer (NK) cells, 3) the propensity to progress to MDS/AML, and 4) mutations in the gene GATA2.  In this pilot study we propose to evaluate the efficacy and safety of a reduced-intensity allogeneic hematopoi etic stem cell transplantatio n (HSCT) regimen for patients 
with mutations in GATA2.  We are particularly interested in determining whether allogeneic HSCT using this regimen reconstitutes normal hematopoiesis in patients with mutations in GATA2. 
Objectives
xPrimary Objective:
1) To determine efficacy, namely whether reduced-intensity allogeneic HSCT results in 
engraftment and restores normal hematopoiesis by da y +100 in patients with 
mutations in GATA2. 
2) To determine the safety of this HSCT regimen in patients with mutations in GATA2, 
including transplant related toxicity, the in cidence of acute and chronic graft-versus-
host disease, immune reconstitution, overall survival, and dis ease-free survival 
Eligibility
Eligibility includes patients 12-60 years old with mutations in GATA2 who have a life-
expectancy of > 3 months but < 24 months , and who have a 10/10 matched related donor, 
a 10/10 or 9/10 matched unrelated donor (HLA -A, -B, -C, DRB1, DQB1 by high resolution typing identified through the Na tional Marrow Donor Program),  a 4/6 (or 
greater HLA -A, -B, DRB1) matched unrelated umbilical cord donor, or a haploidentical 
donor.  Patients with GATA2 mutations who ar e 12-17 years of age are required to have 
MDS with chromosomal a bnormalities to be eligible for this protocol.
Design
xPatients with mutations in GATA2 with a 10/10 matched related or 10/10 matched 
unrelated donor, will receive a reduced-intensity pre-transplant conditioning regimen 
consisting of fludarabine 30 mg/m
2/day on days -4, -3, and -2, 200 cGy total body 
irradiation (TBI) on day -1, and HSCT on day 0.  Patients with mutations in GATA2 and 
a 9/10 matched unrelated donor will receiv e a reduced-intensity  pre-transplant 
conditioning regimen consisting of fludarabine 30 mg/m2/day on days -4, -3, and -2, 300 
cGy total body irradiation (TBI) on day -1, a nd HSCT on day 0.  Patients with mutations 
in GATA2 with umbilical cord blood units wi ll receive a reduced-i ntensity conditioning 
regimen with cyclophosphamide 50 mg/kg on day -6, fludarabine 40 mg/m2on days -6 to 
-2, equine ATG 30 mg/kg IV on days -6, -5 and -4, 200 cGy TBI on day -1, and HSCT on day 0. Patients with a haploidentical donor w ill receive a reduced intensity-conditioning 
regimen with cyclophosphamide 14.5 mg/kg on days -6 and -5, fludarabine 30 mg/m
2 on 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
days -6 to -2, and 200 cGy TBI on day -1.  Donor bone marrow cells will be infused on 
day 0.
xPost-transplant immunosuppression for graft-vers us-host-disease prophylaxis will consist 
of sirolimus (Rapamycin) and tacrolimus until day +180, provided that there is no 
evidence of graft-versus-host disease.  Post-transplant immunosuppression for graft-
versus-host-disease prophylaxi s for recipients of haploidentical donors will consist of 
cyclophosphamide 50 mg/kg on days +3 and +4, along with sirolimus from day +5 to day 180, and tacrolimus from day +5 to day 180, providing that there is no GVHD. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
TABLE OF CONTENTS
Table of Contents.............................................................................................................. .............. 5  
1 INTRODUCTION .................................................................................................................. 8  
1.1 Primary Study Objectives................................................................................................. 8  
1.2 Background and Rationale ............................................................................................... 8  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT....................................................... 26  
2.1 Inclusion Criteria - Recipient ......................................................................................... 26  
2.2 Exclusion Criteria- Recipient......................................................................................... 27  
2.3 Inclusion Criteria- Matc hed Related Donor ................................................................... 27  
2.4 Inclusion Criteria- Matched Unrelated Donor ............................................................... 28  
2.5 Inclusion Criteria- Haploidentical Related Donor ......................................................... 28  
2.6 Exclusion Criteria- Matc hed Related Donor.................................................................. 28  
2.7 Exclusion Criteria- Matc hed Unrelated Donor .............................................................. 29  
2.8 Exclusion Criteria- Haploidentical donor ...................................................................... 29  
2.9 Inclusion Criteria- Umbilical Cord Blood Unit-HLA Typing and Dose ....................... 30  
2.10  Review of UCB Unit HLA Typing a nd Selection of the UCB Unit .......................... 30  
2.11  Recipient Research Eligibility Evaluation.................................................................. 31  
2.12  Matched Related Donor and Haploidentical Donor Research Eligibility Evaluation 31  
2.13  Unlicensed Cord Blood Units..................................................................................... 32  
2.14  Patient Registration..................................................................................................... 32  
3 STUDY IMPLEMENTATION ............................................................................................ 34  
3.1 Study Design .................................................................................................................. 3 4 
3.2 Drug Administration ...................................................................................................... 37  
3.3 Treatment Modifications................................................................................................ 42  
3.4 Pharmacokinetic Studies (Not Applicable).................................................................... 44  
3.5 Protocol Evaluation........................................................................................................ 44  
3.6 Concurrent Therapies ..................................................................................................... 46  
3.7 Surgical Guidelines (Not Applicable)............................................................................ 46  
3.8 Radiation Guidelines...................................................................................................... 46  
3.9 Off Treatment Criteria- Not Applicable......................................................................... 47  
3.10  Off Study Criteria ....................................................................................................... 47  
3.11  Post Study Evaluation (Follow-Up) ........................................................................... 47  
3.12  Immunologic Studies.................................................................................................. 48  
3.13  Restrictions for Blood Drawn for Research Samples:................................................ 48  
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
4 SUPPORTIVE CARE........................................................................................................... 49  
4.1 Infection Prophylaxis ..................................................................................................... 49  
4.2 Management of Engraftment Syndrome ........................................................................ 49  
4.3 Treatment of Graft-Ve rsus-Host Disease....................................................................... 49  
4.4 Menses Suppression and Contraception......................................................................... 49  
4.5 Blood Product Support................................................................................................... 50  
4.6 Nutritional Support......................................................................................................... 50  
4.7 Anti-emetic Usage.......................................................................................................... 50  
4.8 Intravenous Immune Globulin (IVIG) ........................................................................... 50  
4.9 Hepatic Function Support............................................................................................... 50  
4.10  Central Nervous System Prophylaxis......................................................................... 51  
5 DATA COLLECTION AND EVALUATION..................................................................... 52  
5.1 Data Collection............................................................................................................... 52  
5.2 Response criteria ............................................................................................................ 53  
5.3 Toxicity Criteria:............................................................................................................ 5 4 
5.4 Statistical Considerations ............................................................................................... 54  
5.5 Data and Safety Monitoring Plan................................................................................... 55  
6 HUMAN SUBJECTS PROTECTIONS ............................................................................... 56  
6.1 Rationale for Subject Selection...................................................................................... 56  
6.2 Evaluation of Benefits and Ri sks/Discomforts- Patients ............................................... 56  
6.3 Risks in Relation to Benefit ........................................................................................... 58  
6.4 Consent and Assent Proc esses and Documents.............................................................. 59  
7 DATA REPORTING............................................................................................................ 60  
7.1 Definitions...................................................................................................................... 60  
7.2 NCI-IRB Reporting........................................................................................................ 62  
8 PHARMACEUTICAL INFORMATION............................................................................. 64  
8.1 Fludarabine (Fludara, Berlex Laboratories)................................................................... 64  
8.2 Sirolimus (Rapamune®) ................................................................................................ 64  
8.3 Tacrolimus (FK506, Prograf)......................................................................................... 65  
8.4 Filgrastim (G-CSF; Neupogen ®).................................................................................. 65  
8.5 Diphenhydramine........................................................................................................... 66  
8.6 Acetaminophen............................................................................................................... 67  
8.7 Acyclovir........................................................................................................................ 67  
8.8 Trimethoprim/Sulfamethoxazole (TMP/SMX, Cotrimoxazole, Bactrim, Septra)......... 67  
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
8.9 Ursodeoxycholic Acid (Ursodiol, Actigall®) ................................................................. 68  
8.10  Ceftazidime  (Fortaz ®).............................................................................................. 68  
8.11  Levofloxacin  (Levaquin ®) ....................................................................................... 69  
8.12  Cyclophosphamide  (CTX, Cytoxan) ......................................................................... 69  
8.13  Equine Anti-thymocyte globulin (Atgam).................................................................. 70  
9 APPENDICES ..................................................................................................................... .7 1 
9.1 Appendix A:   Prep arative Regimen .............................................................................. 71  
9.2 Appendix B:   Protocol Evaluation Checklist ................................................................ 73  
9.3 Appendix C:  Immunizations Post-Transplant............................................................... 76  
9.4 Appendix D:  Grading and Management of  Acute Graft-Versus-Host Disease ............ 77  
9.5 Appendix E:  Management of  Engraftment Syndrome.................................................. 79  
9.6 Appendix F- NMDP Criteria for Matched Unrelated Donor ........................................ 81  
9.7 Appendix G: Experimental Tr ansplantation and Immunology Branch Preclinical Service 
Policy for Sample Handling..................................................................................................... .8 3 
10 REFERENCES ..................................................................................................................... 87  
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
1 INTRODUCTION
1.1 P RIMARY STUDY OBJECTIVES
1) In a pilot fashion, to determine efficacy, namely whether reduced-intensity allogeneic 
hematopoietic stem cell transplant (HSCT) results in engr aftment and restores normal 
hematopoiesis by day +100 in pa tients with mutations in GATA2.
2) To determine the safety of reduced-intensity allogeneic HSCT regimen in patients with 
mutations in GATA2 including transplant relate d toxicity, the incidence of acute and chronic 
graft-versus-host disease, immune reconstituti on, overall survival, and disease-free survival.
1.2 B ACKGROUND AND RATIONALE 
1.2.1 Introduction
Since its first description 50 years ago, the nu mber of hematopoietic stem cell transplants 
(HSCT) has increased steadily; 50,000 patients wo rldwide received a HSCT in 2006 (Thomas et 
al. 1957; Appelbaum 2007).  Although allogeneic HSCT can cure hematological malignancies, 
bone marrow failure syndromes, and genetic hematolo gical and immunodeficiency diseases, the 
success of therapy depends upon the prompt identi fication of a suitable donor.  Because matched 
related donors were required in  the initial HSCT, this limited the number of HSCT performed; 
only 30 percent of otherwise eligible patients with leukemia in the United States have a related 
histocompatible donor.  A major factor in the increase in HSCT over the preceding 20 years has 
resulted from the use of alternative donors.  
1.2.2 Reduced-Intensity Conditioning Re gimens for Matched Related Donors
Allogeneic hematopoietic stem cell transplantation with a myel oablative-conditioning regimen 
represents a potentially curative therapy for hematological malignancies, however this treatment 
approach has not been pursued in many instances due to the high regimen-related toxicity with 
age greater than 60 years, or with concomitant co-morbidities.  The un acceptable risk of death 
from conventional myeloablative transplantation has also precl uded this curative therapy for 
patients with other non-ma lignant hematological diseases.  However, it has recently been shown 
that these high intensity regimens may not be required for engraftment.  As a result of these findings, many centers are now exploring reduced-i ntensity conditioning regimens in order to 
reduce the toxicity associated with HSCT in  both malignant and non-malignant hematological 
diseases.  The evolution in thinking regard ing myeloablative versus reduced-intensity 
conditioning regimens is descri bed in the ensuing paragraphs.
The use of conditioning regimens containing high doses of alkylating agents, often in 
combination with total body irradiation, are cons idered “myeloablative;” these regimens were 
perceived to be essential both for eradication of  malignant disease and for suppression of the 
host-versus-graft response to the donor stem cells  (i.e. rejection) (Cope lan 2006). Myeloablative 
conditioning regimens caused severe damage to  normal organs within the body resulting in a 
high incidence of morbidity and mortality (Bear man et al. 1988). This limited the application of 
allogeneic HSCT to younger patients (< 60 years of age) who could tolerate these toxicities.  Subsequent studies and observations challenged the assumption th at myeloablative conditioning 
was necessary to eliminate malignancy and per mit the engraftment of the donor hematopoietic 
and immune systems. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
The high frequency of relapse observed in the setting of T-cell-depleted allogeneic HSCT 
suggested that a significant proportion of the curative potential of alloge neic HSCT resulted from 
a T-cell-mediated graft-versus-tumor (GVT) effect  (Champlin 1990).  It was also recognized that 
conventional myeloablative regimens do not completely eliminate the host response to the allograft, even in recipients of HLA-matched allografts.  For example, one study indicated that 30 to 40% of patients will reject a T-cell-depleted, HLA-matched allogeneic stem cell graft after myeloablative conditioning (Martin et al. 1988).  In addition, there are certain clinical situations where the malignancy is very susceptible to the allogeneic GVT effect (e.g. AML in complete remission, chronic leukemia or low-grade lymphoma.  In these clinical situations, the use of a 
myeloablative-conditioning regime n may be adding toxicity without eradicating the tumor. 
These limitations of myeloablative conditioning re gimens, combined with the high levels of 
morbidity and mortality associated with myel oablation, result in a compromised therapeutic 
index for this form of allogeneic HSCT.  Redu cing treatment-related toxicity would improve the 
therapeutic index of allogeneic HSCT, permitting the broader application and potential benefit of 
this treatment to more patients.  This principle led to the development of less intensive 
“nonmyeloablative” and “reduced-intensity” cond itioning regimens for allogeneic HSCT, which 
were designed with the purpose of allowing en graftment of donor cells to exploit the potential 
allogeneic GVT effect (Giralt et al. 1997; Slav in et al. 1998; Childs et al. 1999; Spitzer et al. 
2000; Khouri et al. 2001).
The early reports of studies employing nonmye loablative and reduced-intensity conditioning 
regimens prior to allogeneic HSCT demonstrated that early engraftment occurred in the majority 
of patients, and early transpla nt-related toxicities (first 100 days  after transplantation) were 
reduced.  This indicated that reduced-intensity regimens could be used for older patients and 
patients with co-morbidities.  However, it was also observed that both nonmyeloablative and 
reduced-intensity conditioning we re associated with high incidences of incomplete donor 
chimerism, higher incidences of graft rejection/failure, and increased relapse rates, as compared to results with myeloablative conditioning regimens (Khouri et al. 1998; Aoudjhane et al. 2005).Mixed chimerism and graft rejection were also associated with HLA-disparity and the use of unrelated donors, and correlated inversely with the amount of therapy prior to transplant 
(McSweeney et al. 2001; Maris et  al. 2003; Carvallo et al. 2004).  It was also observed that a 
GVT effect was not observed until full donor ch imerism was achieved (Truitt and Atasoylu 
1991; Mackinnon et al. 1994; Childs et al. 2000;  Orsini et al. 2000; Petrus et al. 2000).
To decrease toxicity, and to develop immunosuppre ssive as opposed to myeloablative regimens, 
many centers explored combinations of regimens including the use of low dose radiation.  Low dose radiation alone has been shown to have an ti-leukemia properties.  A dose of 200 cGy total 
body irradiation (TBI) was adequate for inducin g remission, albeit short lived, in refractory 
patients ineligible for other st andard treatments (Shulman et al . 1998).  Doses of 100 to 500 cGy 
have been shown to have very little toxicity in both murine and rhesus transplant models (Huhn et al. 1999; Kang et al. 2001).  Even patients wi th Fanconi anemia, who would be considered 
high risk for radiation induced toxicity, tole rate moderate dose (500 cGy) radiation based 
regimens (Dufour et al. 2001).  While regarded as a method designed for the creation of “space” 
within the marrow in bone marrow transplanta tion (BMT) regimens, radiation has long been the 
basis of the establishment of immunosuppressive protocols for both BMT and solid organ transplantation in animal models (Myburgh et al. 1980; Myburgh et al. 1984).  There is extensive 
clinical experience demonstrating stable mixed  chimerism with the use of 200 cGy total body 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
irradiation and fludarabine, followed by GVH D prophylaxis with Cyclosporine (CSP) and 
mycophenolic acid (MMF) (Hegenbart et al. 2006).
This protocol aims to ta ke advantage of the immunodeficiency st ate in patients with mutations in 
GATA2 to achieve a high level of donor chimerism following HSCT using a reduced intensity 
conditioning regimen with low-dose TBI and fludar abine.  Because opportunistic infections are 
present in many of these patients, along with  MDS, both high levels of chimerism and low 
regimen related toxicity are important considerations in designing a transplant regimen for this cohort.
1.2.3 Reduced-Intensity Conditioning Reg imens for Matched Unrelated Donors
Allogeneic HSCT is potentially curative for many hematological malignancies, however, as 
previously noted, stem cell donor availability limits the broader a pplication of this treatment.  
Only 25% to 30% of patients have a sibling donor who is fully matched at the class I and II major histocompatibility complex (MHC) loci that encode for the human leukocyte antigens (HLA-A, -B, -C, DRB1, and DQB1) (Appel baum 2007).  This limitation prompted the 
exploration of alternative stem cell sources for allogeneic HSCT including the use HLA-matched unrelated donors (Kernan et al. 1993).  Enro llment of volunteer donors in national and 
international registries, such as National Marro w Donor Program (NMDP) in the United States, 
has facilitated the identification of unrelated stem cell donors for patient s without HLA-matched 
sibling donors.  However, transplants from unrelat ed donors are complicated by higher rates of 
graft rejection, acute and chronic GVHD, and treatm ent-related mortality.  These complications 
are partially balanced by lower relapse rates attributed to increased histocompatibility differences.  These complications have limited ma tched unrelated donor myeloablative HSCT to 
patients less than 55 years of age and without any significant co-morbidity.  Within these limitations, matched unrelated donor  transplant has become widely utilized to treat 
hematological malignancies. 
In light of the high treatment-related morbidity and mortality associated with myeloablative 
allogeneic HSCT from unrelate d donors, clinical studies utilizing nonmyeloablative and reduced-
intensity conditioning regimens were initiated after encouraging results with these regimens for HLA-matched siblings had been reported.  Ho wever, because of greater genetic disparity 
between the donors and recipients, it was hypothesized that nonmyeloablative conditioning regimens for unrelated donor transplantation might require more intense immunosuppression 
than a transplant from an HLA-matched sibli ng.  Since 2001, there have been a number of 
relatively large single-institution and multi- institutional studies on nonmyeloablative and 
reduced-intensity allogeneic HSCT utilizing unre lated donors (Tables 1A a nd 1B) (Giralt et al. 
2001; Chakraverty et al. 2002; Kroger et al. 2002;  Maris et al. 2003; Nied erwieser et al. 2003; 
Wong et al. 2003).  Of note, the median ages of recipients has ranged from 44 to 59 years with patients as old as 72 years successfully undergoing this procedure. 
The incidence of graft rejection in these HSCT  ranged from 0 to 21%.  The primary adverse 
factors related to graft rejec tion were: use of nonmyeloablative conditioning regimens, HLA-
mismatching, transplant with  bone marrow rather than mobilized peripheral blood, and a 
minimal amount of prior therapy prior to transp lant.  Using a variety of GVHD prophylaxis 
regimens, the reported incidences of Grade II-IV and Grade III-IV acute GVHD have been 21-
63% and 6-39%, respectively.  Early (< 100 days  post-transplant) treat ment-related mortality 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
rates have varied from 10 to 48%; one-year treatment-related mortality rates have varied from 17 
to 55%.  One-year overall survival rates have b een reported to be 32 to 75% (Tables 1A and 1B).
The majority of the reduced-intensity reg imens are based on chemotherapy, however a 
considerable experience, primarily from the Fred Hutchinson Cancer Research Center, has accumulated using 200 cGy low-dose TBI in the conditioning regimen along with fludarabine (Maris et al. 2003; Nieder wieser et al. 2003).  This work was first described in the 1990’s in the 
canine model and demonstrated that 200 cGy TBI pre-transplant combined with post-transplant immunosuppression with Cyclosporine (CSP) a nd Mycophenolate (MMF) resulted in stable 
engraftment of dog leukocyte antigen (DLA)-mat ched littermate recipients  (Storb et al. 1999).
When these results were translated to humans it was shown that the addition of fludarabine 
significantly increased the rate of engraftment of donor hematopoietic stem  cells (Mielcarek et 
al. 2007).  Using this regimen the Seattle grou p recently reported comparable engraftment 
between matched unrelated an d matched related recipient.
This protocol uses a reduced-int ensity regimen to treat patients with mutations in GATA2 who 
have a 10/10 matched related donor, a 10/10 ma tched unrelated donor, or a 9/10 matched 
unrelated donor.  This regimen carries one of th e lowest incidences of transplant related 
mortalities (Maris et al. 2003).  This factor is important since patients with mutations in GATA2 are frequently debilitated from infections with opportunistic organisms such as mycobacterium avium complex (MAC).   
Table 1A - Patient and Treatment Characteristic s of Reported Trials of Non-myeloablative 
and Reduced-intensity Allogeneic HSCT Utilizing HLA-matched Unrelated Donors
Author/Institute
Journal/DatePatient #
Median 
AgeHLA 
LociDegree 
matchLevel of HLA 
MatchConditioning Regimen GVHD
ProphylaxisStem Cell 
SourceCD34
Dose 
(106/kg)CD3 Dose 
( 108/kg)
Class I Class II
Giralt et al. MDACC 
Blood 2001N = 86 
(URD = 
40)
52 years 
(22-70)6 6/6 Serology Molecular Flu (25 mg/m 2/d) x 5d
Mel 90–140 mg/m 2
Clad (12 mg/m 2/d) x 5d
Mel 90–140 mg/m 2FK506 x 6 months
MTX (5 mg/m 2)
+1,+3,+6,+11NA NA NA
Chakraverty et al. 
UK multi-institute 
Blood 2002N = 47
44 years 
(18–62)10 9-10/10 
(s)
8-10/10 
(m)serologic 
–A , B
mole – CMolecular Flu (30 mg/m 2/d) x 5d
Mel 140 mg/m 2
CAMPATH (20 mg/kg) 
-8,-7,-6,-5,-4,-3CsA x 3 months
[CAMPATH]BM = 46
PB = 1NA NA
Kroger et al. German 
multi-institute 
Blood 2002N = 21 
(all 
multiple 
myeloma)
50 years
(32-61)8
HLA-A,B, 
DRB1,DQB17-8/8 Serology
cMolecular Flu (30 mg/m 2/d) x 5d
Mel 100 mg/m 2
ATG (10 mg/kg) -3,-2,-1CsA x 3 months
MTX (10 mg/m 2)
+1,+3,+6BM = 6
PB = 153.9
(0.4 -
12.5)NA
Niederwieser et al. 
FHCRC Consortium 
Blood 2003N = 52
48 years
(6–65)8 (10)
HLA-A,B,C, 
DRB1, 
(DQB1)7-8/8 (s)
6-8/8 (m)Serologi
cMolecular Flu (30 mg/m 2/d) x 3d
TBI 200 cGyCsA x 2-3  
months, taper until 
+180)
MMF x 40d,taperBM = 13
PB = 396.0 (1.5 –
21.6)
(BM = 
2.7)3.4 (0.8 –
10.0)
(BM = 0.3)
Maris et al. FHCRC 
Consortium 
Blood 2003N = 85
53 years
(5–69)10
HLA-A,B,C, 
DRB1,DQB110/10 serologic
(81% 
molecula
r at 
Class I)Molecular Flu (30 mg/m 2/d) x 3d
TBI 200 cGyCsA x 3 months, 
taper until +180
MMF x 40d,taperBM = 18
PB = 716.99 (1.26 
-16.4)2.61 
(0.8 -37.7)
Wong et al. MDACC 
Blood 2003N = 29
59 years 
(55-69)6 6/6
5/6 (n = 2)Serologi
cMolecular Flu (25 mg/m 2/d) x 5d
Mel 90–140 mg/m 2
+/- ATG (n = 17)FK506 x 6 - 8 
months
MTX (5 mg/m 2)
+1,+3,+6,+11BM = 28
PB = 14.46 (0.37 
–8 . 6 )NA
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Table 1B - Clinical Outcomes of Reported Trials of Non-myeloablative and Reduced-
intensity Allogeneic HSCT Utilizing HLA-matched Unrelated Donors
Author/Institute
Journal/DateGraft 
Rejection 
and FailureAcute GVHD Chronic 
GVHDTRM OAS
II-IV III-IV Day 100 1 year 2 year 1 year 2 year
Giralt et al. 
MDACC Blood 
20015% (n =2) 62%
(11 deaths)39% 68% 37.4% NA 45% (all 
patients) 32%
(URD)28% (all 
patients)
Chakraverty et al. 
UK multi-institute 
Blood 20023% (n= 2) 21.3% 6.4% 8% (all 
limited)15% 20% (~25%) 75% NA
Kroger et al. 
German multi-
institute Blood 
20020 38% 19% 37%
Limited = 
25%
Extensive = 
12%10% 26% NA 74% 74%
Niederwieser et al.
FHCRC 
Consortium Blood 
200312%
(low CD3; 
low CD34)63% 21% 60%
Limited = 
30%
Extensive = 
30%11% 29% 40% 44% 35%
(19 mo)
Maris et al. 
FHCRC 
Consortium Blood 
200321% (PB vs. 
BM: 15% vs. 
44%)52% 10% 45% (85)
Extensive = 
37%11% 17% NA 52% (~42%)
Wong  MDACC 
Blood 200314% (n= 4) 41% 20% 62.5% 48% 55% NA 44% (~44%)
1.2.4 Effect of HLA on Transplant Outcomes :
Since its inception, the NMDP has required ev aluation of donor-recipient histocompatibility 
matching (HLA-A, -B, and -DR) prior to unrelated donor HSCT (Bray et al. 2008). The 
minimum acceptable match was originally defined by serologic testing at these 3 loci (6 possible 
antigens) and required at least 5 matches, that is, a “5 of 6 match”. This requirement has changed little over the years. Currently, to request a donor for transplantati on, the minimal acceptable 
level of matching remains a 5 of  6 match for HLA-A, -B, and -DRB1. Although only evaluated 
at antigen level of resolution (“low resolution”) fo r donor release, each of these 3 loci must now 
be typed at high-resolution by DNA-based met hods. High-resolution typing is defined as the 
identification of alleles based on differences in the antigen recognition site (ARS) domains (Exons 2 and 3 of Class I and exon 2 of Cla ss II genes). In 2005, a requirement for HLA-C
typing was added. The most recent studies have clearly shown that transplant outcomes can be improved by matching strategies that increase the overall degree of HLA compatibility above the minimum accepted level by matching also for HLA-C, -DP, -DQ, and haplotypes (Petersdorf 2006).As data on high resolution typing accumulated, the NMDP performed an analysis on the effects 
of HLA matching (low or high resolution or both) on engraftment, graft-versus-host disease 
(GVHD), and mortality in 1874 donor-recipient pairs that were retrospectively typed using high resolution techniques for HLA-A, -B, -C, -DRB 1, -DQ, and -DP (Flomenberg et al. 2004).
There was no effect of any mismatch on engraftment, and only a mismatch at HLA-A affected whether the patients experienced Grade II-IV acute GVHD or chronic GVHD. Single 
mismatches at HLA-A, -B, -C, and -DRB1 each had similar adverse effects on mortality (relative risk 1.23 - 1.33), as compared to individuals matched at all four loci.  The 5-year overall survival 
rates for a match at all four loci (“8 of 8” as compared to a single mismatch (“7 of 8”) was 39% 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
and 31%, respectively.  In this analysis, mismatc hes at HLA-DQ or -DP did not appear to exert 
any significant effect on survival (5-year overall survival = 39%) or any other outcome.  The 
observed adverse effects on outcome were more evid ent in transplants with low-resolution versus 
only high-resolution mismatches.  When high-re solution mismatches at HLA-A, -B, -C, and -
DRB1 were considered together, adverse ef fects on survival and GVHD were observed.  The 
authors concluded that ma tching for HLA-C should be incorporat ed into algorithms for unrelated 
donor selection, along with HLA-A, -B, and -DRB1 (i.e. “8 of 8”).
In a subsequent analysis, the NMDP looked at  data from 3857 transplant ations.  Patient-donor 
pairs were fully typed for HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, and -DPA1 alleles 
(Lee et al. 2007).  High-resoluti on DNA matching for HLA-A, -B, -C , and -DRB1 (8 of 8 match) 
was the minimum level of matching associated with the highest survival.  A single mismatch 
detected by low- or high-resolution DNA testing at  HLA-A, -B, -C or -DRB1 (7/8 match) was 
associated with higher mortality (relative ri sk = 1.25; 95% CI, 1.13-1.38; P < 0.001) and 1-year 
survival of 43% compared with 52% for 8 of 8 matched pairs.  Single mismatches at HLA-B or 
HLA-C appeared to be better tolerated than mism atches at HLA-A or HLA-DRB1.  Mismatching 
at 2 or more loci compounded the risk.  Mismat ching at HLA-DP or -DQ loci and donor factors 
other than HLA type were not associated with survival.  In multivariate modeling, patient age, race, disease stage, and cytomegalovirus status were as pred ictive of survival as donor HLA 
matching. The authors concluded that high-res olution DNA matching for HLA-A, -B, -C, and -
DRB1 alleles is associated with higher rates of survival.
Based on these results, the NMDP has established guidelines relative to donor selection based on 
HLA-typing (Bray et al. 2008).  The optimal donor  should be matched at HLA-A, -B, -C, and -
DRB1 by high-resolution typing.  When there are multiple donors with this degree of matching, further matching at HLA-DQ may be utilized; however, the clinical utility does not reach 
statistical significance.  If a mismatch is unavoidable, a single mismatch at HLA-A, -B, -C, and -DRB1 should be sought.  In the NMDP data , mismatches at HLA-B and -C may be less 
detrimental than those at HLA-A and -DRB1.
1.2.5 Reduced Intensity Umbilical Cord Blood TransplantationUmbilical cord blood (UCB) represents an altern ative to bone marrow as a source of HSC for 
transplantation in individuals who lack an HLA- matched donor, and has been used as a source of 
donor hematopoietic stem  cells HSC to treat a variety of malignant and non-malignant 
hematological disorders (Kurtzberg et al. 1996; Wagner et al. 2002).  The advantages of UCB 
include the ease of procurement, lack of donor attrition, absence of maternal risk, reduced risk of 
GVHD, and less stringent criteria for HLA matchi ng (Wagner and Kurtzberg 1997).  The major 
limitations in UCB are the relatively decreased cell dose leading to delayed engraftment, extended post-transplant neutropenia and thrombocytopenia, a nd an increased incidence of 
infection and bleeding.  The developments since the first HSCT using UCB in 1989 are 
described in the ensuing paragraphs. 
Unrelated Donor UCB HSCT in Pediatrics 
The initial descriptions of signif icant cohorts of patients treated  using UCB transplant involved 
the use of single UCB units in children and myeloablative conditioning regimens (Kurtzberg et 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
al. 1996; Gluckman et al. 1997).  Both studies confirmed the potential of  UCB transplant to 
induce remission in patients with refractory hematological malignancies.  The two studies also 
reported a lower than predicted frequency of GVHD. 
These early studies with UCB HSCT from sibling donors led to the banking of unrelated donor 
UCB.  Using banked UCB (from the New York Blood Center) in 167 children with hematological malignancies, congenital / acquire d bone marrow failure syndromes, and genetic 
diseases, 93% of the patients engrafted.  Engraf tment was subsequently found to correlate with 
the number of CD34+ cells transpla nted, rather than the degree of  HLA matching.  Retrospective 
analysis indicated that a dose of CD34+ cells <2-3 x 10
5CD34+ cells/kg resulted in diminished 
and delayed engraftment of platelets and neutrophils.  Multivariate analysis revealed that any dose >3 x 10
5CD34+ cells/kg results in fairly consistent engraftment. 
Unrelated Donor UCB HSCT in AdultsThree studies specifically addressed the use of UCB grafts in adults (Gluckman 2000; Laughlin et al. 2001; Sanz et al. 2001).  These studies consisted of adult patients with hematological 
diseases who underwent myeloablative conditioni ng followed by HLA-ma tched or mismatched 
UCB infusion.  The probability of myeloid engraf tment and the probability of developing acute 
GVHD grades II-IV ranged from 81% to 100% and 38% to 60%, respectively.  The event free 
survival (EFS) (with at least 1 year of follow up)  ranged from 21% to 53%.  These data indicated 
that UCB SCT led to lower than expected rates of acute GVHD, especially in the setting of mismatched HLA grafts, and encouraged further study using UCB.   
Two recent reports specifically compared the outcomes of adult patients with acute leukemia or 
myelodysplastic syndrome (MDS) transplanted with either HLA-mismatched UCB or HLA-matched and mismatc hed BM grafts (Laughlin et al. 2004; Rocha et al. 2004).  Time to 
neutrophil and platelet engraftment and recovery were significantly longer after UCB SCT than BMT.  Acute GVHD was more likely after mismatched marrow transplant, however chronic GVHD was more likely after UCB transplant.  Tr eatment-related mortality (TRM), treatment 
failure (i.e. relapse or death), and overall mortality were lowest in patients receiving HLA-matched BM grafts.  There was no difference in the rate of recurrence of leukemia among the 
groups.  The adjusted probability of three-year survival was 26% for patients receiving UCB grafts; this was similar to patients receiving HLA-mismatched BM. 
The conclusion from these studies was that UCB represented a curative alternative donor source 
for patients with hematological malignancies who lacked a bone marrow donor.  When compared 
with URD BMT, there is a delay in neutrophil and platelet engraftment, a higher risk of graft 
failure, and an increase in TRM during the first 100 da ys.  This is balanced in part by a decrease 
in acute GVHD seen in recipients of UCB. Reduced Intensity Unrelated Donor UCB HSCT
The use of UCB SCT in the adult population has b een tempered by the increased risk of graft 
failure and decreased survival associated with the small cell dose in physically larger patients.  Investigators at Case Western Reserve University found that a higher nucleated cell dose and higher CD34+ cell dose correlated with more ra pid neutrophil recovery and improved survival, 
respectively in adult patients undergoing UCB HS CT (Laughlin et al. 2001).  The importance of 
cell dose was further supported by data which showed that UCB recipients infused with < 1.8 x 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
107NC/kg or < 1.7 x 105CD34+ cells/kg body weight had sign ificantly decreased engraftment 
and survival (Wagner et al. 2002).
Anti-thymocyte globulin (ATG) has been used as part of the preparative regimen prior to the 
infusion of donor cells to decrease the incidence of  graft rejection and to decrease the incidence
of GVHD by eliminating donor T-cells in the graft.  Animal expe riments originally 
demonstrated the synergistic immunosuppressive effects between ATG and alkylating agents. 
The combination of ATG and cyclophosphamide was subsequently used widely in HSCT.
In a non-malignant disease setting, substitution of cyclophosphamide by fludarabine and rabbit 
ATG in a busulfan based regimen of matched related donor  transplant in 5 children and adults 
with beta-thalasse mia, all patients engrafted with 2 of the 5 maintaining 100% donor chimerism 
(Sauer et al. 2005).Additional support for the use of ATG in UCB appeared in late 2007 with the description of 110 
adult patients who received UCB following a non myeloablative-conditioning  regimen (Brunstein 
et al. 2007).  This large study of 110 patient s utilized a conditioning regimen consisting of 
Fludarabine 200 mg/m2, Cytoxan 50 mg/kg, and 200 cGy TBI, and Equine ATG (ATGAM) 15 
mg/kg IV every 12 hours on day -6, -5, and -4.  The i nvestigators aimed to tr ansplant at least 3 x 
10
7total nucleated cells (TNC)/kg in each patient, a nd if the cord blood unit contained less than 
that amount, two UCB units were infused.  This resulted in 85% of patients receiving two UCB 
units.  With the double UCB units neutrophils recovered to 500/ μl at a median of 12 days and 
platelets required a mean of 49 days to achieve a level of 20,000/ μl.  Grade 3 and 4 GVHD 
occurred in 22% and 23% of patients, respectively.   Interestingly, by 21 days post-transplant one 
of the units prevailed in over 80% of the patients. Survival was 45% at 3 years with an event free 
survival of 38%. 
Advantages of UCB
The reasons for the expanded use of UCB as a donor  source are many.  The first advantage lies 
in the immediate availability of cells.  The median time from request to acquisition of the UCB is 13.5 days (Barker et al. 2002).  Since there is no risk to the donor, there is no donor unavailability, such as that which occurs with  unrelated donors in which an estimated 25 percent 
of donors who are identified are subsequently unable to donate HSC (Wagner et al. 2002).
Second, acceptable cord-blood units can be identified for most patients because less stringent HLA-compatibility with the recipient is required (Rocha et al. 2000).  Third, the incidence and 
severity of GVHD are not excessive with UCB, even with cord-blood units mismatched for more 
than one HLA antigen (Brunstein et al. 2007).   Moreover, the graft-versus-leukemia effects are 
maintained with UCB grafts (Laughlin et al. 2004).
UCB banks have been developed worldwide and standardized banking procedures have been 
implemented (Rubinstein et al. 1998).  The low rate of viral infection at birth and the collection 
of cord blood from ethnic groups not well repr esented in bone marrow donor registries are 
additional advantages of UCB.  There are an estimated 170,000 units in 37 cord blood registries 
in 21 countries (Bone Marrow Donors Worldwide Homepage  ( www.bmdw.org ).
The main obstacle for use of cord blood transplant  in adults has been the low number of stem 
cells in cord blood units leading to delayed en graftment and graft failu re.  The number of HSC 
in a unit of cord blood is approximately one tenth the number of HSC in a marrow harvest 
(Laughlin et al. 2001).  The low number of HSC in UCB results in more  gradual reconstitution 
of hematopoiesis following UCB grafts compar ed to bone marrow or peripheral blood stem cell 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
grafts, and this contributes to the increased ra tes of post-transplant in fection and early death 
(Rocha et al. 2000).  This limitation in UCB SCT ha s been decreasing with the increasing use of 
double cord units. 
We propose to consider the use UCB as the sour ce of donor HSC for patients with mutations in 
GATA2 who lack a 10/10 matched related or unrelated donor.  The ability to acquire UCB 
within two weeks of the request represents a pot ential advantage for patients with mutations in 
GATA2 who may have a narrow window of opportunity for transplant between severe 
infections.  
1.2.6 HLA-Haploidentical Hemat opoietic Stem Cell Transplant ation Using Nonmyeloablative 
Conditioning and High-Dose, Post-Transplantation Cyclophosphamide
During the previous decade there has been an increasing body of evidence that high-dose 
cyclophosphamide given post-transplant prevents both graft rejection and graft-versus-host 
disease.  Cyclophosphamide has a long history as an immunosuppressive agent that is selectively 
toxic to lymphocytes that are proliferatin g in response to recent antigen stimulation. 
Cyclophosphamide can be safely administered in high doses after allogeneic HSCT with a 
favorable safety profile, especially a lack of t oxicity to hematopoietic stem cells. In animal 
models both graft rejection and GVHD were i nhibited by administration of high-dose 
cyclophosphamide after allogeneic bone marrow transp lantation.  When given in high doses after 
allogeneic HSCT cyclophosphamide targets prolif erating, alloreactive T-cells and prevents 
GVHD (Luznik et al. 2002).
In 2002 O'Donnell and colleagues at Johns Hopkins described results using a nonmyeloablative 
bone marrow transplant from par tially HLA-mismatched relate d donors using post-transplant 
cyclophosphamide (O'Donnell et al. 2002).  Donors were partially HLA-ma tched (up to 3 HLA 
antigens) from first-degree relatives.  They demonstrated comparable levels of engraftment and GVHD to that seen with matched unrelated donor tr ansplants.  The regimen is shown (Figure 1).
Figure 1. Nonmyeloablative haploidentical BMT conditioning and post grafting 
immunosuppressive regimen.
Non-malignant diseases were also amenable to the nonmyeloablative regimen described.  In 
2008 Brodsky described HSCT for thrombotic pa roxysmal nocturnal hemoglobinuria using the 
regimen described (228, Brodsky, BMT).  Two of three patients were disease free with full donor 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
chimerism and on no immunosuppressive therapy and nonmyeloablative HLA-haploidentical 
HSCT using post-transplant cyclophosphamide. 
The largest series of HLA-haploidentical nonmyeloablative HSCT was reported from Johns 
Hopkins and the Fred Hutchinson Cancer resear ch Center by Luznik in 2008 (Luznik et al. 
2008).  A total of 67 patients were  transplanted using the regimen shown in Figure 1 only with 
either one day of cyclophosphamide post-transpla nt on day +3 or two days of cyclophosphamide 
on days + 3 and +4.  There were 9 graft failures (13%).  There was no difference in GVHD with one or two days of cyclophosphamide post-transpla nt.  The overall survival at one year was 46% 
with an event-free survival of 34% in a hi gh risk population of patients with  leukemia. 
When this data was summarized recently, ther e was a total of 210 recipients of mini-Haplo 
HSCT at Johns Hopkins with 87% sustained dono r engraftment(Munchel et al.).  The cumulative 
incidence of grades II-IV acute GVHD and chronic GVHD were 27% and 13%, respectively.  The 5-year cumulative incidence of non-relapse mortality was 18%; relapse was 55%, actuarial 
overall survival 35%, event-free survival 27%.  Thus, mini-Haplo HSCT with post-transplant 
cyclophosphamide was associated with favorable toxicity and overall survival for patients 
without matched relate d or unrelated donors. 
1.2.7 Hematopoietic Stem Cell Transplant for Primary Immunodeficiency Disease 
Most primary immunodeficiency diseases (PID) consist of intrinsic genetic defects of 
hematopoietic lineage-deri ved cells.  Therefore, replacement of genetically impaired cells by 
normal HSC represents a logical therapeutic appro ach. It has now been demonstrated that HSCT 
can reverse the phenotype in a variety of PID.  The initial reports of successful HSCT in PID 
included severe combined immunodeficiency di sease (SCID) and Wiskott-Alrich Syndrome 
(WASP) (Bach et al. 1968; Gatti et al. 1968).  By 2003, over 1200 patients with PID had 
undergone allogeneic HSCT (Buckl ey 2003).  In all, 26 different inherited immune deficiencies 
had been corrected by HSCT, including a nu mber of SCID variants, WASP, and various 
phagocytic disorders such as chronic granul omatous disease (CGD), and leukocyte adhesion 
deficiency (LAD) (Le Deist et al. 1989; Buckley 2003).
In the largest cohort of patie nts with SCID receiving HSCT, Buckley reported on 89 infants 
transplanted at Duke between 1992 and 1998 (Buckl ey et al. 1999).  The majority of patients 
with SCID were boys with X- OLQNHGFRPPRQ -chain SCID.  However, six had Janus kinase 3 
(Jak3) mutations, 13 had adenosine deaminase de ficiency (ADA)-SCID, three had IL-7R alpha-
chain defects, and 21 infants had unclassified autosomal recessive SCID.  A total of 77 infants 
received T-cell depleted, HLA haploidentical parental marrow and 12 received HLA-identical 
marrow from a related donor.  Just over 80 percent of the patients were alive 3 months to 16.5 
years post-transplant, including all 12 patie nts who received HLA-identical related donor 
marrow.  None of these patients received chem otherapy pre-transplant or GVHD prophylaxis.  
T-cell function became normal within two weeks of transplant in the patients who received unfractionated HLA-identical marrow.  B-cell function was reconstituted in less than 50 per cent of the long-term survivors necessitating life-long immunoglobulin replacement in those patients without B-cell reconstitution.  Although GVHD deve loped in 28 of the 77 infants who received 
T-cell depleted haploidentical marrow, in mo st cases the GVHD was mild and did not require 
treatment. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Although most of the initial studies in PID us ed related donors, matche d unrelated donor HSCT 
has been successfully employed in a number of pa tients with PID (Ash et al. 1990; Filipovich et 
al. 1992; Kernan et al. 1993).  Kernan reported a 50 percent success rate using matched URD 
HSCT to treat PID (Kernan et al. 1993).
In primary immune deficiency diseases (PID) donor engraftment may be achieved following 
allogeneic HSCT with no or reduced-intensity conditioning due to the inability of the host 
immune system to mediate graft rejection (Buckley et al. 1999; Rao et al. 2005).  Thus, PID constitutes an experiment of nature in which a nonmyeloablative-conditioning regimen may result in sufficient levels of donor engraftment to  mediate a graft-versus-leukemia effect without 
the toxicity of a myeloablative-conditioning regimen. Reduced in tensity conditioning regimens 
are particularly well suited for allogeneic stem cell transplantation in pa tients with non-malignant 
stem cell disorders where tumor kill is not requi red and co-morbid conditions are frequent.  Also, 
since a reduced-intensity conditioning regimen allo ws autologous recovery if the graft should 
fail, a second transplant remains a possibility. 
The optimal nonmyeloablative-conditioning regimen for HSCT in PID has yet to be defined.  
However, a number of non-malignant diseases ha ve been successfully treated using reduced-
intensity conditioning regimens in stem cell transplantation, often leading to a state of mixed 
chimerism.  Immunodeficiency dise ases treated with non-myeloabl ative transplantation include 
hyper-IgM syndrome (Kato et al. 1999), adenosin e deaminase deficiency  (Honig et al. 2007),
chronic granulomatous disease (H orwitz et al. 2001), Wiskott-Al drich syndrome (Kapoor et al. 
1981; Longhurst et al. 2002), and leukocyte adhesion deficiency–I (LAD-I) (Engel et al. 2006).
In a study of 14 patients with PID receiving e ither no conditioning or conditioning with 200 cGy 
TBI +/- fludarbine prior to matc hed related or unrelated donor HSCT, event-free survival was 62 
per cent (Burroughs et al. 2007).  This was a heterogeneous group with six patients receiving 
matched related donor HSCT, and 8 receiving matched unrel ated donor HSCT.  Correction of the 
immune dysfunction was achieved in  8 of 10 patients with stable donor engraftment.  There was 
a transplant-related mortality of 23 percent.The use of unrelated donors for HSCT in PID has b een successful in a several other studies.  In 
the most extensive use of reduced-intensity cond itioning in patients with PID receiving unrelated 
donor HSCT, Veys and colleagues demonstrated a 94 percent survival in 33 patients treated with 
a reduced-intensity regimen consisting of Melphalan 140 mg/m
2, fludarabine 150 mg/m2, and 
alemtuzumab (Campath 1H 1 mg/kg) (Veys et al . 2005).  All HSCT were T-cell replete.  They 
observed rapid engraftment in 32 of the 33 pati ents with neutrophil recovery at 13 days and 
platelet recovery at 16 days.  Of  note, at one-year post-transplant only 55 percent of the patients 
had 100 percent donor chimerism.  Possibly as a result of the low level of complete donor chimerism, only 9 percent of the patients in the RIC group had acute GVHD more than grade II.  There was also a very high rate of viral reactivation associated with the use of Campath.
The lower regimen-related toxicity with  low-dose TBI plus fludarabine 30 mg/m
2/day for 3 days 
supports the use of this regimen in patients with mutations in GATA2 who have co-morbidities 
related to their underlying immunodeficiency.  The use of Campath, although an effective immunoablative agent, poses an unacceptable risk in patients who are already at high risk for opportunistic infections.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
1.2.8 GATA2 Mutation Syndrome
Nearly three years ago Dr. Steve Holland of the NIAID Clinical Infectious Diseases Branch at
the NIH identified a unique immunodeficiency disease syndrome, subsequently named MonoMAC, in which patients have a severe deficiency of monocytes (Mono) in the peripheral blood, and the propensity to develop Mycobacterium Avium Complex (MAC) infections (Vinh et al. 2010).  These patients have now been shown  to harbor mutations in GATA2 (Hsu et al.).
The important differences between  patients with mutations in GAT A2 and previously described 
primary immunodeficiency diseases are that patient s with mutations in GATA2 have: 1) onset of 
disease beyond infancy, frequently in late adolescence or early adulthood, 2) a clinical history of life-threatening opportunistic inf ections, primarily MAC, 3) a peripheral blood leukocyte subset 
profile with the presence of T-lymphocytes, but a severe deficiency of B-lymphocytes, NK cells, 
and monocytes, 4) a genetic component suggestive of a dominant pattern of  inheritance, and 5) 
frequent progression to MDS.  Th is contrasts with the vast majority of genetic PID which 
manifest in infancy, rarely have both dissemin ated MAC and disseminated fungal infections, 
lack T-lymphocytes, and do not progress to MDS/AML.  
Previously described PID are characterized by loss of the T-lymphocyte compartment.  The first 
category, recognized over 50 years ago, consists of T-, B+, and Natural Killer (NK)- (severe combined immunodeficiency disease (SCID).  The largest group of these patients is X-SCID due to mutations in the common gamma chain of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.  Autosomal recessive forms of T-,B+, NK- S CID are due to mutations in the Jak3 kinase.  
The second group of PID consists of T-, B-, NK+ SCID.  These patients have defects in the variable, diversity, joining (VDJ) recombination machinery.  Examples of this form of PID include Rag (Recombination activating gene) defe cts, Omenn syndrome, and Artemis deficiency. 
Both these forms of PID manifest at birth with severe infections; these infections commonly lead to death by 6 months of age. 
Patients with mutations in GATA2 present in their late teens or early twenties, and ultimately 
succumb to either disseminated infection or MDS/ AML over 2-10 years.  It appears that the loss 
of monocytes and NK cells accounts for the propensi ty to develop opportunistic infections with 
MAC and fungal organisms, including histoplasmosis and aspergillus.  The onset of MDS is variable, but usually develops within several years of the onset of the disease.  Current 
management of the GATA2 mutation syndrome is palliative and revolve s around treatment with 
antibiotics, anti-viral, anti-t uberculous, and anti-fungal agents .  However, relapses with 
additional opportunistic inf ections invariably occur leading to pr ogressive disability.  The lung is 
the organ system most frequently affected.  Total lung pulmonary alveolar lavage has been used 
to transiently improve pulmonary function.  HS CT has been used successfully to treat both 
genetic immunodeficiency diseases and MDS/AML, the two characteristics of the patients with 
mutations in GATA2, and therefore represents a potential therapy to reverse the inevitably fatal course in these patients.
A brief case history of a patient with a GATA2 mutation illustrates the natural history of the 
disease.
JD: 33 yr old man presented in November of 2006 with disseminated histoplasmosis.  He had a 
history of pneumonias every few months for the preceding year, and a history of severe warts. 
During his 16-month hospitalization he suffered multiple pulmonary infections including 
pulmonary histoplasmosis, Neosartorya utagawa, and disseminated Mycobacterium avium.  He 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
was subsequently found to have severely reduced B-lymphocytes, natural killer (NK) cells, and 
monocytes with CD4 496, CD8 150, NK cells 0, B-cells 0, monocytes 0. In February of 2007 he 
developed myelodysplasia with 5-10 % blasts and monosomy 7 in 4-5% of metaphase spreads. By August 1997 95% of metaphase spreads di splayed monosomy 7.  While hospitalized he 
developed cerebral aspergillus a nd died in March of 2008.  His family history was significant for 
an older sister who developed an immunodeficiency at age 14 and died from disseminated zoster 
at age 17 awaiting HSCT for MDS.  The patient JD was 13 yr old at the time of his sister’s death.
Thus, patients with mutations in GATA2 succumb to either from opportunistic infection or bone 
marrow failure from MDS/AML.  Six of the 20 patients with mutations in GATA2 have died 
either from infection or progressi on to MDS and/or leuke mia.  Patient JD desc ribed above died at 
the Clinical Center in March of 2008 awaiting unrelated donor transplant for MDS.  Several of 
the current patients with mutations in GATA2 have  had first-degree relati ves die from infections 
or MDS/AML.  The biological question for pati ents with mutations in GATA2 is whether the 
individual leukocyte compartments that are lost in  this syndrome (B-lymphocytes, NK cells, and 
monocytes) will be constituted with HSCT. , 
Both autosomal dominant and sporadic cases of GATA2 mutation occurs in this syndrome.  To 
date, we have identified 12 distinct mutations in GATA2 affecting 20 patients and relatives with 
this syndrome, including recurrent missense mu tations affecting the zinc finger-2 domain 
(R398W and T354M) (Hsu et al.).  Four discrete insertion/deletion mutations leading to frame shifts and premature termination implicate haploinsufficiency as a possible mechanism of action.  
These mutations were identified in several families, indicating germ line transmission in those kindred's.  Thus, GATA2 joins RUNX1 and CEBPA not only as familial leukemia genes, but also 
as a cause of a complex congenital immunodeficien cy that evolves over decades and combines 
predisposition to infection and myeloid malignancy. 
Table 2. GATA2 Mutations Identified in MonoMAC Patients
Kindred*Patient*DNA change#Codon#Null&
1 1.II.1 c.1192 C>T R398W
1 1.II.5 c.1192 C>T R398W
2 2.II.3 c.1192 C>T R398W
3 3.I.1 c.1192 C>T R398W
5 5.II.1 c.1061 C>T T354M
8 8.I.1 c.243_244delAinsGC G81fs +
9 9.III.1 c.1192 C>T R398W
10 10.1.1 c.1113 C>G N371K
12 12.I.1 c.1083_1094del 12bp R361delRNAN
13 13.II.1 c.1-200_871+527del 2033bp M1del290 +
13 13.I.2 c.1-200_871+527del 2033bp M1del290 +
15 15.II.1 c.1186 C>T R396W
17 c.1061 C>T T354M
18 c.1187 G>A R396Q
19 c.1061 C>T T354M
20 c.778_779ins 10bp D259fs +
21 c.1192 C>T R398W
22 c. 951_952ins 11bp N317fs +
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
23 c. 751 C>T P254L
24 c. 1018-1 G>A D340-381
* - Numbering refers to patient and kindred numbers from Vinh et al. BLOOD 2010.
#- Numbering relative to adenine in the ATG start codon of GATA2 (GenBank 
NM_001145661.1) and the first methionine (GenBank NP_116027.&- Predicted to result in loss
of mRNA or protein from mutant allele. 
Figure 2. Genomic organization of GATA2 showing two 5’ untranslate d and five coding exons. 
Dark boxes indicate coding regions.  Insertion/ deletion mutations predicted to result in null 
alleles are shown above.  B. Protein domains of GATA2, showing N and C-terminal zinc fingers 
(ZF-1, ZF-2) and nuclear localization signal (N ). C. Missense and in-frame deletion mutations 
identified within ZF-2. Superscript numerals indicate number of in dependent mutations.
1.2.9 HSCT for Myelodysplasia
MDS are a heterogeneous group of clonal hema topoietic disorders characterized by impaired 
peripheral blood cell production (cyt openias) and most commonly a hypercellular, dysplastic-
appearing bone marrow (Nimer 2008).  The incidence of MDS increases with increasing age; the 
median age at diagnosis is in the seventh d ecade (Greenberg et al. 1997).  Survival after 
diagnosis varies from a few months to several years.  MDS were originally called pre-leukemia, but the term MDS replaced pre-leukemia in the 
1970’s due to the clinical observation that that many individuals with MDS succumbed to the 
effects of the cytopenias without transforming to acute myelogenous leukemia (AML) (Nimer 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
2008).  Approximately 50 percen t of patients with MDS will de velop leukemia.  Progressive 
single or multilineage cytopenias account fo r the majority of the remaining deaths.
There are a number of different prognostic syst ems developed to predic t outcomes for patients 
with MDS with the most widely utilized system  being the International Prognostic Scoring 
System (IPSS) (Greenberg et al. 1997).  The IPSS uses cytogenetics, bone marrow myeloblast 
percentage, and peripheral cytopenias to predict leukemia transformation a nd survival.  Patients 
are grouped into one of four prognostic categories: low-risk, intermediate 1 risk, intermediate 2 risk, and high risk.
In MDS cytogenetic risk groups defined by the IP SS are: good -normal isol ated –Y, del (5q), and 
deletion 20q; poor- complex >3  abnormalities, and/or any chromosome 7 anomalies; 
intermediate- all other abnormalities (Greenberg et al. 1997). In terms of frequency, deletions of 
all or part of chromosome 7 represent the second most common cyto genetic abnormality in 
MDS, next to deletions of 5q.  In a recent co mprehensive analysis correlating the cytogenetics 
with the clinical outcome in MDS, monosomy 7 as an isolated abnormality led to a median 
survival of 14 months (Haase et al. 2007).
Monosomy 7 is a characteristic cytogenetic a bnormality in acquired aplastic anemia and 
congenital neutropenia (Maciejewski et al. 200 2).  Cells lacking chromosome 7 frequently 
express a short isoform of the G-CSF receptor, and this short isoform preferentially signals 
proliferation over differentiation leading to clona l expansion in the setting of neutropenia or 
cytokine administration (Maciejewski et al. 2002).
Good prognostic factors for HSCT include: age, lo w IPSS score, short duration of disease (< 3-6
months), blast percentage < 5%, and complete  remission before transplant.  The long-term 
disease-free survival with HSCT for MDS from e ither a matched related or unrelated donor in 
patients less than 50 years old ranges from 36% for matched related donor s to 25% for matched 
unrelated donors (de Witte et al. 2001).In patients with mutations in GATA2 allogeneic HSCT represents a potential curative therapy 
for MDS.  Of particular relevance to patients with mutations in GATA2with progression to MDS, many centers are now using a reduced-intensity approach because of age and frequent co-morbidities in patients with MD S.  In a Spanish study 20 MDS patients received conditioning 
with busulfan 10 mg/kg and fludarabine 150 mg/m
2and peripheral blood stem cells from HLM-
matched related donors (Mar tino et al. 2002).  The transplant related mortality at one year was 
5%.
In one of the largest studies using reduced-intensity conditioning followed by allogeneic HSCT 
to treat 148 patients with MDS a nd MPS, patients received a cond itioning regimen consisting of 
low-dose TBI (200 cGy) alone or with fludarabine 30 mg/m2/day for 3 days, and post-grafting 
immunosuppression with CSP and MMF  (Laport et al. 2008).  Approximately one-half of the 
patients received matched related donor HSCT, and the other half received matched unrelated 
donor HSCT.  The three-year relapse-free survival and overall survival were 27% for all patients.  
Recipients of matched unrelated  donor grafts did not have higher non-relapse mortality, and 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
relapse did not constitute the leading cause of death.  These results provide support for the use of
this regimen in patients with mutations in GATA2 who also have co-morbidities. 
1.2.10 Sirolimus and Tacrolimus for GVHD Prophylaxis after HSCT
The optimal series of drugs for GVHD prophylaxis following allogeneic HSCT would include 
medications that are well tolerated with minimal side effects/toxicities, prevent GVHD, and enable engraftment without an excess rate of disease relapse.  Commonly used drugs for the prevention of GVHD after HSCT include: cycl osporine (CSP), methotrexate (MTX), and 
corticosteroids. For patients undergoing transplantation w ith either HLA matched or 
mismatched unrelated donors who are receiving reg imens of the above medi cations the incidence 
of acute GVHD has been reported being 40-70% (B eatty et al. 1985; Anase tti et al. 1990; Hansen 
et al. 1998).  In addition to incompletely su ppressing GVHD, these medications are also 
associated with a wide variety of undesirable side effects.  Due to these problems, there is a continued interest in the development of more efficacious regimens.
In recent studies the immunosuppressive agent si rolimus (Rapamycin) has been shown to prevent 
GVHD (Antin et al. 2003).  Sirolimus inhibits T-cell and dendritic cell function through 
inhibition of mTOR, which in contrast to the mRNA inhibition associated with calcineurin 
blockade, operates via a post-tran scriptional mechanism to redu ce cell signaling and modulates 
protein translation and phosphorylation (Hackstein  et al. 2003).  It appears that sirolimus 
prevents the translation of mRNAs encoding cell cycle regulators and inhibits the ability of lymphocytes to proliferate in response to IL2 (Chakraverty et al. 2002).  Sirolimus also has 
profound effects on dendritic cell func tion and survival, and this may contribute to prevention of 
GVHD (Chakraverty et al. 2002). Initial results indicate that sirolimus may be an effective agent for prevention of graft rejection and GVHD when  used in conjunction with a second agent. 
Recently, sirolimus has been used as a thir d agent for GVHD prophylaxis after genetically 
disparate transplantation (Antin et al. 2003).  Cl inical studies have not evaluated single-agent 
sirolimus for GVHD prophylaxis, and in fact, murine  data indicate that single-agent sirolimus 
potently abrogates CD8
+T cell mediated GVHD, but not CD4+T cell mediated GVHD (Blazar, 
1998).  As such, sirolimus may represent a repla cement of calcineurin inhibitor mediated GVHD 
prophylaxis.  In a study of matched sibling allotransplant in sickle cell anemia, sirolimus prevented both graft rejection and GVHD (Hsieh et al. 2009). Sirolimus was also reported to be 
well tolerated at a dosing schedule designed to maintain a level of 10, with hypertriglyceridemia 
representing the primary specific drug toxicity.
The use of tacrolimus for the suppression of GVHD has been supported by research in canine 
and murine models and pilot studies in humans (M arkus et al. 1991; Storb et al. 1993; Nash et al. 
1995; Fay et al. 1996).  Several phase III studies have prospectively compared tacrolimus to CSP 
with or without MTX in adolescent or adult pa tients undergoing related or unrelated SCT (Nash 
et al. 2000; Hiraoka et al. 2001). The incidences of grade II-IV acute GVHD were significantly 
decreased when patients were treated with tacrolimus.  The incidence of acute GVHD for 
patients receiving tacrolimus versus CSP ranged from 17.5% to 56% and 44.4% to 74%, 
respectively.  However, there was no statistically significant difference in the rate of chronic GVHD between the groups.  Data from the first two tr ials revealed that the relapse rate and OS 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
were also similar between those receiving tacrolim us and CSA.  Both trials found that tacrolimus 
was well tolerated, but was associated with increased (but transient) nephrotoxicity that resolved 
over time.  Although the third tria l supported the previous two with regards to the decreased 
incidence of acute GVHD and relapse rate, the 2-year OS was worse in the arm receiving tacrolimus than cyclosporine, 50.4% and 40.5%, respectively.  When the DFS among patients 
with no advanced disease was compared, the outcomes were similar.  
Although sirolimus and tacrolimus both bind to FKBP12, the two drugs are not competitive and 
appear to be synergistic (Stepkowski et al. 1997).  To take advantage of this synergistic effect, 
the combination of the two drugs was evaluated in a trial using myeloablative HSCT with matched related or unrela ted donors at the Dana Farber Cancer Institute (Antin et al. 2003).  In 
that study the incidence of grade II-IV GVHD wa s markedly reduced compared to historical 
controls.  
1.2.11 Interim Summary of HSCT for Patients with Mutations in GATA2
Ten patients have been enrolled on this study to date: three patients received a matched related 
donor hematopoietic stem  cell transplant (HSCT), three pa tients received matched unrelated 
donor HSCT, and four patients have received umbilical  cord transplant.  The results to date with 
HSCT for MonoMAC are summarized below.
Patient # 1: 33 yo man with R81fs mutation in GATA2 on 5 liters of oxygen from extensive 
pulmonary alveolar proteinosis received his pe ripheral blood stem cell (PBSC) transplant on 
5/12/2009.  He tolerated his conditioning regimen (Fludarabine and 200cGY TBI) well.  He 
engrafted within two weeks of transplant a nd was discharged from the hospital within one 
month of transplant. He is now 24 months from transplant with a normal hematocrit, white blood cell count, and platelet count. He now ha s normal levels of m onocytes, NK cells, and B-
cells. His donor lymphoid chimerism is 100% an d his donor myeloid chimerism is 100%.  He 
had a re-admission 6 months post-transplant for chronic GVHD, which occurred when the immunosuppression was tapered. The acute GVHD re solved on corticosteroids, however he 
now has chronic GVHD.  He is now almost three years post-transplant, and off all 
immunosuppressive agents.
Patient #2: 33 yo man with R398W mutation in GATA 2 and myelodysplasia (MDS) received 
his PBSC from an unrelated donor on 8/12/2009.  He tolerated his conditioning regimen 
(Fludarabine and 200cGY TBI) well with the exception of an episode of emesis.  He engrafted 
within 14 days of HSCT and was discharged. He has had a completely unremarkable course 
since transplant.  He is now nearly two and one-half years after transplant with a normal hematocrit, white blood ce ll count, and platelet count. He now  has normal levels of monocytes, 
NK cells, and B-cells.   His most recent donor  lymphoid chimerism was 91% and his donor 
myeloid chimerism is 100% at 12 months post- transplant. The patient had no acute GVHD and 
no signs of chronic GVHD at this time.  He is off all medications.  
Patient #3: 41 yo woman with T354M mutation in GATA2 and MDS with monosomy 6. 
Following conditioning with Cytoxan 50 mg/kg, Fludarabine 150 mg/m2, and 200 cGy TBI, she 
underwent a single umbilical cord hematopoietic  stem cell transplant on December 29, 2009. The 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
cord blood unit was a 4/6 match. Chimerism on the bone marrow was 100% at day 28, 60, 100, 6 
months, 12 months and two years. Her course wa s complicated by slow engraftment requiring 
100 days.  She now is 24 months post-transplant, living at home, and requiring no transfusions. 
Both lymphoid and myeloid chimerism was 100% 18 months post-transplant. The recipient did 
not develop acute GVHD and has no signs of chronic GVHD.  
Patient #4: 23 yo woman with R396Q mutation in GATA2 and MDS with trisomy 8. 
Following conditioning with Fludarabine 90 mg/m2, and 200 cGy TBI, she underwent a 
matched unrelated donor transplant on 8/5/ 2010. She is now one and one-half years post-
transplant and was recently ad mitted for GVHD requiring immunosuppression.
Patient #5: 15 yo adolescent with D259fs mutation in GATA2 and MDS with monosomy 7. 
He received a double umbilical cord blood transpla nt in September of 2010.  His course was 
complicated by autoimmune hemolytic anemia and thrombocytopenia and nephrotic syndrome. 
He is now one and one-half years post-transplant and has returned to school.  He is on no immunosuppressant.
Patient #6: 26 yo man with R361delRNAN in GATA2 alon g with fibrotic liver injury, and 
MDS with monosomy 7 who died of sepsis 5 days after double cord blood transplant. 
Patient #7: 41 yo woman with mutation in GATA2 a nd MDS who received conditioning with 
Fludarabine 90 mg/m2, and 200 cGy TBI followed by a matched relate d donor transplant on 
12/14/2010. She has had an uncomplicated course, however at one-year post-transplant she as 
found to have recurrence of her cytogenetic abnormality.
Patient #8: 26 yo woman with a 318fs mutation in GATA2 and MDS with primary graft failure 
after double umbilical cord blood transplant. She received a haplo/cord transplant on April 28, 
2011 and engraftment primarily with haploidentical cells. She died 8 months post-second 
transplant from septic shock from Klebsiella pneumonia.
Patient #9: 32 yo Hispanic man with a T354M mu tation in GATA2 and MDS received a 
matched related donor HSCT.  He engrafted on day 14 and ha s now returned home.  He is now 
more than 100 days post-HSCT.Patient #10: 39 yo woman with an N371K mutation in GATA2 and MDS who received a 
matched unrelated donor transplant over 100 days ago. She had engraftment within 14 days and 
has had no re-admissions. She has returned home.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT
2.1 I NCLUSION CRITERIA -RECIPIENT
a) Patient age of 12-60 years.
b) Mutation in the GATA2 gene performe d by the CLIA certified laboratory 
c) Clinical history of at least two episodes of life-threatening infection d Available 10/10 HLA-
matched related donor, 10/10 or  9/10 matched unrelated donor, 4/6 (or greater) matched 
umbilical cord blood (UCB) unit(s) with a total dose of greater than or equal to 3.5 x107
TNC/kg, or a haploidentical donor.
e) Patients may have evidence of  MDS with one or more periphera l blood cytopenias and greater 
than 5% blasts but less than 10% blasts in the bone marrow in the absence of G-CSF .
Patients previously treated for acute myelogenous leukemia are eligible if  they have less than
or equal to 5% blasts in the bone marrow in the absence of G-CSF. Subjects 12-17 years of 
age are required to have MDS with chromosoma l abnormalities in additi on to mutation in the 
GATA2 gene for enrollment on this protocol.  
f) Left ventricular ejection fraction > 50%, preferably by 2-D echo, or by MUGA, or shortening 
fraction > 28% by ECHO, obtained within 28 days of enrollment  
g) Pulmonary Function Tests:  Adult patients:  Corrected DLCO diffusion capacity and FEV1 > 
10% of expected value obtained within 28 days of enrollment.  Pediatric patients:  DLCO corrected for hemoglobin and alveolar volume > 20% of predicted.  
h) Creatinine: Adult patients:  < 2.0 mg/dl and creatinine clearance > 30 ml/min; Pediatric 
patients:  age-adjusted normal serum creatinine (see Table below) OR a creatinine clearance > 60 mL/min/1.73m
2.
ge (years) aximum Serum Creatinine (mg/dl)
8
< age < 10 0
< age < 15 2
5 5
d) Serum tRWDOELOLUXELQPJGOVHUXP$/7DQG$67WLPHVXSSHUO LPLWRIQRUPDO
e) Adequate central venous access potential.f) Written informed consent/assent obtained from patient/parent or legal guardian.g) Life expectancy of at least 3 months but less than 24 months.h) Disease status: Patients are to be referred in remission for evaluation. Should a patient have 
progressive disease or a donor not be availabl e after enrollment, the patient will be referred 
back to their primary hematologist-oncologist for treatment. If this course of action is not in the best interest of the patient according to the clinical judgment of the PI/LAI, then the patient may receive standard treatment for the malignant disease under the current study. If 
under either of these settings, it b ecomes apparent that the patient will not be able to proceed 
to transplant, then he/she must come off study. Recipient-Subjects receiving a standard therapy will be told about the therapy, associated  risks, benefits altern atives of the proposed 
therapy, and availability of receiving the same  treatment elsewhere, outside of a research 
protocol. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
2.2 E XCLUSION CRITERIA -RECIPIENT 
a) HIV infection. 
b) Chronic active hepatitis B. Patient may be hepatitis B core antibody positive.  For patients 
with a concomitant positive hepatitis B surface antigen, patients will require a hepatology consultation.  The risk-benefit profile of transplant and hepatitis B will be discussed with the 
patient, and eligibility determined by the PI and the protocol chairperson
c) History of psychiatric disorder which may co mpromise compliance with transplant protocol, 
or which does not allow for appropriate informed consent. 
d) Active infection that is not responding to antimicrobial therapy.e) Active CNS involvement by malignancy (patients with known positive CSF cytology or 
parenchymal lesions visible by CT or MRI). 
f) Pregnant or lactating. g) Sexually active individuals capable of becoming pregnant who are unable or unwilling to use 
effective form(s) of contraception during time enrolled on study and for 1 year post-transplant.  Effective forms of contracep tion include one or more of the following: 
intrauterine device (IUD), hormonal (birth control pills, injections, or implants), tubal ligation/hysterectomy, partner’s vasectomy,  barrier methods, (condom, diaphragm, or 
cervical cap), or abstinence.  The effect s on breast-milk are also unknown and may be 
harmful to the infant; therefore, women should not breast feed during the interval from study 
entry to one year post-transplant.  Males on the protocol must use an effective form of 
contraception at study entry, and for one year post-transplant.  The effects of transplant, the radiation, and the medications used after transplant may be harmful to a fetus.
h) Presence of active malignancy in another organ system other than the hematopoietic. 
No available 10/10 HLA-matche d related donor,9/10 or 10/10 ma tched unrelated donor,  4/6 
(or greater) matched UCB unit(s) with a total dose of greater than or equal to 3.5 x10
7
TNC/kg, or haploidentical donor.
i) Lack of mutation in GATA2 as demonstr ated by the CLIA certified laboratory
2.3 I NCLUSION CRITERIA -MATCHED RELATED DONOR 
a) Related donor matched at HLA-A, B, C, DR, an d DQ loci by high resolution typing (9/10 or 
10/10 antigen/allele match) are accep table donors (Maris et al. 2003).
b) Matched related donors for pediatri c recipients must be 18 years of age or older.  If more 
than one matched related donor is available, we will select  the oldest donor to further 
decrease the risk of potential disease transmission.
c) Ability to give informed consentd) Age 18-60 yearse) No history of life-threatening opportunistic infection f) Adequate venous access for pe ripheral apheresis, or consen t to use a temporary central 
venous catheter for apheresis.
g) Donors must be HIV negative, hepatitis B surf ace antigen negative, and hepatitis C antibody 
negative.  This is to prevent the possible tran smission of these infections to the recipient.
h) A donor who is lactating must be willing and ab le to interrupt breast-feeding or substitute 
formula feeding for her infant during the period of filgrastim administration and for two days following the final dose. Filgrastim may be secreted in human milk, although its bioavailability from this source is not known. Limited clinical data su ggest that short-term 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
administration of filgrastim or sargramostim to neonates is not associated with adverse 
outcomes (Bernstein et al. 2002).
2.4 I NCLUSION CRITERIA -MATCHED UNRELATED DONOR
a) Unrelated donor matched at 10/10 or 9/10 HLA- A, B, C, DRB1, and DQB1 loci by high 
resolution typing (Maris et al. 2003).
b) Matched unrelated donors for pe diatric recipients must be  18 years of age or older.
c) The evaluation of donors shall be in accordance with existing NMDP Standard Policies and 
Procedures. General donor inclusion criteri a specified in the NMDP Standards (19thEdition, 
Appendix F). 
2.5 I NCLUSION CRITERIA -HAPLOIDENTICAL RELATED DONOR
a) A haploidentical donor that sh ares one haplotype in common with the recipient such that 
HLA compatibility will be a minimum of 5 out of 10 HLA loci matched. The HLA loci to be tested will be HLA A, B, Cw, DRB1, and DQB1. A minimum number of mismatches is desirable; however if several options are ava ilable the selection of a donor will be based on 
the loci where the mismatch occurs and the relative importance of its potential immunological function. Donor-recipient pairs will initially be typed molecularly to provide 
a low resolution typing (antigen-level) to aid in the selection of the potential donor. Upon 
review of the familial inheritance pattern, a qualified HLA staff member will review haplotype inheritance. High resolution (allele-level) typing will be performed. Final selection of a donor will be in consultation with NCI ph ysicians and qualified HLA 
personnel. Haploidentical related donors for pediatric recipien ts must be 15 years of age or 
older.  If more than one haploidentical relate d donor is available, we will evaluate each donor 
individually according to overall health, AB O matching, CMV, etc. to select the donor
b) Age 15-60 yearsc) No history of life-threatening opportunistic infection d) Adequate venous access for pe ripheral apheresis, or consen t to use a temporary central
venous catheter for apheresis.
e) Donors must be HIV negative, hepatitis B surf ace antigen negative, and hepatitis C antibody 
negative.  This is to prevent the possible tran smission of these infections to the recipient.
f) Haploidentical donors will undergo marrow harves t with general anesthesia.  Subjects will 
undergo anesthesia consultation, and meet criteria for eligibility/enrollment. CD34+ fraction will be determined.  
g) Subjects will also undergo the Donor Health Hi story Screen to determine donor eligibility 
using standard DTM criteria in the Dowling Apheresis Clinic by skilled staff in the Blood Services Section for adult patients and age- appropriate questioning when indicated for 
pediatric subjects.  
h) Subjects will undergo follow-up history and phys ical examination within 1 week of donation. 
2.6 E
XCLUSION CRITERIA -MATCHED RELATED DONOR
a) Age less than 18 years.b) HIV infectionc) Chronic active hepatitis B.  Donor ma y be hepatitis core antibody positive. 
d) History of psychiatric disorder which in the opinion of the PI may compromise compliance 
with transplant protocol , or which does not allow for appropriate informed
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
e) History of hypertension that is not controlled by  medication, stroke, or severe heart disease.  
Individuals with symptomatic angina will be considered to have severe heart disease and will 
not be eligible to be a donor.
f) Other medical contraindicati ons to stem cell donation (i.e . severe atherosclerosis, 
autoimmune disease, iritis or episcleritis, deep  venous thrombosis, cerebrovascular accident) 
(Anderlini et al. 1997).
g) History of prior malignancy. However, can cer survivors who have undergone potentially 
curative therapy may be considered for st em cell donation on a case-by-case basis. The 
risk/benefit of the transplant and the possibility of transmitting viable tumor cells at the time of transplantation will be discussed with the patient.
h) Donors must not be pregnant.  Pregnancy is an  absolute contraindication under this protocol. 
The effects of cytokine administration on a fetus are unknown. Donors of childbearing 
potential must use an effective method of c ontraception. Effective forms of contraception 
include one or more of the following: intrau terine device (IUD), hor monal (birth control 
pills, injections, or implants), tubal ligation/hysterectomy, partner’s vasectomy, barrier 
methods, (condom, diaphragm, or ce rvical cap), or abstinence.  
i) Thrombocytopenia (platelets less than 150,000 per Pl) at baseline evaluation.
j) Donors receiving experimental th erapy or investigational agents.
k) Sensitivity to filgrastim or to E. co li-derived recombinant protein products.
l) History of autoimmune disorders, with  the exception of thyroid disorders  
m) History of documented deep vein thrombosis or pulmonary embolism
n) Mutation in GATA2
2.7 E
XCLUSION CRITERIA -MATCHED UNRELATED DONOR 
Failure to qualify as an NMDP donor as described in Appendix F.2.8 E
XCLUSION CRITERIA -HAPLOIDENTICAL DONOR
a) Age less than 15 years.
b) HIV infectionc) Chronic active hepatitis B.  Donor ma y be hepatitis core antibody positive. 
d) History of psychiatric disorder which in the opinion of the PI may compromise compliance 
with transplant protocol , or which does not allow for appropriate informed
e) History of hypertension that is not controlled by  medication, stroke, or se vere heart disease.  
Individuals with symptomatic angina will be considered to have severe heart disease and will not be eligible to be a donor.
f) Other medical contraindicati ons to stem cell donation (i.e . severe atherosclerosis, 
autoimmune disease, iritis or episcleritis, deep  venous thrombosis, cerebrovascular accident) 
(Anderlini et al. 1997).
g) History of prior malignancy. However, cancer  survivors who have undergone potentially 
curative therapy may be considered for stem cell donation on a case-by-case basis. The risk/benefit of the transplant and the possibility of transmitting viable tumor cells at the time of transplantation will be discussed with the patient.
h) Donors must not be pregnant.  Pregnancy is an  absolute contraindication under this protocol. 
The effects of cytokine administration on a fetus are unknown. Donors of childbearing 
potential must use an effective method of c ontraception. Effective forms of contraception 
include one or more of the following: intrau terine device (IUD), hor monal (birth control 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
pills, injections, or implants), tubal ligation/hysterectomy, partner’s vasectomy, barrier 
methods, (condom, diaphragm, or ce rvical cap), or abstinence.  
i) Thrombocytopenia (platelets less than 150,000 per Pl) at baseline evaluation.
j) Donors receiving experimental th erapy or investigational agents.
k) Sensitivity to filgrastim or to E. co li-derived recombinant protein products.
l) History of autoimmune disorders, with  the exception of thyroid disorders  
m) History of documented deep vein thrombosis or pulmonary embolismn) Mutation in GATA2
2.9 I
NCLUSION CRITERIA -UMBILICAL CORD BLOOD UNIT-HLA T YPING AND DOSE
a) At least an HLA UCB 4/6 match (Class I-A, B by low resolution, and Class II-DR by high 
resolution) to recipient.  The following algorithm will be applied to determine if patient will 
receive single or double umbilical cord graft: 
b) For Single UCB SCT:
xIf 6/6 match the unit must have > 3 x 107nucleated cells /kg of recipient body weight.
xIf 5/6 match the unit must have > 4 x 107 nucleated cells /kg of recipient body weight.
xIf 4/6 match the unit must have > 5 x 107 nucleated cells/kg of recipient body weight. 
Recipient body weight will be determined as per standard guidelines.
c) If no single UCB with the above character istics is available, a double UCB will be 
considered.  Units will be selected with the following criteria:
xBoth units will be at least 4/ 6 match (Class I-A, B by low resolution, Class II-DR by high 
resolution) to recipient, and should be at  least a 4/6 match (Class I-A, B by low 
resolution, Class II-DR by high resolution) to each other.
xAt least one UCB will have a minimum cell dose of 2.0 X 107TNC/kg of recipient body 
weight.  
xThe minimum combined dose of both units must be at least 3.5 x 107TNC/kg of recipient 
body weight.
xThe smaller of the two units (UCB 2) will have a minimum of 1.5 X 107TNC/kg of 
recipient body weight. 
xThe TNC of non-RBC reduced units will be dose corrected by -25% to allow for cell loss 
while washing the unit. 
2.10 R EVIEW OF UCB U NIT HLA T YPING AND SELECTION OF THE UCB U NIT
a) Single UCB SCT: First preference will be given to cell dose, as long as the UCB units are 4/6 
matches or greater.  Second preference will be given to HLA matching (e.g. if two units have 
the same cell dose, the unit with a better HLA match will be selected).  Priority will be given to Class II matched units.  
b) Double UCB SCT: First preference will be give n to cell dose, as long as the UCB units are 
4/6 matches or greater.  Second preference w ill be given to HLA ma tching (DR matching 
will be preferred over Class I matching) (e.g. if two units have the same cell dose, the unit with a better HLA match will be selected).  In  double UCB SCT, the units should be at least 
a 4/6 HLA match or greater to the recipient, and at least a 4/6 HLA match to each other. The matching between the UCB units and recipient, and UCB units to each other can be at different loci.  Dr. Hickstein or his delegate will review all HLA typing on the patient and potential cord units.  High-resolution HLA typi ng will be reviewed, and, if necessary, an 
aliquot of the cord unit will be retyped as per st andard practice.  After review of the typing, 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
the cord unit(s) will be requested and will be at the DTM Laboratory prior to the start of the 
conditioning therapy. 
2.11 R ECIPIENT RESEARCH ELIGIBILITY EVALUATION 
The following clinical, laboratory, and radiologic al assessment must be performed in the patient 
(recipient) within 28 days before the recipi ent signs the consent form (unless otherwise 
specified)a) Complete medical history and physical examination.
b) Antibody screen for hepatitis A, B, and C; HIV, T.Cruzi (Chagas agent), HTLV-I/II, CMV, 
adenovirus, EBV, HSV, Toxoplasmosis, and syphilis.
c) PPD test (in recipients considered to be in a high-risk group).d) The following should be obtained at initial scr eening and also within 48 hours before starting 
induction chemotherapy:
xCBC with differential, PT , and PTT, and ABO typing
xAcute care panel, hepatic panel,  mineral panel, and lipid profile
xUrine EHCG in women of childbearing potential
e) Urinalysis and 24 hour urine collection (fo r determination of creatinine clearance).
f) CT scans of head, sinus, chest, abdomen, and pelvis.
g) Cardiac 2-D Echo or MUGA exam.h) Pulmonary Function Test, including DLCO measurement.i) Bone marrow aspiration and biopsy; flow cytometry, cytogenetics, and molecular studies 
(within 60 days of signing consent, unless clinically indicated).
j) All biopsy specimens will be reviewed by the Laboratory of Pathology/CCR/NCI, for 
confirmation of the histological diagnosis prior to enrollment on study.
k) Lymphocyte phenotyping panel (T, B, NK). l) Serum troponin. m) Lipid profile with triglycerides.n) MRI scan of the head if there is clinical suspicion of CNS disease.o) Radiation Oncology Consult (within 28 da ys of initiating conditioning chemotherapy).
2.11.1 Recipient (perform within 90 days befo re initiation of conditioning chemotherapy)
a) Nutritional assessment (initial consult).b) Social work consultation. c) Electrocardiogram.
2.11.2 Recipient (perform within 6 months before initiation of conditi oning chemotherapy)
a) Dental consultation to assess need  for teeth cleaning or removal.
2.11.3 Recipient pre-transplant evaluation (per form any time before initiation of induction 
chemotherapy)
a) Typing for HLA-A, -B, -C, and DR.
PCR test of DNA mini-satellite regions fo r future determina tion of chimerism.
2.12 M
ATCHED RELATED DONOR AND HAPLOIDENTICAL DONOR RESEARCH ELIGIBILITY 
EVALUATION
2.12.1 Donor Research Evaluation (perform any time before in itiation of induction 
chemotherapy)
a) Typing for HLA A, B, C, DR, DQ.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
b) PCR test of DNA mini-satellite regions fo r future determina tion of chimerism.
2.12.2 Donor Research Evaluation (perform within 90 days of signing consent)
a) Complete medical history and physical examination.
b) Antibody screen for hepatitis A, B, and C; HIV, HTLV-I/II, CMV, adenovirus, EBV, HSV, 
Toxoplasmosis, T. cruzi (Chagas agent), and syphilis.
c) CBC with differential, PT, and PTT, and ABO, Rh typing.
d) Acute care panel, hepatic  panel, and mineral panel.
e) Urinalysis. 
f) Urine E-HCG in women of childbearing potential.
g) Chest radiograph.
h) Electrocardiogram.i) Screening for Hb S. j) Lymphocyte phenotyping panel (T, B, NK). 
2.13 U
NLICENSED CORD BLOOD UNITS
There is a new federal requirement for li censing UCB units. In October, 2009, the FDA 
released licensure guidance for UCB which outlines how a cord blood bank can apply for 
licensure of UCB units. If the unit meets the criteria for licensure, then that unit can be distributed as a licensed produc t. However, starting October 20, 2011, units that do not meet 
the requirements are considered "unlicensed" and can only be distributed for transplant under an 
IND.
For those patients whose best cord blood option is  an unlicensed unit, the unit will be obtained 
under an IND which allows access to unlicensed cord blood units. For ease of access, the 
NMDP has developed a protocol  through which most unlicensed CBUs may be obtained. The 
corresponding NCI protocol number is 12-C-0027. Pa tients will be consented and signed on to 
this protocol, unless their CB is obtained from a non-participating cord  blood bank. Unlicensed 
CBs from non-participating cord blood banks will be  obtained through a single patient IND if 
deemed appropriate by the PI, or through the bank’s own IND protocol, which will be submitted to the NCI IRB for review.
2.14 P
ATIENT REGISTRATION
a) Protocol “entry date” is considered to be the day that the informed consent form has been 
signed by the recipient and donor (matched re lated donor, when appli cable) OR confirmation 
from the NMDP that the requested donor is avai lable (unrelated donor),  meets the inclusion 
criteria, and has signed the intent  to donate form.  The treatment start date is considered to be 
the day the recipient begins his/her conditioning regimen.
b) Authorized staff must register an eligible candidate with Central Registration Office (CRO) 
no later than 24 hours after the patient (recipient)  has signed an informed consent form.  The 
patient may not sign consent before the ma tched unrelated donor has been identified and 
cleared by NMDP and the patient has been deter mined to be eligible, OR the patient may not 
sign consent before the matc hed related donor has been iden tified and has signed consent 
(when applicable).  The patient will not be registered before she/he has signed consent and confirmation from the NMDP that the donor has signed consent.  The patient and matched 
related donor (when applicable) must be regist ered prior to beginning this study.  A 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
registration Eligibility Checklist is available from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) for NCI patients and must be 
completed and faxed to 301-480-0757.  After confirmation of  eligibility at Central 
Registration Office, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol.  For questions regardin g registration authorized staff should call 301-
402-1732 between the hours of 8:30 a.m. and 5: 00 p.m., Monday through Friday.  Voicemail 
is available during non-business hours.
2.14.1 Off-Study Procedure: Authorized staff must notify Central Registration Office (CRO) when a patient is taken off-study. An off-study form from the web site ma in page must be comp leted and faxed to 301-480-
0757. The website is: http://home.ccr.cancer.gov/intra/eligibility/welcome.htm )
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
3 STUDY IMPLEMENTATION 
3.1 S TUDY DESIGN
10/10 HLA 
Matched Related 
Donor Mutation in GATA2 +/- MDS, General Eligibility Except Donor Type Confirmation
No10/10 HLA 
Matched Unrelated 
Donor9/10 HLA Matched 
Unrelated Donor, orHaploidentical Donor, or 6/6, 5/6 or 4/6  Matched Umbilical Cord Blood No
Yes,
Eligible
Preparative Regimen for 10/10 MRD and 10/10 URD
1) Fludarabine 30 mg/m2per day, IV, Days -4, -3, -2
2) Total Body Irradiation (TBI) 200 cGy, Day -1
Preparative Regimen for 9/10 URD
1) Fludarabine 30 mg/m2per day, IV, Days -4, -3, -2
2) Total Body Irradiation (TBI) 300 cGy, Day -1
Preparative Regimen for Haploidentical Donor
1) Fludarabine 30 mg/m2per day, IV, Days -6, -5, -4, -3, -2
2) Total Body Irradiation (TBI) 300 cGy, Day -1
3) Cyclophosphamide 14.5 mg/kg IV, Days -6, -5
Preparative Regimen for UCB
1) Fludarabine 40 mg/m2per day, IV, Days -6, -5, -4, -3, -2
2) Cyclophosphamide 50 mg/kg on Day -63) Total Body Irradiation (TBI) 200 cGy, Day -14) Equine ATG 30mg/kg IV on Days -6, -5, -4 (3 doses total)
Allogeneic HSC Transplantation
1) Mobilized PBSC (Day 0); > 5 x 106CD34+ /kg if Matc hed Related or Unrelated Donor 
> 3.5 v 105TNC/kg if UCB, and > or equal to 350 x106 TNC/kg.2). Sirolimus from  Day -2
tapering at Day +1803) Tacrolimus 0.02 mg/kg continuous IV infusion from Day -3 tapering at Day +180.4) For Haploidentical Donors Cyclophophamide 50 mg/kg IV on days +3 and +4, and 
Sirolimus and Tacrolimus from day +5 tapering at day +180. 
Figure 3. Protocol schematic.  NoIneligible
Yes,
EligibleYes,
Eligible
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
3.1.1 Donor Stem Cell Mobilization and Collection 
a) Matched related and unrelated donors will receive filgrastim as  an outpatient for stem cell 
mobilization at a dose of 10 Pg/kg/day by subcutaneous injection.  Doses can be rounded to 
vial sizes (300 mcg and 480 mcg) according to NMDP standards.  The dose should not 
exceed 1200 Pg/day, and the volume per injection site  shall not exceed 2.0 ml.  Filgrastim 
will be administered upon awakening in the morning.  The fifth dose should be given at least 
one hour prior to apheresis. 
b) Apheresis will typically start on the fifth day of filgrastim administration and 15-25 liters will 
be processed daily based on: (1) donor pre-aphe resis circulating CD34 ce ll count in related 
donors undergoing apheresis in DTM, or (2) r ecipient weight for unrelated NMDP donors. 
(Table 3).  The target cell dose will be > 5 x 106CD34+ cells/kg-recipient weight. 
c) Whole blood apheresis will be performed via a 2-armed approach or a temporary central 
venous catheter in the femoral position using th e Baxter CS3000Plus, Cobe Spectra, or an 
equivalent instrument (typi cally 4 to 6 hour procedure). 
d) The apheresis procedure will use ACD-A anti-coagulant or heparin at the discretion of the 
DTM physician.
Table 3 - Blood Volume Processed in Relation to Recipient Weight
Recipient 
Weight 
(kg)Volume Processed 
(L)Procedure
<3 5 12 Single 12 liter apheresis.
36 – 45 15 Single 15 liter apheresis.
46 – 55 18 Single 18 liter apheresis or two 12 L 
aphereses.
56 – 65 22 Single 22 liter apheresis or two 12 liter 
aphereses.
> 65 24 Single 24 liter apheresis or two 12 liter 
aphereses.
e) For related donors, PBSC will be  processed, cryopreserved, and stored in liquid nitrogen 
until the day of transplant upon delivery to th e NIH Department of Transfusion Medicine 
(DTM).  Donor cells from unrelated donors wi ll be used without cryopreservation under 
routine circumstances. 
f) The concentration of CD34+ cells in the ap heresis product will be determined by flow 
cytometry, and the number of CD34+ cells in each cryopreserved bag calculated. 
g) Matched related donors w ill be evaluated clinically followi ng apheresis, and they will be 
seen in the day hospital for follow-up one day following the apheresis.  The nurse practitioner or physician assistant covering the Day Hospita l will conduct this evaluation.
3.1.2 Cord Blood Collection:
The cords will be obtained from qualified cord blood banks through the NMDP. The cordswill be scheduled for shipping in order to arrive 1 week prior to the patient beginning the transplant conditioning regimen. They will remain frozen until ready for use. If the cord has an attached segment, the segment will be sent to the HLA lab where DNA will be extracted 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
from the segment for HLA confirmatory typing. The DNA will be shared with the 
Chimerism Lab who will use it to develop the STR profile for later use. If there is more than one segment, the second segment will be used to check viability of the cord. This will be done using 7-AAD which is a flow cytometric ma rker which separates viable from apoptosed 
cells. Note: The viability of the segment does not  necessarily correlate with the viability of 
the cord unit. The number and type of available cord blood specimens vary by bank, collection date and typing histor y. Viable cell aliquots and spot cards may also be used for 
HLA testing and STR analysis. Once they are thawed, the cords will be diluted 1:1 with a dextran/HSA mix and transferred to a larger bag. From that bag, CBC, nucleated cell count, colony forming units, flow cytometry, and sterility will be sent. This volume should total about 1.5 mL. After the CBC is 
done, the concentration of cells  will be known and the number of  cells can be calculated. If 
the unit did not have a detached segment, HL A testing and the STR pr ofile will be done from 
this sample. The viability will be repeated on the diluted cord unit.  
3.1.3 Haploidentical Donor Bone Marrow Harvest
a)  Haploidentical donors will undergo marrow harv est with general anesthesia.  Subjects will 
undergo anesthesia consultation, and meet criteria for eligibility/enrollment. CD34+ fraction 
will be determined.  Subject s will also undergo the Donor Health History Screen to 
determine donor eligibility using standard DTM criteria in the Dowling Apheresis Clinic by 
skilled staff in the Blood Services Section for adult patients and age-appropriate questioning 
when indicated for pedi atric subjects.  Subjects will undergo follow-up history and physical
examination within 1 week of donation.  The target dose is > or equal to 3.5 x 10
8total 
nucleated cells per kilogram.  Of this product,  5 million total donor nucleated cells will be 
reserved for biologic studies and go to the clinical core of ETIB (Bldg 10, Room 12C-216,
301 402 3627. Cell selection will not be pe rformed on the HSC grafts.     
3.1.4 Transplant Procedure (Day 0)a) On day 0, the patient will receive fresh or cryopreserved peripheral blood stem cells from an 
HLA-matched related or unrelated donor, um bilical cord blood units, or fresh or 
cryopreserved haploidentical donor bone marro w. The cryopreserved PBSC product will be 
thawed and immediately administered int UDYHQRXVO\7KHWDUJHWGRVHRIWKH3%6&LV[
10
6CD34+cells per kg.  If the collection exceeds 5 x 106CD34+cells per kg, the PI will 
decide if greater than 5 x 106CD34+cells per kg will be infused.  The target dose for 
haploidentical bone marrow is > 3.5 x 108 nucleated cells/kg recipient body weight. 
b) Approximately 5 x 106donor total nucleated PBSC will be  reserved for Dr. Fran Hakim 
(Bldg. 10, Room 12C-216, Tel 301-402-3627). 
3.1.5 Determination of Engraftment 
a) Neutrophil Recovery: Designated by the firs t of 3 consecutive days with an ANC above 
500/mm3.
b) Platelet Recovery: Designated by the first of 7 days where the platelet count remains above 
20,000/mm3 without transfusion support.
c) Sustained Donor Engraftment: Neutrophil re covery associated with complete donor 
chimerism at day 100.  Any patient who dies  before day 28 will not be evaluated for 
engraftment.
d) Primary Graft Failure: Failure to  achieve sustained donor engraftment
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
e) Secondary Graft Failure:  Documented su stained donor engraftment as defined above 
followed by:  1) severe neutropenia (ANC < 500/mm3) and bone marrow biopsy revealing a 
cellularity of less than 25% or 2) absen ce of donor cells in the marrow or blood as 
demonstrated by a chimerism assay without subsequent improvement occurring either 
spontaneously or after growth factor treatme nt.  Improvement is defined as ANC > 500/mm3
consistently.  Severe neutr openia with marrow cellularity > 25% is not secondary graft 
failure.
f) Aplasia: Less than 5% marrow cellularity as measured on bone marrow biopsy. 
3.1.6 Complication of Mixed Chimerism or  Persistent/Progressive Disease
a) Donor Lymphocyte Infusion: Patients with pe rsistent or progressive MDS post-HSCT, or 
mixed chimerism that does not improve after ta pering or discontinuing immune suppression 
may be eligible to receive donor lymphocytes (donor lymphocyte infusion, or “DLI”) or G-
CSF mobilized DLI if they can be obtained from the donor.  Additional lymphocytes will be collected by apheresis from the patient’s stem cell donor, either in steady state (i.e. no donor therapy) or after filgrastim.  DLI or mobilized DLI may be administered alone or after 
chemotherapy.
b) DLI may be sequentially administered for mixed chimerism or progression of the MDS at 
doses 1 -10 x 10
6CD3+T cells per kg. Recipients with mixed chimerism or progression of 
MDS will receive DLI consisting of unmanipulated donor T cells.  
c) Alternatively, in cases where additional donor  stem cells are desired, the donor product may 
be administered without lymphocyte purification.  
d) Recipients with mixed chimerism at day + 30 will undergo repeat chimerism assessment at 
day +60 and every 30 days thereafter as deemed necessary.  If there is persistent mixed 
donor-recipient chimerism (< 95% donor chime rism on whole blood, lymphoid, or myeloid 
subsets), recipients without Grade 2 or high er GVHD, patients will be eligible to receive 
DLI.  DLI may be repeated every 4 weeks wi th dose escalation as indicated above, until 
donor chimerism > 95% is achieved or until GVHD develops. 
e) Recipients with progression of MDS and without Grade 2 or higher GVHD will be eligible to 
receive DLI every 4 weeks with dose escalati on as indicated above, until donor chimerism > 
95% is achieved or until GVHD develops. 
f) In addition to DLI, patients with persistent or  progressive disease may be offered therapy on 
other NCI protocols. Alternativel y, persistent or progressive di sease may be treated with any 
approved therapy thought to be in the best in terest of the patient including chemotherapy, 
radiation therapy, or monoclonal antibody therapy.
3.2 D RUG ADMINISTRATION
3.2.1 Transplant Conditioning Regimen for 10/10  Matched Related Donor  or a 10/10 Matched 
Unrelated Donor Transplant
a) Central line access will be required prior to the start of the preparative regimen, and a triple 
lumen Hickman catheter is recommended, however clinical determination for the most appropriate line type and placement will be made on a case-by-case basis.
b) Conditioning Regimen with 200 cGy TBI and Fludarabine for 10/10 matched related and 
10/10 matched unrelated donor transplant.  If anesthesia is required in pediatric patients, an additional consent will be obtained for TBI anesthesia.
Agent Dose Days
Fludarabine 30 mg/m2per day Transplant Days –4, -3, -2
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
IV infusion over 30 
min, daily for 3 days
Total body Irradiation 200 cGy Transplant Day -1
c) The dose of Fludarabine will be dose adjusted for renal dysfunction. For Creatinine 
Clearance of 30-70 mL/min/1.73m2, there will be a 20% dose reduction. If the Creatinine Clearance is less than 30mL/min/1.73m2, Fl udarabine will not be administered.  
3.2.2 Transplant Conditioning Regimen for 9/10 Matched Unrelated Donor Transplant
a) Central line access will be required prior to the start of the preparative regimen, and a triple 
lumen Hickman catheter is recommended, however clinical determination for the most appropriate line type and placement will be made on a case-by-case basis.
b) Conditioning Regimen with 300 cGy TBI an d Fludarabine for 9/ 10 matched matched 
unrelated donor transplant.  If anesthesia is required in pediatric patients, an additional 
consent will be obtained for TBI anesthesia.
c) The dose of Fludarabine will be dose adjusted for renal dysfunction. For Creatinine 
Clearance of 30-70 mL/min/1.73m2, there will be a 20% dose reduction. If the Creatinine 
Clearance is less than 30mL/min/1.73m2, Fl udarabine will not be administered.
Agent Dose Days
Fludarabine 30 mg/m2per day
IV infusion over 30 min,daily for 3 daysTransplant Days –4, -3, -2
Total body Irradiation 300 cGy Transplant Day -1
3.2.3 Transplant Conditioning Regimen for Ha ploidentical Related Donor Transplant
a) Central line access will be required prior to the start of the preparative regimen, and a triple 
lumen Hickman catheter is recommended, however clinical determination for the most appropriate line type and placement will be made on a case-by-case basis.
b) Conditioning Regimen with 200 cGy TBI and Fludarabine and Cyclophosphamide for 
Haploidentical Related Donor.  
c) The dose of Fludarabine will be dose adju sted for renal dysfunction. For Creatinine 
Clearance of 30-70 mL/min/1.73m2, th ere will be a 20% dose reduction. 
Agent Dose Days
Fludarabine 30 mg/m2per day
IV infusion over 30 min,daily for 3 daysTransplant Days -6, -5. –4, -3, -2
Cyclophosphamide 14.5 mg/kg Transplant days -6, -5
Total body Irradiation 200 cGy Transplant Day -1
3.2.4 Transplant Conditioning Regimen for Umbilical Cord Blooda) A triple lumen Hickman catheter will be placed by an interventional radiologist or surgeon at 
least 7 days before the start of the preparative regimen.
b) Conditioning with 200 cGy TBI, Fludarabine,  and Cyclophosphamide for umbilical cord 
blood transplant will occur as follows:
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Day - -6 Fludarabine 40 mg/m2IV,   Cyclophosphamide 50 mg/kg IV, Equine ATG  
30mg/kg IV
Day- -5 Fludarabine 40 mg/m2IV, Equine ATG 30 mg/kg IV
Day- -4 Fludarabine 40 mg/m2IV, Equine ATG 30 mg/kg IV 
Day- -3 Fludarabine 40 mg/m2IV
Day- -2 Fludarabine 40 mg/m2IV 
Day- -1 TBI 200 cGy 
Day 0 Cord blood transplantIf anesthesia is required in pediatric patients, an additional consent will be obtained for TBI anesthesia.
Agent Dose Days
Fludarabine 40 mg/m2per day
IV infusion over 30 min, daily for 5 daysTransplant Days -6, -5, -4, -3, -2
Cyclophosphamide50 mg/kgTransplant Day -6
Total body Irradiation200 cGyTransplant Day -1
Equine ATG 30 mg/kg IV daily 
for 3 daysTransplant Days -6, -5, -4
c) Equine ATG Instructions
1. Equine ATG will be administered at a dose of 30 mg/kg/day for 3 consecutive days (days 
-6, -5, -4) for a total dose of 90 mg/kg.  
2. Equine ATG will be infused IV over 4 hour s.  Infusion times may be extended up to 24 
hours to improve tolerance if necessary. 
3. An epinephrine Auto-Inj 0.3 mg (EpiPen) should be kept at bedside on days of equine 
ATG administration
4. Because of risk of allergic reaction to ATGAM , at least 24 hours before the first infusion 
of ATGAM, patients will be tested with an intradermal injection of 0.1 ml of a 1:1000 dilution (5 μ g horse ATG) of ATGAM in sodium ch loride injection and a contralateral 
sodium chloride injection control.  The patient should be observed every 15 to 20 min over the first hour of intradermal injection.  A local reaction of 10 mm or more with a 
wheal or erythema or both should be considered a positive test.  If there is a positive skin test, the patient will undergo ATG desensitization per standard of care guidelines or receive a 24-hour infusion of ATG.
5. Subjects will receive pre-medication prior to Equine ATG infusion consisting of:  
xOral acetaminophen 650 mg
xOral diphenhydramine 25-50 mg IV
The dosages of these drugs may be adjusted for weight based dosing if necessary 
following pediatric dosing recommendations.
Oral prednisone at 1mg/kg/day will begin on day -5 prior to the first dose of h-ATG for 
serum sickness prophylaxis, and will be continued at this dose for 10 days.  Thereafter, prednisone will be slowly tapered over the next 2 weeks until it is discontinued on day 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
+19.   Likewise, patients where it is clinically  indicated to use a shorter course or taper 
schedule will be dosed individually as clinically indicated.  Those patients who develop 
serum sickness may require a longer tapering schedule and will be dosed individually as clinically indicated.  Infusion reactions will be treated symptomatically (e.g. antiemetics, IV fluid hydration, acetaminophen, antihistamines, inhaled 
bronchodilators, and me peredine.  In cases of mode rate to severe reactions, 
hydrocortisone will be given and the infusion will be discontinued and restarted at a slower rate once the symptoms have subside d.  If a patient has a persistent severe 
infusion reaction that does not respond to meas ures to ameliorate the sings/symptoms 
associated with the infusion, the infusi on will be discontinued and further study 
participation will continue as planned with the exception that no further ATG will be administered.
d) The dose of Fludarabine will be dose adjusted for renal dysfunction. For Creatinine 
Clearance of 30-70 mL/min/1.73m
2, there will be a 20% dose reduction. If the Creatinine 
Clearance is less than 30mL/min/1.73m2, Fludarabine will not be administered.
e) Cyclophosphamide will be dosed on actual body we ight. Hydration will be carried out according 
to the NIH supportive care guidelines for the pr evention of hemorrhagic cystitis as outlined 
below. 
Background: 
Hemorrhagic cystitis (HC) is a well documented complication of cyclophosphamide therapy. The 
mechanism of cyclophosphamide-induced HC is sec ondary to bladder wall damage from contact 
with the acrolein metabolite of cyclophosphamide.  The risk of cyclophosphamide-induced HC is 
greater with high dose cyclophosphamide regimens such as those employed in hematopoetic stem cell transplant (HSCT) preparative regimens.  Routine prevention strategies including intravenous hydration, forced diur esis, and mesna are imperative to reduce the risk of HC.  This 
guideline is intended to provide a consistent approach to HC prevention in patients receiving high-dose cyclophosphamide in chemotherapy prepar ative regimens prior to HSCT at the NIH. 
Definitions: 
High-dose cyclophosphamide : There is no absolute cut off for defining a dose of 
cyclophosphamide that would necessitate an ag gressive strategy for HC prevention. 
Cyclophosphamide doses employed in HSCT prepar ative regimens at the NIH that equal or 
exceed 50 to 60 mg/kg/dose OR 1200 mg/m
2/dose should always be accompanied by the HC 
prevention strategies outlined below. 
xIntravenous hydration should be initiated at a minimum of 12 hours prior to the first dose 
of cyclophosphamide
xThe rate of intravenous infusion for hydration is 0.9% Sodium Chloride Inj with 10 mEq / 
liter of potassium chloride infused at a rate of 90 mL/m 2/hour. 
xContinue hydration until 24 hours af ter last cyclophosphamide infusion. 
xFurosemide 20mg intravenously will be given once daily - Adult Patients Only -
(preferably in the AM hours) on a schedul ed basis on the days of cyclophosphamide 
administration to maintain diuresis.  Pediatric patients may receive furosemide as 
clinically indicated at a dose of 1mg/kg up to a maximum of 20 mg. (Furosemide doses may be adjusted based on patient weight, di uretic response or othe r clinical factors; 
oMonitor intake and output closely (2 hour intervals).  Accurate documentation of 
intake and output is essentia l to make good clinical decisions regarding diuresis. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
oIf fluid intake exceeds urine output by  500 ml (10 ml/kg for pediatric patients < 
50 kg) over an 8 hour period, an additional 20 mg of furosemide (1mg/kg for 
pediatric patients up to a maximum of 20 mg) will be administered intravenously. 
Notify PI/LAI when PRN doses of furosemide are administered. 
oAdditional doses of furosemide maybe administered as needed for weight gain due to fluid retention. In general, furosemide doses should be separated by at least a four hour observation interval. 
oNotify PI/LAI if patient’s input is greater than output by 1 liter (20 ml/kg for pediatric patients < 50 kg) in an 8 hour period during cyclophosphamide 
hydration. 
oStop IV hydration (24 hours af ter last cyclophosphamide dose). 
xMESNA 
For detoxification of acrolein, the urotoxic  metabolite of cycl ophosphamide, Mesna will
be given in a dose equal to that of cyclophosphamide. Total MESNA dose should = the 
cyclophosphamide dose. Mesna will be administered as a continuous intravenous 
infusion over 24 hours on each day that cyclophosphamide is administered. The initial 
bag of mesna should be started concurrently with the start of cyclophosphamide. 
Example: For preparative regimens that  dose cyclophosphamide at 60 mg/kg/day, the 
MESNA will also be given at a dose of 60 mg/kg administered as a continuous 
intravenous infusion over 24 hours. 
The MESNA infusion should continue for a minimum of 22-24 hours after the last dose 
of cyclophosphamide. The entire MESNA dose pr escribed should be administered each 
day of cyclophosphamide therapy 
3.2.5 GVHD Prophylaxis with Sirolimus
a) Patients will receive GVHD prophylaxis with sirolimus and tacrolimus.  
b)
For recipients of matched related and unrel ated donors, and umbilical cord blood, Sirolimus 
will be administered continuously from day –2 by mouth as Rapamune tablets at an initial 
“loading dose” of 12 mg, p.o. in adults > 18 years of age. In pediatric patients >40 kg the 
loading dose will be 6 mg. In pediatric patien ts <40kg, the loading dose will be 3mg/m2. 
c) For recipients of hapl oidentical donors, Sirolimus will be administered continuously from
day +5 by mouth as Rapamune tablets at an in itial “loading dose” of 12 mg, p.o. in adults > 
18 years of age. In pediatric patients >40 kg the loading dose will be 6 mg. In pediatric 
patients <40kg, the loading dose will be 3mg/m2. 
d) Sirolimus will be administered each day in the morning.
e) From days -1 in matched related and unrel ated donor transplants, and umbilical cord 
blood transplants, and continuing post-transplant, Sirolimus dosin g will be Rapamune 
tablets, 4 mg, p.o., each day in adult patients.  In pediatric patients > 40 kg the initial dose 
will be 2 mg every 24 hours.  For patients < 40 kg, the initial dose will be 1 mg/m2.  This 
may be delayed or held during the peri-engraftment phase for severe oral mucositis or delayed platelet engraftment. Sirolimus dose s hould be adjusted to maintain a target 
therapeutic concentration of 10 ng/L  with a range of 5 to 15 ng/L. 
f) In haploidentical blood recipients Sirolimus dosing will be Rapamune tablets, 4 mg, p.o., 
each day in adult patients.  In pediatric pa tients > 40 kg the initial dose will be 2 mg 
every 24 hours.  For patients < 40 kg, the initial dose will be 1 mg/m
2.  This may be 
delayed or held during the peri-engraftment phase for severe oral mucositis or delayed 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
platelet engraftment. Sirolimus dose should be ad justed to maintain a target therapeutic 
concentration of 10 ng/L with a range of 5 to 15 ng/L
g) Sirolimus levels will be drawn on a Monday,  Thursday. For sirolimus levels, 2.5 cc of 
blood will be collected into EDTA tubes a nd analyzed at the NIH Clinical Center.
h) Because sirolimus has a long half-life (appr oximately 60 hours), si rolimus levels should 
be monitored once per week beyond day 60 until levels are undetectable.  This 
information will be informative relative to the duration of time post-transplant that individual subjects have exposure to biologically significant levels of sirolimus.
i) The total dose of sirolimus will continue w ith tapering beginning at day +180. (+/- two 
days) unless clinically indicated per PI discretion.
j) The initial Sirolimus dosing maybe adjusted if clinically indicated for known drug 
interactions that cannot be avoided.
3.2.6 GVHD Prophylaxis with Tacrolimusa) Tacrolimus will be used as the second ag ent in the immunosuppressive regimen, and in 
recipients of matched related and unrelated donors and umb ilical cord blood, Tacrolimus  
will be initiated on day -3 befo re transplant as a continuous intravenous infusion at 0.02 
mg/kg/day for a target level of 5 to 10 ng/ml
b) For recipients of haploidentical donors, Tacrolimus will be administered 
continuously from 
day +5.
c) When the patient is reliably taking oral me dications, tacrolimus will be converted to an 
equivalent oral dose using a 1:3 conversion from the IV form.  The total daily dose will be divided into two equal doses, one dose given approximately every 12 hours.
d) The total dose of tacrolimus will continue with tapering starting at day +180, unless clinically 
indicated per PI.
e) The initial Tacrolimus dosing may be adjusted if clinically indicated for known drug 
interactions that cannot be avoided.
3.2.7 GVHD Prophylaxis with Cyclophosphamid e for Haploiden tical Recipients
a) Cyclophosphamide will be used as the third agent in the immunosuppressive regimen for 
haploidentical recipients and will be given on days +3 and +4 after transplant as an infusion over 90 min. 
b) Cyclophosphamide will be accompanied by Mesna 80% of cyclophosphamide dose in 4 
divided doses on day +3, the day of high dose cyclophosphamide.
c) Tacrolimus and Sirolimus will be started on day +5 for haploidentical recipients. 
3.2.8 Post Transplant Treatment  with Filgrastim (G-CSF)
Filgrastim will be administered at a dose of 5 micrograms/kg/day IV starting on day 0 for 
matched related, unrelated, and cord  blood recipients, and on day +4 in haploidentical recipients, 
and continued until the ANC is greater than 1000 for 3 days or greater than 5000 for 1 day. 
3.3 T
REATMENT MODIFICATIONS
3.3.1 Donor Hematopoietic Stem Cell Harvest Modifications
a) The dose of filgrastim for ma tched related donor st em cell mobilization will not be changed 
from a dose of 10 Pg/kg/day by subcutaneous injection.  
b) There will be no additional dose of filgrastim if a sixth day of apheresis is performed. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
c) For apheresis an additional 12 L apheresis may be performed on day 6 if the target dose of 5 
x 106CD34_+ cells/kg is not reached on the day 5 collection.
d) If greater than 5 x 106 CD34+ cells per kg are harvested after apheresis, then no further 
mobilization or apheresis will be performed, and the patient will be eligible to receive the 
stem cell transplant with that dose of CD34+ cells. 
e) In the event that < 3 x 106 CD34+ cells per kg are harves ted, the donor will be given two 
weeks of rest, and then will be re-treated with filgrastim 8 μg/kg subcutaneously BID for five 
days followed by repeat blood stem cell harvesting.
f) If the donor stem cells are cryopreserved, th e apheresis product will be cryopreserved in 
Plasmalyte A, Pentastarch, human serum al bumin, DMSO, and preservative free heparin 
(10U/ml). In the event that unrelated donor cells are to be collected and cryopreserved prior 
to transplant, permission will be obtained from the NMDP.
g) If an ABO incompatibility exists between th e donor and patient, the donor erythrocytes will 
be removed from the graft in the cell-proce ssing laboratory, according to standard DTM 
operating procedures.
h) Bone marrow may also be obtained from the donor if conditioning has already begun and the 
PBSC collection is not to be carried out or results in a suboptimal collection. 
3.3.2 Transplant Treatment Modificationa) If donor apheresis on days 5, 6, and 7 yields a to WDORI[
6CD34+cells per kg, this level 
of CD34+cell dose will be allowed.  
b) If PBSC cell transplant results in DMSO-related toxicities (chills, muscle aches), 
diphenhydramine 25 mg IV and meperidine 50 mg IV may be administered one time.
3.3.3 Post-transplant Rejection
This protocol uses a nonmyeloablative-conditioning regimen, thus autologous recovery is anticipated in patients who fail to engraft.  Pa tients who have less th an 1% donor neutrophils 
in the peripheral blood on two occasions more than one month apart and occurring more than one month after transplant will be c onsidered to have graft rejection. 
3.3.4 Dose Modification for Sirolimusa) The total duration of sirolimus will be determined by the presence or absence of GVHD and 
the level of donor/recipient chimerism, however the schedule is to continue sirolimus until 
day +180 (+/- 2 days) and then taper as long as the severity of GVHD is less than grade II, and the patient is not requiring systemic steroids.  Sirolimus will subsequently be reduced by one-third on day +180 (+/- 2 days  as long as the severity of GVHD is less than grade II, the patient is not receiving systemic steroids, and the donor chimerism is 100 percent. If the 
donor chimerism is less than 100%, sirolimus w ill be continued without taper for up to 2 
years at the discretion of the PI.
b) Because prolonged dosing of sirolimus is associated with increased cholesterol and 
triglycerides, a lipid panel that includes chol esterol and triglyceride s should be measured 
every 2 weeks during sirolimus therapy.  If elevated cholesterol and triglyceride levels are documented on two consecutive tests, therap y with an HMG-CoA reductase inhibitor 
(“statin” therapy) will be initiated. Since the patients will be on Fluconazole, it is recommended to start Pravastatin 40 mg/day. In the event that this 40 mg daily dose is not sufficient (elevation of cholesterol or triglyce rides at a level 50% above baseline values), 
then consideration may be given to increase the dose of the Pravastatin therapy to 80 mg. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
3.3.5 Dose Modification for Tacrolimus
a) Subsequent doses of tacrolimus will be adjusted according to levels monitored at least bi-
weekly and/or upon symptoms or alterations in renal function. The target level will be 5 to 10 
ng/ml
b) When the patient is reliably taking oral me dications, tacrolimus will be converted to an 
equivalent oral dose using a 1:3 conversion from the IV form.  The total daily dose will be divided into two equal doses, one dos e given approximately every 12 hours.
c) The total dose of tacrolimus will continue until day +180 and then begin tapering until day +
365 (+/- two days), per PI discretion as long as the severity of GVHD is less than grade II, 
and the patient is not requ iring systemic steroids. 
3.4 P
HARMACOKINETIC STUDIES (NOT APPLICABLE )
3.5 P ROTOCOL EVALUATION
3.5.1 Recipient pre-transplant evaluation (perfo rm within 48 hours of the initiation of pre-
transplant conditioning) 
a) CBC with differential
b) PT, and PTT
c) Acute Care Paneld) Hepatic Panele) Mineral Panelf) Uric Acid, Serumg) Protein, Total, Serumh) Lactate Dehydrogenasei) Creatine Kinase
c) Urine EHCG in women of childbearing potential
3.5.2 Evaluation During Transplantation (see Appendix B)
The following studies will be obtained in  the recipient during hospitalization for 
transplantation:
a) CBC twice daily; differential count dailyb) Acute Care Panel BIDc) Hepatic Paneld) Mineral Panele) Uric Acid, Serumf) Protein, Total, Serumg) Creatine Kinaseh) LDH dailyi) Lipid panel weeklyj) Type and screen twice a weekk) Sirolimus levels two times a weekl) Tacrolimus levels will be evaluate twice weeklym) Weekly CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosisn) Donor: Recipient Chimerism St udies: Determination of donor  vs. host chimerism will be 
performed by VNTR-PCR of microsatellites. A CLIA-certified lab will perform these assays.  Initial baseline dete rmination on donor and recipi ent DNA will be done at the 
time of study entry. Post-transplant chimerism will be determined at the discrete time points (+/- 2 days) starting with day 30 post-tr ansplant to evaluate T-lymphoid, myeloid, 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
and total blood chimerism. Blood chimerism w ill also be evaluated at  day +100, 6 
months,  12 months, and 24 months post-transplant (+/- 3 days), and as clinically 
indicated (i.e., mixed chimerism).  Chimerism may be measured at other time-points if clinically indicated (e.g., to determine e ffect of manipulating immune suppression in 
order to increase donor chimerism). Send 5 cc  blood in yellow top ACD tube to Jody 
Keary, Clinical Center Pathology.
o) A bone marrow aspirate will be collected at  days 30 and 100 post-transplant (+/- 3 days) 
to help elucidate the contribution of donor hema topoietic progenitor cells to the graft, and 
to determine whether there are differences be tween the levels of donor chimerism in the 
peripheral blood compared to the bone marro w.  DNA chimerism will be performed by 
CLIA certified laboratories.  If MDS is present pre-tr ansplant, then a bone marrow 
aspirate with cytogenetics w ill be performed on days 30, 100, 6 months and 12 months  
post-transplant.  A portion of the sample wi ll be sent to Dr. Fran Hakim, Bldg 10, Room 
12C-216.
p) A lymphocyte phenotyping panel (T, B, NK) will be performed on days +30, +60, +100, 
6 months, 12 months, and 24 months post-trans plant.  All times are +/- 3 days.  A CBC 
with absolute monocyte count will be performed at these same time points.
q) In order to determine the rate and contribu tion of each UCB unit or units to engraftment 
after UCB transplant, unsorted chimerism studies using quantitative polymerase chain reaction (PCR) for polymorphic variable numbe r tandem repeat (VNTR) or short tandem 
repeat (STR) microsatellite regions from DN A from peripheral blood will be evaluated.  
A CLIA-certified lab will perform these a ssays. Initial baseline determination on donor 
and recipient DNA will be at time of study en try.  Send 5 cc of blood in purple top tube 
to Dr. Roger Kurlander, C linical Center pathology.
r) The patient will also be evaluated at leas t twice weekly during the first 100days after 
transplantation for the development of ac ute GVHD. Weekly CMV, Adenovirus, EBV, 
HHV6 PCR, and Toxoplasmosis will be performed.
3.5.3 Post-Transplant Evaluation (also see Appendix B)
After completion of therapy the patient will be followed for potential complications related to allogeneic SCT.  The patient will be seen in follow-up to evaluate disease status and late problems related to allogeneic HSCT at days + 30, +60, and +100; and at 6, 12, 
and 24 months post-transplant.  At these times patients will have the following tests performed to determine clinical response (+/- 3days): 
a) CBC with differential count b) Acute Care Panelc) Hepatic Paneld) Mineral Panele) Uric Acid, Serumf) Protein, Total, Serumg) Lactate Dehydrogenaseh) Creatine Kinasei) Lipid panel (weekly)j) Type and screen k) Sirolimus levell) Tacrolimus level
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
m) CMV, Adenovirus, EBV, HHV6, and toxoplasmosis weekly
n) Donor: Recipient Chimerism Studies: A CLIA-c ertified lab will perform  these assays. Initial 
baseline determination on donor and recipient DNA will be done  at the time of study entry. 
Post-transplant chimerism will be determined at the discrete time points (+/- 3 days) starting with day 30 post-transplant to evaluate T- lymphoid, myeloid, and total blood chimerism. 
Blood chimerism will also be evaluated at day +100, 6 months, 12 months, and 24 months 
post-transplant, and as clinically indicated (i.e., mixed chimerism). Chimerism may be measured at other time-points if clinically indicated (e.g., to determine effect of manipulating immune suppression in order to increase donor chimerism).
o) In order to determine the rate and contribution of each UCB unit or units to engraftment after 
UCB transplant, unsorted chimerism studies using quantitative polymerase chain reaction (PCR) for polymorphic variable number tandem repeat (VNTR) or short tandem repeat 
(STR) microsatellite regions from DNA from peri pheral blood will be eval uated on days +30, 
+100, 6, 12, and 24 months post-transplant.  A CL IA-certified lab will perform these assays. 
Initial baseline determination on donor and recipient DNA will be  at time of study entry. 
p) A bone marrow aspirate will be collected at day 100 post-transplant (+/- 3 days) to help 
elucidate the contribution of donor hematopoietic progenitor cells to the graft, and to determine whether there are differences betw een the levels of donor chimerism in the 
peripheral blood compared to the bone marrow.  DNA chimerism will be performed by CLIA certified laboratories.  A sample  will also be delivered to Dr. Fran Hakim, Bldg 10, Room 
12C-216.
q) If MDS is present pre-transplant, then a bone marrow aspirate with cytogenetics will be 
performed on days +30, +100, 6 months, 12 mo nths, and 24 months post-transplant (+/- 2
days).  If the patient has normal cytogenetics at day +30 cytogenetic will not be repeated 
until day 100.
r) A lymphocyte phenotyping panel (T, B, NK ) will be performed on days +30, +100, 6 
months, 12 months, and 24 months post-transplant. All times are +/- 3 days.  A CBC with absolute monocyte count will be perfo rmed at these same time points. 
s) The patient will also be evaluated at least twice weekly during the first 100 days after 
transplantation for the development of acute GVHD.
3.6 C
ONCURRENT THERAPIES
Please see section 4.1 for concurrent therapy with anti-bacterial, anti-fungal, and anti-viral agents 
during transplant. 
3.7 S URGICAL GUIDELINES (NOT APPLICABLE )
3.8 R ADIATION GUIDELINES
a) Patients receiving 10/10 matche d related and 10/10 matched unr elated donor hematopoietic 
stem cells, and haploidenti cal donor bone marrow cells, w ill receive 200 cGy total body 
irradiation on day -1. Patients with 9/10 matched unrelated donors will receive 300 cGy TBI 
on day -1. Following consultation with the Ra diation Oncology Branch, patients will be 
measured to determine the maximal lateral separation at the level of the hip with the patient 
lying supine.  The lateral head and neck separa tion will also be measured to determine the 
appropriate thic kness of compensators for this treatment. On day -1 patients will receive a 
total body dose of either 200 or 300 cGy delivered to the lateral midplane at a source distance 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
of 6 meters to isocenter.  The treatment will be delivered with oppos ed lateral treatment 
fields with head and neck compensation to minimize dose heterogeneity.  Modifications to 
the radiation treatment palm, with the exception of the total dose, may be made to the treatment technique at the discretion of the treating radiation oncologist based on the patient’s thickness or other technical factors. Approximately one hour prior to radiation, 
patients should be given one 8mg ta blet of Zofan (Ondansetron) or ally with water.  Pediatric 
patients who require anesthesia will be requested to sign an additional consent for anesthesia.
3.9 O
FFTREATMENT CRITERIA -NOT APPLICABLE
3.10 O FFSTUDY CRITERIA 
The donor or recipient will be removed from pr otocol for any of the following reasons:
a) Inadequate stem cell collection from the selected donor. If this occurs, another eligible donor 
may be enrolled and may undergo filgrastim mob ilization and PBSC collection as outlined in 
the donor selection criteria.  If no other eligible donor is available, or if there is insufficient 
time to arrange donor cell collection, then the recipient will be removed from the trial and 
referred back to their physician.
b) Unacceptable toxicity (> grade 3) from the initiation of G-CSF until cells are harvested, for 
the donor.
c) The donor or recipient refuses to continue therapy.d) In addition, the patient may at any time be  removed from protocol at the principal 
investigator’s discretion, if the PI deems the patient to be at unacceptable risk to remain on study.  Reasons for this action may include  (but are not limited to): declining organ 
function/performance status before transplant ation; inadequate family/caregiver support; 
noncompliance. 
e) Lost to follow-upf) Deathg) Off-Study Procedure: Authorized staff must notify Central Registration Office (CRO) when a 
patient is taken off-study. An off-study form from the web site (http://intranet.cancer.gov/ccr/welcome.htm ) main page must be completed and faxed to 301-
480-0757.
*Note:  Donors will be considered “Off Study” 1 day post collection of cells or until resolution 
of a pending adverse event.
3.11 P OST STUDY EVALUATION (FOLLOW -UP)
a) Patients will be followed post-therapy at least weekly in the outpatient setting until at least 
day +100 (post transplant) to evaluate diseas e status and problems related to allogeneic 
HSCT
b) Clinic visits will be scheduled at day’ s +30, +60, and +100; and at 6, 9, 12, 18, and 24 
months post-transplant at which time the following tests will be performed to determine 
clinical response: 
xCBC with differential count 
xAcute Care Panel
xHepatic Panel
xMineral Panel
xUric Acid, Serum
xProtein, Total, Serum
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
xLactate Dehydrogenase
xCreatine Kinase
xCMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosis
xDonor: Recipient Chimerism Studies: 
xLymphocyte phenotype panel (T, B, NK). A CBC with absolute monocyte count will be 
performed at these same time points. 
c) A bone marrow aspirate will be collected at day 100 post-transplant (+/- 3 days) to help 
elucidate the contribution of donor hematopoie tic progenitor cells to the graft, and to 
determine whether there are differences betw een the levels of donor chimerism in the 
peripheral blood compared to the bone marrow. 
d) If MDS is present pre-transplant, then a bone marrow aspirate with cytogenetics will be 
performed on days +30, +100, and 6, 9, 12, 18, and 24 months post-transplant (+/- 3days).  If 
the patient has normal cytogenetics at day +30 cytogenetics will not be repeated until day 
100.
e) The patient will also be evaluated at least twice weekly during the first 100 days after 
transplantation for the development of acute GVHD.
3.12 I MMUNOLOGIC STUDIES
a) Immune reconstitution of donor leukocyte subsets will be assessed on days +30, +100, 6 
months, 12 months, and 24 months post-transplant  (+/- 2 days).  Peripheral blood (five green 
(CPT) tubes will be collected) will be sent to the Dr. Fran Hakim, ETIB, Bldg 10, Room 12C-216. After lysis of RBC, flow sorting of T-lymphocytes (CD3+), B-lymphocytes (CD20+), NK cells (CD56+), and monocytes (CD14+) will be carried out.  If 10,000 to 
100,000 cells can be obtained from the individu al cell population, then chimerism will be 
carried out on the individual cell populations.  So rted cell populations will be analyzed for 
donor chimerism by the Clinical Center pathology, attn: Jodi Keary. 
3.13 R
ESTRICTIONS FOR BLOOD DRAWN FOR RESEARCH SAMPLES :
Research blood sample aliquot size will be minimized for patie nts < 18 years of age and the 
total amount restricted.  The amount of blood drawn from adult (those 18 years of age or 
older) for research purposes shall not exceed 10.5 mL/kg or 550 mL, whichever is smaller, in 
an 8 week period.
The amount of blood drawn for research purpo ses from pediatric patient subjects (those 
under 18 years of age) will not exceed 5 mL/kg in a single day, and no more than 9.5 mL/kg 
over an 8 week period.
In the event that blood draws are limited due to  patient size, research studies will be 
performed in order of priority. Small volume apheresis collections will notbe included in this 
calculation since such is performed isovolumetrically with minimal red cell loss.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
4 SUPPORTIVE CARE 
4.1 I NFECTION PROPHYLAXIS 
(For a full description of infection prophyl axis please refer to the NIH BMT Consortium 
Supportive Care Guidelines at http://intranet.cc.nih.gov/bmt/clinicalcare/guidelines.shtml ).  
Infection prophylaxis for pediatric patients should follow the NIH BMT Consortium Supportive 
Care Guidelines found at http://intranet.cc.nih.gov/bmt/clinicalcare/guidelines.shtml
4.2 M ANAGEMENT OF ENGRAFTMENT SYNDROME  
Engraftment syndrome may occur at the time of neut rophil recovery.  Its c linical manifestations 
include noninfectious fever, ras h, and vascular leak causing non-cardiogenic pulmonary edema, 
weight gain, and renal insufficiency (Spitzer 2001).  Diagnostic criteria and a treatment schema 
for engraftment syndrome are included in Appendix E. 
4.3 T REATMENT OF GRAFT -VERSUS -HOST DISEASE
a) In patients in whom GVHD is suspected, standa rd clinical criteria and biopsy findings (when 
clinically indicated) will be used to establish the diagnosis. Acute GVHD will be assessed 
according to 1994 Consensus Conference on Acut e GVHD Grading criteria (Przepiorka et al. 
1995). Chronic GVHD will be assessed acco rding to 2005 Chronic GVHD Consensus 
Project (Filipovich et al. 2005). See Appendix D for details concerning the assessment of 
acute and chronic GVHD.
b) Patients with clinical Stage 1 or 2 (Grade I) GVHD of the skin without any other organ 
involvement will be treated with a topical corticosteroid cream.
c) In general, patients with tGrade II acute GVHD will be treated with high-dose, systemic 
corticosteroids.
d) Patients who fail to respond to corticosteroids will be considered for second-line 
immunosuppressive therapy. These agents incl ude Tacrolimus as a continuous intravenous 
infusion at 0.02 mg/kg/day; Mycophenolic acid 1 Gm po BID,  Infliximab (Remicade) 10 mg/kg/dose IV every week for a maximum of 4 doses, Daclizumab 1mg/kg IV on Days 1, 4, 8, 15, and 22, or  other exper imental acute GVHD protocol s, if they are available.
4.4 M
ENSES SUPPRESSION AND CONTRACEPTION
a) For a full description of menses suppression and contraception please refer to the NIH BMT 
Consortium Supportive Ca re Guidelines at: 
b)http://intranet.cc.nih.gov/bmt/clinicalcare/guidelines.shtml
c) Pre-menopausal women who have not undergone hysterec tomy will be placed on a 
monophasic oral contraceptive to provide both menses suppression and contraception. This 
therapy will begin upon enrollment and continue un til platelet recovery after transplantation 
(> 50,000/ μl without transfusion).  Treatment should be starte d prior to the onset of 
thrombocytopenia usually when withdrawal bl eeding begins. Once thrombocytopenia occurs 
therapy is less likely to be effective. As general recommendations: Prescribe Lo-Ovral (300μ g norgestrol and 30 μg ethinyl estradiol) 1 tablet daily. Instruct patient not to take 
placebo tablets. If the patient is on another oral  contraceptive, she should be switched to Lo-
Ovral. If Lo-Ovral is started when the patient is bleeding and bleeding persists for more than 2-3 days, increase the dose to 1 tablet twice dail y. If bleeding persists for more than an 
additional 2-3 days (total 5 to 6 days after starting hormones), consult the NIH Gynecology 
Consult Service.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
d) Female transplant recipients will be advised to use an effec tive form of contraception for at 
least 1 year after transplantation, and to have their male partners use condoms.  
e) Male transplant recipients w ill be advised to use contrace ption, preferably condoms, for 1 
year after transplantation.
4.5 B LOOD PRODUCT SUPPORT
a) Patient’s blood counts will be  monitored daily during the hospitalization. Patients will 
receive packed red blood cells and platelets as needed to maintain Hb > 8.0 gm/dl, and 
platelets > 10,000/mm3(or higher, if clinically indicated).  
b) All blood products, with the exception of the st em cell product and DLI, will be irradiated.
c) Leukocyte filters will be utilized for all blood and platelet tran sfusions to decrease 
sensitization to transfused leukocytes and decr ease the risk of CMV infection. The patient, 
who is seronegative for CMV and whose donor is seronegative, should receive CMV-
negative blood products whenever possible.
d) Transfusion of irradiated blood and cellula r blood products will begin at a minimum of two 
weeks prior to hematopoietic cell collection. Transfusion of irradiated blood and cellular 
blood products will continue to at least one ye ar after transplanta tion. Patients receiving 
immunosuppressive medica tion will continue to have all blood and cellular blood products 
irradiated until discontinuation of immunosuppressi ve treatment.
e) Patients sensitized to HLA or platelet specific antigens should receive HLA matched 
apheresis platelet collections.
4.6 N UTRITIONAL SUPPORT
If mucositis or GVHD prevent adequate PO intake, parenteral hy peralimentation will be 
instituted and discontinued with input from the Pharmacy and Nutr ition Departments. Oral intake 
will resume when clinically appropriate under the supervision of the dietary service of the Clinical Center.
4.7 A
NTI-EMETIC USAGE 
Anti-emetic usage will follow recommendations from the Pharmacy. 4.8 I
NTRAVENOUS IMMUNE GLOBULIN (IVIG)
a) Will follow Guidelines for Infection Manageme nt in Allogeneic HSCT Recipients by the 
NIH Blood and Marrow Consor tium standard practices.
b) IgG level will be measured only in patients who have had t 2 respiratory infections that 
required antibiotic therapy in the six months prior to transplant. 
c) IgG values less than 400 mg/dl, 500 mg/kg IVIG will be administered intravenously.
4.9 H EPATIC FUNCTION SUPPORT
All patients will receive  ursodeoxycholic acid (Ursodiol)  for the prevention of hepatic 
complications after alloge neic stem cell transplant ation.  Ursodiol will start day -4 prior to the 
transplant and will continue un til day +100 post-transplant. Patient s weighing less than 90 kg 
will receive 300mg orally twice daily (600mg to tal dose each day). Those patients weighing 
more than 90 kg will receive 300 mg orally each morning and 600 mg orally each evening (900 
mg total dose each day).
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
4.10 C ENTRAL NERVOUS SYSTEM PROPHYLAXIS
Pediatric patients < 18 years of age may receive standard intrathecal (IT) chemotherapy on a 
monthly basis on a case by case basis after confe rring with the PI and the treating physician, to 
prevent meningeal dissemination in patients with select hematologic malignancies.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
5 DATA COLLECTION AND EVALUATION
5.1 D ATA COLLECTION
a) Data will be prospectively collected and entered in real time into the Cancer Center Clinical 
Data System database (NCI C3D database) (information at http://ccrtrials.nci.nih.gov).  It is
expected that clinical data be entered into C3D no later than after 10 business days of the 
occurrence.  The NCI PI and research nurse will have access to these data via web access.
5.1.1 Adverse Events during the Conditioning Therapy phase:5.1.1.1 Grade 1 and 2 adverse events will not be recorded, with the exception of All Grade 2 
events that are not in the consent form, but ar e possibly, probably or definitely related to 
the research; 
5.1.1.2 All expected and unexpected Grade 3 and 4 adverse events possibly, probably or 
definitely related to the research will be recorded with the exception of:
a) Blood/Marrow abnormalities (will include grade 3&4 hemolysis)
b) Coagulation abnormalitiesc) Metabolic abnor malities (will include grade 3&4 LFTs and creatinine)
5.1.1.3 All grade 5 adverse events will be recorded regardless of attribution.
5.1.2 Adverse Events during the Transplant phase (Day 0 to Day 100):
5.1.2.1 Grade 1 adverse events will not be recorded.5.1.2.2 Grade 2 adverse events that will be recorded:a) those potentially, probably and definitely related to GVHD.b) infection including fever in  the absence of neutropenia.
c) Those unexpected potentially, probably, and definitely related to the research.d) Any that are deemed clinically significant by the PI5.1.2.3 All expected and unexpected Grade 3 and 4 adverse events possibly, probably or 
definitely related to the research will be recorded with the exception of:
a) Blood/Marrow abnormalities (will in clude grade 3 &4 hemolysis)
b) Coagulation abnormalities with the exception of TTP/HUS which will be recordedc) Metabolic abnorma lities (will include grade 3 &4 LFTs and creatinine)
5.1.2.4 All grade 5 adverse events will be recorded regardless of attribution.
5.1.3 Adverse Events during the Follow-up phase (beyond Day 100):
5.1.3.1 Grade 1 adverse events will not be recorded.5.1.3.2 Grade 2 adverse events that will be recorded:a) those potentially, probably and definitely related to GVHD.b) infection including fever in  the absence of neutropenia.
5.1.3.3 All expected and unexpected Grade 3 and 4 adverse events possibly, probably or 
definitely related to the research will be recorded with the exception of:
a) Electrolyte abnormalities (will include  grade 3&4 LFTs and creatinine)
5.1.3.4 All grade 5 adverse events will be recorded regardless of attribution.a) After obtaining Informed Consent, a file will be created in the database with standardized 
forms.  The NCI C3D will maintain data fo r described endpoints in the protocol.  The 
medical record will maintain complete records on each patient including any pertinent supplementary information obtained from outside laboratories, outside hospitals, radiology 
reports, laboratory reports, or other patient records.  The NCI C3D will serve as the primary source from which all research analyses will be performed.  
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
b) Data collection will include the eligibility criteria checklist, patient history, , specialty forms 
for pathology, radiology, weekly toxicity monitoring, monitoring of GVHD, engraftment 
data, chimerism data, immune reconstitution and relapse data and an off-study summary 
sheet, including a final assessment by the treating physician. After patients are seen in clinic 
on day +30, +100 and 6, 9, 12, 18, and 24 months post-transplant, the NCI C3D will be updated in real-time. Additional da ta that is obtained during the transplant process may be 
utilized in the analysis of this protocol (e.g. chimerism testing performed as clinically indicated on dates other than thos e specifically required under the guidelines of the protocol). 
Please see appendix H for detailed data entry requirements for C3D.
c) Data will also be sent to the International Bone Marrow Transplant Registry (IBMTR).d) Unrelated donor recipients will be offered to participate in a cross-institute data and 
repository sample collection protocol though NIAID which fulfills the NMDP requirements 
for data reporting as described in the Clinical Center’s Transplant Center Agreement with NMDP.
e) Protocol Deviations: Any protoc ol deviations should be directly  reported to the PI or LAI.  
These deviations will be reported to the NCI IRB. 
5.2 R
ESPONSE CRITERIA
a) Patients will also be assessed for complete c linical and hematological response at day +30, 
+60, and +100, and 6, 12, and 24 months post-transplant.
In the unlikely events that bone marrow is used as the source of stem cells for HSCT, the data from these individuals will be analyzed separately for the primary and secondary end-
points, however this data will be in cluded in the stopping point criteria.
xParameters to be monitored:
xTotal nucleated cell dose, CD 34+ cell dose, CD3+ cell dose
xDegrees of reconstitution of monocytes, B-lymphocytes, NK cells, T-lymphocytes, by 
lymphocyte phenotype on peripheral blood leukocytes for CD3+, CD20+, CD56+, 
and CD14+ cells 
xAbsolute neutrophil and absolute monocyte count
xNeutrophil recovery (days to  neutrophil count of 5 x 10
9/l
xPlatelet recovery (days to  platelet count of 50 x 109/l, days to transfusion 
independence. 
xRed cell recovery (days to RB C transfusion independence) 
xIncidence and severity of acute GVHD
xIncidence and severity of chronic GVHD
xIncidence of graft rejection
xNon-hematological effects attributable to the preparative regimen
xTransplant related mortality
xIncidence and type of infectious episodes
xDisease-free and overall survival
b) Complete hematological res ponse (CR) for GATA2 Mutation Sy ndrome consists of normal 
levels of T-lymphocytes, B-lymphocytes, NK cells, monocytes, and neutrophils at 100 days 
post-transplant.  CRIS order to be entered for TBNK cells by flow cytometry.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
c) A partial hematological response (PR) fo r GATA2 mutation syndrome consists of 
normalization at 100 days post-tran splant of one or more of the leukocyte subsets which were 
severely decreased prior to transplant, i. e., B-lymphocytes, NK cells, or monocytes.  
d) No response for GATA2 mutation syndrome  cons ists of lack of normalization any of the 3 
leukocyte subsets that were severely  decreased prior to transplant 
e) Complete response (CR) for MD S consists of  normalizati on of the peripheral blood counts 
$1& ! ȝO DQG SODWHOHWV ! O ZLWKRXW FLUFXODWLQJ  EODVWV ERQH PDUURZ
cellularity > 20% with normal maturation and fe wer than 5% blasts in bone marrow 100 days 
after transplant (Schetelig et al. 2003).  The absence of specific molecular or cytogenetic 
markers of disease that were previously pres ent further defines molecular or cytogenetic 
remission, respectively. 
f) Partial response (PR) for MDS is defined as improvement in  markers of leukemia or by 
having all criteria for comple te remission satisfied, except that the bone marrow may contain 
> 5% but < 25% blasts, or < 5% blasts are present. 
g) No response for MDS is defined as bone ma rrow and peripheral blood morphological 
features consistent with relapse or progression, including rising  blast count and re-emergence 
of specific molecular or cytogenetic markers.
h) Samples will be collected and analyzed at day’s +30, +60, and +100, and at 6 and 12 months 
post-transplant for clinical and hematological response. 
5.3 T OXICITY CRITERIA :
Adverse Events on this study will be reported using the NCI Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).  A copy of the CTCAE v3.0 can be downloaded 
http://ctep.info.nih.gov/CTC3/default.html .
All appropriate treatment areas should have access to a copy of the CTCAE version 3.0.
5.4 S TATISTICAL CONSIDERATIONS
a) The primary objectives of this feasibility study are:
1) In a pilot fashion, to determine whether reduced-intensity allogeneic HSCT results in 
engraftment and restores nor mal hematopoiesis by day + 100 in patients with GATA2 
mutation syndrome 
2) To determine the safety of this HSCT regimen in patients with GATA2 mutation 
syndrome, including transplant related toxicity , the incidence of acute and chronic graft-
versus-host disease, immune reconstitution, ove rall survival, and di sease-free survival 
b) Up to 15 patients in total will be prospectively recruited over a 2-year period for this HSCT 
protocol.  We currently have six patients w ith mutations in GATA2 who are candidates for 
transplant.  This study utilizes a matched re lated donor if one is pr esent, however if no 
matched related donor  is identified, but a 10/10 matched unrelated donor is available, then 
that donor will be utilized. If neither a 10/ 10 matched related dono r nor a 10/10 matched 
unrelated donor is available, then either a 9/10 matched unrelated donor, a haploidentical 
donor or UCB units will be used if they ar e available and meet the dose and matching 
requirements.  The choice between a 9/10 matched unrelated donor, an UCB donor, or a 
haploidentical donor will de pend upon the nature of the HLA mismatch, the clinical 
condition of the patient, and the urgency for tran splant among other factors.  This decision 
whether to use a 9/10 matched unrelated donor, an UCB donor, or a haploidentical donor will 
be made by the PI or LAI.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
c) It is estimated that approximately one-quarter of the patients with GATA2 deficiency will 
have a 10/10 matched related donor, and that approximately one-qua rter of  the patients will 
have a 10/10 matched unre lated donor. It is anticipated that  the remaining patients will have 
9/10 matched unrelated donors, umbilical cord blood donors, or haploidentical donors. Thus, 
it is anticipated that no more than 5 patient s from each donor category will be enrolled.  To 
date we have enrolled 3 matc hed related donor recipients, three matched unrelated donor 
recipients, and 4 umbilical cord blood recipients
d) Our goal is to learn if the approach is likely to be of beneficial and have an acceptable level 
of toxicity.  The definition of benefit is whether the patient engrafts the donor HSC and 
normal hematopoiesis is reconstituted.  For purposes of sample  size calculations, we will aim 
for 50% with benefit and consider  this procedure to be of less benefit if fewer than half 
(50%) may truly benefit.  As an illustration, we  will aim for 50% with benefit and consider 
the results to be less promising if consistent with only 20% having benefit. If there are 15 
evaluable patients, considered without regard to  type of donor, the probability of having 6 or 
more with a successful outcome is 6.1% if the true probability of bene fit were 20% and the 
probability is 84.9% if the true probability of benefit were 50%.  Thus, observation of benefit 
in 6 or more of 15 patients provides evidence that this method is likely to be useful for these patients. At the conclusion of the trial, 90% and 95% confidence intervals will be formed around the observed benefit results.  Given the rarity  of this condition, this is intended to be a 
guideline, but findings of lesser benefit may be considered useful for fu rther consideration if 
the toxicity profile is not excessively negative.
e) Stopping Rules: Although the patients w ith this disease are debilitated from the 
immunodeficiency disease and the frequency of infections, we anticipate that most will 
survive the transplant itself.  The following st opping rules will be imple mented in order to 
provide patient safety: 1) Separately within each donor category, if two patients fail to engraft, or fail to survive the 
first 100 days following HSCT, then we will stop enrollment, reevaluate the protocol, and 
present this data to the IRB.
2) If while accrual is proceeding, if 1/3 or gr eater of the patients have a grade 3 or higher 
GVHD, this will also pause accrual to the trial,  including IRB review, prior to re-starting 
accrual or amending the trial appropriately. 
5.5 D
ATA AND SAFETY MONITORING PLAN
In accordance with NCI IRB policy, this pilot study will require independent monitors or review by a Safety Monitoring Committee (SMC).
The PI, LAI, and Scientific Chairperson will pr ovide continuous, close monitoring, with prompt 
reporting of serious adverse events to the IRB.  On a weekly basis, the PI, LAI, Protocol 
Research Nurse, and the NCI Transplant Coordinator will review clinical and laboratory data from patient. A complete summary of patient outcomes will be provided every six months to the IRB in the form of a continuing review appli cation.  The research nurse will verify enrollment 
data entered into the C3D for each subject with in 4 weeks of signing consent.  Ongoing data 
entered into C3D will be verified by the research nurse monthly, and at the time of continuing review.  Documentation of data verification will be tracked in C3D.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
6 HUMAN SUBJECTS PROTECTIONS
6.1 R ATIONALE FOR SUBJECT SELECTION
Subjects for this pilot and feasibility study will be males and females of all races and ethnic 
groups with mutations in GATA2 and a life-expectan cy of greater than 3 months but less than 24 
months.  The GATA2 mutation syndrome is characterized by: 1) the onset of disease beyond infancy with least two episodes of a life-threaten ing opportunistic infection including MAC, 2) a 
unique T+, B-, NK-, monocyte- phenotype on flow cy tometry, 3)  propensity to progress to 
MDS/AML, and 4) mutations in the GATA2 gene .  This patient group was chosen because 
allogeneic hematopoietic stem ce ll transplant represents a potentia lly effective treatment for both 
GATA2 mutations and MDS.  There are no treatment options for patients with this disease that provide any significant survival advantage. The approximate survival of these patients with conventional treatment is approximately five years. Because myeloablative preparative regimens 
are associated with a high degree of morbidity and mortality in patients with co-morbidities, such individuals are most likely to benefit from the reduced-intensity transplant approach used in this study.  Individuals with HIV disease will not be candidates for this protocol due to the high rate 
of post-transplant complications in this group.  In dividuals who are pregnant  or lactating will not 
be candidates for this protocol due to the risk to the fetus or newborn.
Information about this pr otocol will be posted on www.clinicaltrials.gov , NIH Clinical Center 
studies, and the NCI Patient recruitment websites. The protocol will also be listed in the 
physician’s data query (PDQ).
6.1.1 Inclusion of Women and Minorities
Both men and women and members of all races and ethnic groups are eligible for this trial.
6.1.2 Participati on of Children
Children below the age of 12 will not be included on this protocol.  Donors less than 15 years of 
age will not be included on this protocol since the protocol involves greater than minimal risk 
without prospect of dir ect benefit to individual patients for this population.
Physicians, nurses, and multidisciplinary support teams of the POB, NCI, and CC will provide 
patient care.  The staff of the POB has expertise in the management of children with complex oncologic disorders and complications of therap y.  Full pediatric support and subspecialty 
services are available at the NIH CC.  
6.2 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS -PATIENTS
6.2.1 Related to the Tran splant in General 
The patients may obtain direct benefit from th e transplant.  However, the radiation and 
immunosuppression utilized in this study carry the risk of direct toxicity.  In addition, immune 
suppression is associated with an increased risk  of opportunistic infec tions.  However, it is 
anticipated that these risks will be lower than the risks associated with traditional allogeneic transplantation utilizing total body irradiation in which the mortality may be as high as 40%.  Although our data as well as that of others sugg est a significant reduction in transplant related 
mortality with reduced-intensity conditioning, the procedure nevertheless carries significant risk.  
It is therefore only appropriate to carry out th is experimental procedure in the context of 
debilitating or life-threatening c onditions and with full informed consent from the patient.  The 
use of 200 cGy low-dose TBI may increase both the degree of myelosuppression and immunosuppression without significantly altering the si de effect profile.  The specific hazards of 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
this study using a reduced-intensity conditioning regimen are graft rejec tion, graft-versus-host 
disease, and disease relapse.  Of these co mplications, GVHD remains the major cause of 
morbidity and mortality.  Therefore, the patient will receive sirolimus (Rapamycin) and 
tacrolimus for GVHD prophylaxis.  It is not known  whether study recipien ts will be protected 
against GVHD by this regimen.  The major disc omforts of sirolimus and/or tacrolimus are: 
nausea, anorexia, diarrhea, fever and malaise, and intolerance of the period of confinement (see 
section 8.2 and 8.3 for full toxicity profile).  Si de effects of those drugs novel to reduced-
intensity transplantation are described in detail in Section 8.
6.2.2 Risks related to matche d related donor transplant
Engraftment is more predictable using a 10/10 matched donor transplant than with a 9/10-
matched unrelated donor transplant.  Treatment with both total bod y irradiation and fludarabine 
is designed to enhance donor engraftment to greater than 90%.  Graft-versus-host disease 
remains a formidable risk with  approximately 50% of patients developing GVHD, and 25% of 
patients having GVHD requiring additional treatment.  The risk of GVHD is least with a 
matched related donor compared to the other two donor sources. 
6.2.3 Risks related to matche d unrelated donor transplant
Engraftment is also predictable using a 10/ 10 matched unrelated d onor transplant with 
approximately 90% or more of patients achieving engraftment. Treatment with both total body 
irradiation and fludarabine, and the increase to 300 cGy TBI for 9/10 matched unrelated donors,
is designed to enhance donor engraftment.  Graf t-versus-host disease remains a formidable risk 
with approximately 60% of pa tients developing some GVHD, and 30% of patients having 
GVHD requiring additional treatment.  The risk of  GVHD is greater with a matched unrelated 
donor than with a ma tched related donor. 
6.2.4 Risks Related to Haploidentical TransplantHaploidentical donor transplant with this conditioning regimen results in 90% or more of 
patients achieving engraftment.  The risk of  GVHD using a haploidentical donor and this 
conditioning regimen is approximately 50%,  however only 10% have grade 3 to 4 GVHD.
6.2.5 Risks related to UCB transplantEngraftment is lowest in this group compared to the other two groups.  This results in an 
increased risk of infection and bleeding.  Howe ver, the risk of GVHD is lower in this group 
compared to matched unrelated donor transplant.  
6.2.6 Related to Total Body Irradiation
The side effects of radiation have been well described. The most common include nausea and 
mucositis. There also exists a risk of hypothyroidism, cataracts, interstitial pneumonitis, nephropathy, and an unspecified long term risk  of developing seconda ry malignancies (Buchali 
et al. 2000) (Deeg et al. 1983).  Importantly, the majority of the non-neoplastic effects were 
subclinical and/or reversible (Thomas et al. 20 01).  Studies attempting to evaluate the risk 
induced by radiation alone suggest that there is a higher rate of solid tumors after radiation-based 
regimens.  Curtis et al. reported on 19,229 patien ts and found a cumulative incidence rate of 
2.2% at 10 years, and 6.7% at 15 years, with higher  doses of TBI associated with a higher risk of 
solid cancers (Curtis et al. 1997).  In a study in  1999, no relationship could be found to radiation 
but the highest risk factor was felt to be the pr esence of chronic graft versus host disease, and 
long-term treatment with cyclosporine (Kolb et al. 1999). Pediatric patients who require sedation 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
in order to undergo TBI will be asked to sign a se parate consent outlining the risk of the selected 
anesthesia.
6.2.7 Related to  Cyclophosphamide (Cytoxan)
Commercially available.  See package insert for further information.
Toxicity:
Common Occasional Rare
Immediate:
Within 1-2 days 
of receiving drugAnorexia (L), nausea (L), vomiting(L)Metallic taste (L), Inappropriate ADH
1Transient blurred vision1
cardiac toxicity with arrhythmias
1myocardial 
necrosis 2(L)
Prompt:
Within 2-3
weeks, prior to the next courseMyelosuppression (L), alopecia (L)Hemorrhagic cystitis (L)
Delayed:
Any time later 
during therapy, excluding the above conditionsImmunosuppression, gonadal dysfunction /sterility (L)Pulmonary fibrosis
3(L)
Late:
Any time after 
completion of treatmentSecondary malignancy, bladder fibrosis
Unknown Frequency and Timing :  **Fetal and teratogenic toxicities and toxicities in breast-
fed children
1Less common with lower doses.
2Only with very high doses.
3 Risk increased with chest radiation.
(L) Toxicity may also occur later.
**Fetal toxicities and teratogeni c effects of cyclophosphamide (alone or in combination with 
other antineoplastic agents) have been noted in humans.  Toxicities include: chromosome 
abnormalities, multiple  anomalies, pancytopenia,  and low birth weight.
**Cyclophosphamide is excreted into breast milk.  Neutropenia has been reported in breast-fed 
infants.  Cyclophosphamide is considered to be contraindicated during brea st feeding because of 
the reported cases of neutropenia and because of  the potential adverse effects relating to immune 
suppression, growth, and carcinogenesis.
6.3 R ISKS IN RELATION TO BENEFIT 
6.3.1 Recipients:
Patients on this study may be directly benefited by this treatment protocol.  Considerable clinical data has demonstrated long-t erm disease-free survival for patients with immunodeficiency 
diseases as well as high-risk hematological ma lignancies following alloge neic HSCT.  Thus, the 
patient on this study may be direct ly benefited by this treatment.  In particular, reduced-intensity 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
allogeneic stem cell transplantation may offer the patient a curative therapy for his disease while 
reducing the risks of a myeloablative transplant . This carefully defined patient cohort is a 
reasonable one in which to explore strategies to  improve the results of allogeneic HSCT from 
unrelated donors, which histori cally has achieved prolonged remission and survival for some 
patients, but has been associated with significant morbidity and high transplant-related mortality.  It is hypothesized that the transplant approach used in this study will result in the successful transfer of allogeneic stem cells with reduced morbidity and mortality from the transplant preparative regimen, and with reduced graft-vers us-host disease. Clinically the approach is 
ethically acceptable because we are treating patients with at least one, and in some cases two, lethal hematological diseases that are both incurable with conventional trea tments.  The protocol 
aims to decrease the risk of transplant related toxicity, thus making mo re patients candidates for
this potentially curative therapy.  Therefore th e research involves more than a minor increase 
over minimal risk to subjects with the prospect of direct benefit (45 CFR 46.102).  The potential 
risks to the transplant recipient have been carefully  considered and are felt to be significantly less 
than would otherwise occur with myeloablative allogeneic HSCT.  The risks graft rejection, 
acute and chronic GVHD, infection, and relapse will be present, as discussed previously.
6.3.2 Donors:
Healthy 10/10 matched related donors, 10/10 matched unrelated donors,9/10 matche d unrelated 
donors, and haploidentical donors w ill be co-enrolled onto this study. The collection aspect of 
this protocol is not investiga tional. There is potential benef it for donors, as they may derive
psychological benefit from participating in a clinical trial designed to improve the health of the recipient of the prior transplant donation. Other potential benefits incl ude the diagnosis of 
previously unknown illnesses (such as viral hepatitis) at the time of donor screening.
6.4 C
ONSENT AND ASSENT PROCESSES AND DOCUMENTS
a) Informed consent will be obtained from all patients, and/or the patient’s parents or legal 
guardian (if he/she is < 18 years of age), and matched related donors ente red on this trial.  
The procedures and treatments involved in this  protocol, with their attendant risks and 
discomforts, potential benefits, and potential alternative therapies will be carefully explained to the recipient and/or parent/guardian.  If applicable, the parent or guardian will sign the designated line on the informed consent attesting to the fact that the child has given assent.
b) The investigators are requesting a waiver from the IRB to allow only one parent to sign the 
informed consent to enter a child on the protocol. Because many patients must travel to the NIH from long distances at substantial expens e, requiring both parents to be present for the 
consent process could be a financial hardship for many families. When necessary, the protocol will be reviewed by telephone with the other parent  and their approval will be 
verified. When guardianship status of the child is uncertain, a social worker will be asked to investigate and, if necessary, seek documentation of custody status. The PI or an associate investigator on the trial will obtain consent. Where deemed appropriate by the clinician and the child’s parents or guardian, the child will also be included in all discussions about the 
trial and verbal assent will be obtained. The parent or guardian will sign the designated line on the informed consent attesting to the fact that the child has given assent.
c) Similarly, the procedures and tr eatments involved in this protoc ol, with their attendant risks 
and discomforts, will be carefully explained to  the matched unrelated donors at the respective 
donor center as required by NMDP.  The original signed informed consent goes to Medical Records; a copy will be kept for the research record.  The Central Registration Office (CRO), 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Data Management Section will also retain a copy of the informed consent document.  A copy 
of the signed informed consent document will also be given to the recipient (and matched related donor, when applicable).  b) The Central Registration Of fice (CRO) will ascertain the 
date of IRB approval before registering the first patient. 
d) The Principal Investigator and/or an authorized designee will consent the patient and 
matched related donor (when applicable) and will be available to answer all patient questions.
e) If any new information becomes available relating to risks, adverse events, or toxicities, 
while patients are participating in this protocol, this information will be provided orally and/or in writing to all enrolled and prospective patient participants.  Documentation will be provided to the IRB and if necessary the info rmed consent amended to reflect relevant 
information.
6.4.1 Telephone re-consent procedure
Reconsent on this study may be obtained via telephone according to the following procedure: the 
informed consent document will be sent to the subject.  An explanation of the study will be 
provided over the telephone after the subject has had the opportunity to read the consent form.  
The subject will sign and date the informed consent. A witness to the subject’s signature will 
sign and date the consent.  The original informed consent document will be sent back to the consenting investigator who will sign and date the consent form with the date the consent was obtained via telephone.  A fully executed copy will be returned via mail for the subject’s records.
The informed consent process will be documented on a progress note by the consenting investigator and a copy of the informed consent document and note will be kept in the subject’s research record.
7 DATA REPORTING
7.1 D
EFINITIONS
7.1.1 Adverse Event
An adverse event is defined as any reaction, side effect, or untoward event that occurs during the course of the clinical trial associated with the use of a drug in humans, whether or not the event is considered related to the treatment or clinically significant. For this study, AEs will include events reported by the patient, as well as clinically significant abnormal findings on physical examination or laboratory evaluation. A new illness,  symptom, sign or clinically significant 
laboratory abnormality or worsening of a pre-exis ting condition or abnormality is considered an 
AE.  All AEs must be recorded on the AE cas e report form unless otherwise noted above in 
Section 5.1.
All AEs, including clinically significant abnorma l findings on laboratory evaluations, regardless 
of severity, will be followed until return to baseline or stabilization of event. Serious adverse events that occur more than 30 days after the last administrati on of investigational 
agent/intervention and have an attribution of at least possibly related to the agent/intervention should be recorded and reported as per section 7.2.
An abnormal laboratory value w ill be considered an AE if the laboratory abnormality is 
characterized by any of the following:
xResults in discontinuation from the study
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
xIs associated with clinical signs or symptoms 
xRequires treatment or any other therapeutic intervention
xIs associated with death or another seri ous adverse event, including hospitalization. 
xIs judged by the Investigator to be of significant clinical impact
xIf any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test  drug and about the patient’s 
outcome.
7.1.2 Suspected adverse reaction
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For th e purposes of IND safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.
7.1.3 Unexpected adverse reaction
An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure or is not listed at the sp ecificity or severity that  has been observed; or, 
if an investigator brochure is not required or available, is not cons istent with the risk information 
described in the general inve stigational plan or elsewhere in the current application. 
"Unexpected”, also refers to adverse events or suspected adverse reactions that are mentioned in 
the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug und er investigation.
7.1.4 Serious An Unanticipated Problem or Protocol Deviation is serious if it meets the definition of a Serious Adverse Event or if it compromises the safety , welfare or rights of subjects or others.
7.1.5 Serious Adverse Event
An adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:
xDeath,
xA life-threatening adverse drug experience
xInpatient hospitalization or prolongation of existing hospitalization
xA persistent or significant disability/incapacity
xA congenital anomaly/birth defect.
xImportant medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious  adverse drug experience when, based upon 
appropriate medical judgment, they may jeopard ize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.
7.1.6 Disability
A substantial disruption of a person’s  ability to conduct normal life functions.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
7.1.7 Life-threatening adverse drug experience
Any adverse event or suspected adverse reaction that places the patient or subject, in the view of the investigator or sponsor, at immediate risk of death from the reaction as it occurred, i.e., it 
does not include a reaction that had it occurred in  a more severe form, might have caused death.
7.1.8 Protocol Deviation (NIH definition)Any change, divergence, or departure from the IRB approved research protocol..
7.1.9 Non-compliance (NIH Definition)
The failure to comply with applicable NIH Human Research Protections Program (HRPP) policies, IRB requirements, or regulatory requirements for the protection of human research 
subject.
7.1.10 Unanticipated Problem
Any incident, experience, or outcome that:
xIs unexpected in terms of nature, severity, or  frequency in relation to the research risks 
that are described in the IRB-approved research protocol and informed consent document; Investigator’s Brochure or other study documents, and the characteristics of 
the subject population being studied; AND
xIs related or possibly related to participation in the research; AND
xSuggests that the research places subjects or others at a g reater risk of harm (including 
physical, psychological, economic, or social  harm) than was previously known or 
recognized.
7.2 NCI-IRB R
EPORTING
7.2.1 NCI-IRB Expedited Reporting of Unanticipated Problems and Deaths
The protocol PI will report to the NCI-IRB:
xAll deaths, expect deaths due to progressive disease
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
7.2.2 NCI-IRB Requirements for PI Reporting at Continuing ReviewThe protocol PI will report to the NCI-IRB: 
1. A summary of all protocol devi ations in a tabular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action.
2. A summary of any instances of non-compliance3. A tabular summary of the following adverse events:
xAll Grade 2 unexpected events that are possibl y, probably or definitely related to the 
research; 
xAll Grade 3 and 4 events that are possibly,  probably or definitely related to the 
research; 
xAll Grade 5 events regardless of attribution; 
xAll Serious Events regardless of attribution. 
NOTE : Grade 1 events are not required to be reported. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
All Grade 4 and 5 unexpected serious adverse events that are related to commercially available 
agents will be reported directly to the FDA via Medwatch ( http://www.fda.gov/medwatch ).
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
8 PHARMACEUTICAL INFORMATION
8.1 F LUDARABINE (FLUDARA ,BERLEX LABORATORIES )
a) Supply - Fludarabine monophosphate will be purchased by the NIH Clinical Center 
Pharmacy Department from commercial sources and is supplied as a white, lyophilized 
powder.  Each vial contains 50 mg of fludara bine phosphate, 50 mg of mannitol, and sodium 
hydroxide to adjust pH.  Fludara is stored at room temperature.
b) Preparation - FLUDARA IV should be prepared for parenteral use by  aseptically adding 
Sterile Water for Injection, USP.  When reconstituted with 2 ml of Sterile Water for Injection, each ml of the resulting solution will contain 25 mg of Fludarabine Phosphate, 25 
mg of mannitol, and sodium hydroxide to adju st the pH to 7–8.5.  Fludarabine will be diluted 
in 100 to 125ml of either 5% dextrose in wate r or 0.9% sodium chloride, and infused IV over 
30 minutes.
c) Storage and Stability - Reconstituted FLUDARA IV  should be stored in the refrigerator 
between 36 and 46 degrees F. Because reconstituted FLUDARA IV contains no 
antimicrobial preservative, care must be taken to assure the sterility of the prepared solution; 
for this reason, reconstituted FLUDARA IV should be used or discarded within 8 hours.
d) Administration - Parenteral drug  products should be inspected vi sually for particulate matter 
and discoloration prio r to administration.
e) Toxicities – Fludarabine toxicities include myelosuppression ( dose limiting toxicity), fever, 
nausea, vomiting, stomatitis, diarrhea, gastrointestinal bleeding, anorexia, edema, skin 
rashes, myalgia, headache, agitation, hearing loss, transient episodes of somnolence and 
fatigue, auto-immune hemolytic anemia, auto -immune thrombocytopenia, paresthesias, 
peripheral neuropathy, renal, and pulmonary toxicity (interstitial pneumonitis).  Severe fatal CNS toxicity presenting with loss of vision and progressive deterioratio n of mental status 
were encountered almost exclusively after ve ry high doses of fludarabine monophosphate.  
Such toxicity has only rarely been demonstrated at the 25-30 mg/m
2/day dosage of 
fludarabine.  Very rarely described complicat ions include transfusion-associated graft-
versus-host disease, thrombotic thrombocytope nic purpura, and liver failure.  Tumor lysis 
syndrome following fludarabine administration ha s been observed, especially in patients with 
advanced bulky disease.  Opportunistic infecti ons (protozoan, viral, fungal, and bacterial) 
have been observed post-fludarabine, especially in heavily pre-treated individuals, and in 
individuals receiving fludarabine combined with other agent.
f) Dose reduction for renal impairment- For Creatinine Clearance of 30-70 mL/min/1.73m2 
there will be a 20% dose reduction. If th e Creatinine Clearance is less than 
30mL/min/1.73m2, Fludarabine w ill not be administered.  
8.2 S IROLIMUS (RAPAMUNE ®)
a) General:  Sirolimus is an immunosuppressant th at is FDA approved for use in combination 
with cyclosporine and corticosteroids for pr ophylaxis of organ rejection after kidney 
transplant. Sirolimus is administered SIROLIMUS (Rapamycin) (Rapamune®, Wyeth-Ayerst Laboratories)
b) Supply - For patient administrati on, oral tablets will be purchased  by the NIH Clinical Center 
Pharmacy Department from commercial sources. 
c) Storage and Stability - Oral tablets should be  stored 20-25 C° (68-77 F°). Oral solution 
should be refrigerated (2-8 C° or 36-46 F°).
d) Administration: Because fatty food can increase the absorption of sirolimus, the tablets 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
should be administered in the setting of a steady diet  that is relatively constant with respect to 
fat content.
e) Toxicities: 1) Sirolimus induces immune suppression, which has been associated with 
opportunistic infection and an increased rate of malignancy, particularly skin cancer. 2) Some 
individuals may develop hypersensitivity to sirolimus.  3) May cause an increase in cholesterol and triglycerides, which may be associated with pancreatitis.  4) With long-term administration, may result in imp aired renal function.  4) Co-a dministration of  voriconazole 
is strongly discouraged on this protocol, as the combination of voriconazole and sirolimus results in an approximate 10-fold increase in sirolimus blood levels. 
f) Drug Interactions: May increase the in vivo drug levels of simvastatin.
8.3 T
ACROLIMUS (FK506, P ROGRAF )
a) Supply: Tacrolimus will be obtained by the NI H Clinical Center Pharmacy Department from 
commercial sources and is availa ble in capsules (0.5 mg, 1mg, and 5mg), and as a parenteral 
concentrate for injection (5 mg/ml, 1 ml ampules).  
b) Preparation: For parenteral doses, tacrolimu s injection concentrate (5 mg/ml) should be 
diluted to a final concentration of 0.004 to 0.02 mg/ml in dextrose 5% in water or sodium 
chloride 0.9%.   Parenteral doses of tacrolimus will be prepared in non-PVC containers and 
infused with non-PVC admin istration sets/tubing.  
c) Storage and Stability: Capsules and ampules of parenteral concentrate bear expiration dates 
and are stored at room temperature.  Tacro limus concentrate for injection that has been 
diluted to a final concentration of 0.004 to 0.02 mg/ml is stable for 24 hours in 5% dextrose or 0.9% sodium chloride injection in glass, PVC or non-PVC plastic containers.  To minimize the potential for sorption to PVC plastic bags and tubing as well the leaching of phthalate plasticizer (DEHP) into the solution, only non-PVC plastic bags and intravenous 
administration sets should be utilized.  
d) Administration: Tacrolimus may be given intravenously over 24 hours or orally.   
e) Toxicities: Acute tacrolimus nephrotoxicity is usually manifested by a moderate decline in 
renal excretory function, which is  readily reversible by a decrease in drug dosage.  Although 
some degree of transient renal dysfunction may occur in patients with therapeutic levels of tacrolimus, significant renal toxicity is associated with elevated trough or steady state levels.  In addition to an increase in BUN and creatinine, hyperkalemic hyperchloremic acidosis, low fractional excretion of sodium and the onset of hypertension with hypomagnesemia are seen 
with tacrolimus nephrotoxicity. Insulin dependent post transplant diabetes mellitus was reported in 20% kidney transplant  patients, which was reversible  in 50% of the patients at 2 
years post transplant.  Hypertension occurs in up to 60% of patients.   Hypomagnesaemia can 
be associated with neurologic symptoms, including seizures, cerebellar ataxia and 
depression.  Dose-related hepatotoxicity, manifested by elev ation of serum transaminases and 
bilirubin, has been reported. The drug carries a warning for increased susceptibility to infection and the possible development of lymphoma may result from resulting immunosuppression.      
8.4 F
ILGRASTIM (G-CSF; N EUPOGEN ®)
(Amgen), Filgrastim   Classification: glycoprotein  
a) Supply – Commercially available as filgra stim injection in a concentration of 300 Pg/ml in 
1ml (300Pg) and 1.6ml (480 Pg) vials from the Clinical Center Pharmacy Department.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
b) Preparation – For subcutaneous  administration, the appropriate prescribed dose is drawn up 
from the vial with no further dilution prior to administration.  For intravenous administration, 
the commercial solution for injection should be  diluted prior to administration.  It is 
recommended that the prescribed dose be diluted with dextrose 5% in water to a 
concentration greater than 5 Pg/ml just prior to administration; storage of the diluted 
filgrastim is not recommended.  Dilution of filgrastim to a final concentration of less than 5Pg/ml is not recommended at any time.  Do not dilute with saline at  any time; product may 
precipitate.  Filgrastim diluted to concentrations between 5 and 15 Pg/ml should be protected 
from absorption to plastic materials by the addition of Albumin (Human) to a final 
concentration of 2mg/ml.  When diluted in 5% dextrose or 5% dextrose plus Albumin 
(Human), filgrastim is compatible with glass bottles, PVC and polyolefin IV bags, and polypropylene syringes.  The dose may be “r ounded down” to within  10% of patient’s 
calculated dose to use the drug cost-effectively.
c) Storage and Stability – Filgrastim for injection should be stored in the refrigerator at 2
oto 
8oC (36oto 46oF).  Avoid shaking.  
d) Administration – Subcutaneous injection is preferred.  If clinically indicated, filgrastim may 
be administered as an intrav enous infusion over 4 or 24 hours.
e) Toxicities – Medullary bone or skeletal pain is the most co mmonly reported toxicity.  In 
addition, reversible elevations in uric acid, lactate dehydrog enase, and alkaline phosphatase 
are common laboratory abnormalities.  Four case s of splenic rupture have been reported in 
healthy donors when given filgrastim or other myeloid growth factors for peripheral blood 
stem cell mobilization; 1 of these cases resulted in fatality.  Five additional cases of splenic rupture have been reported in cancer patient s undergoing chemotherapy or peripheral blood 
stem cell mobilization; splenic rupture may have contributed to deaths in 2 of these cases.  
One additional death due to splenic rupture after filgrastim therapy was reported to the manufacturer without additional information.  According to the manufacturer, the reporting 
rate for splenic rupture with filgrastim is less than 1 in 486,000. 
8.5 D
IPHENHYDRAMINE
a) Supply – Commercially available.  Diphenhy dramine HCl injection is available in an 
injectable solution at a 50mg/ml concentration in single dose ampules, syringes and vials as well as multi-dose vials from multiple manufacturers.
b) Preparation – Diphenhydramine HCl may be give n by direct intravenous injection without 
additional dilution.  Alternatively the prescribed dose may be diluted in a small volume (e.g. 25-50ml) of 5% dextrose in water (D5W) or 0.9% sodium chloride (NS) and infused over 10-15 minutes.
c) Storage and Stability – Store commercially available injectable product at controlled room 
temperature.
d) Administration – Diphenhydramine HCl injection may be administered by direct IV injection 
(IV push) at a rate generally not exceeding 25mg/min.  Alternatively, diphenhydramine HCl 
injection may be diluted and given over 10-15 minutes (see Preparation).
e) Toxicities – Sedation, sleepiness, dizziness, di sturbed coordination, epig astric distress, and 
thickening of bronchial secretions.  Diphenhydramine can provide additive effects with alcohol or other CNS depressa nts.  Diphenhydramine can cause  anticholinergic side effects 
(e.g. dry mouth, fixed or dilated pupils, flus hing, urinary retention).  Diphenhydramine 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
should be used with caution in patients with  a history of bronchial asthma, increased 
intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension.
8.6 A CETAMINOPHEN
a) Supply: Commercially available as 325 mg or 500 mg tablets for oral administration from 
multiple manufacturers. 
b) Storage: Store at contro lled room temperature. 
c) Administration: Oral.  For analgesia and an tipyretic, the usual dose is 650 to 1000 milligrams 
every 4 to 6 hours, to a maximum of 4 grams/day. 
d) Toxicities: No toxicities are anticipated to result from single doses of acetaminophen 
administered as premedication for rituximab infusions.
8.7 A CYCLOVIR  
a) Supply: Commercially available.
b) Product description: Acyclovir is availabl e in 200mg capsules, 400mg tablets, and 800mg 
tablets. It is also available in an oral suspension at a concentration of 200mg/5ml. Parenteral acyclovir sodium is availabl e in vials containing 500mg or  1gm powder for injection of 
acyclovir as the sodium salt. Acyclovir sodium for injection is also available as a 50mg/ml solution for injection in 1gm/20ml vials.
c) Preparation: For parenteral administration, ac yclovir sodium powder for injection should be 
reconstituted with sterile water for injection to a concentration of 50mg/ml (10ml of diluent for 500mg vial and 20ml of diluent for 1gm vi al). The calculated dose should be further 
diluted in 0.9% sodium chloride or 5% dextro se in water to a concentration of < 7mg/ml 
prior to administration.
d) Storage and Stability: Oral capsules, tablet s and oral solution should be stored at 15
oto 25oC
(59oto 77oF). Capsules and tablets should be protected from moisture.  Acyclovir powder for 
injection and solution for inj ection should be stored at 15oto 25oC (59o to 77oF).  The powder 
for injection once reconstituted should be used  within 12 hours. After final dilution for 
administration, the dose may be stored at room  temperature; it should be used within 24 
hours.
e) Route of administration: Oral  and parenteral. Parenteral dos es should be administered by 
slow intravenous infusion over one hour at  concentrations of 7mg/ml or less.
f) Toxicities: Oral administration: nausea and/or vomiting, diarrhea, headache, malaise, skin 
rash, asthenia; Parenteral administration: inflammation or phlebitis at the injection site, transient elevations of serum creatinine or BUN, nausea and/or vomiting, itching, rash or hives, elevation of transaminases, and encephalopathic changes. Renal toxicity can occur and is secondary to precipitation of acyclovir crystals  in the renal tubules. The risk of toxicity can 
be minimized by avoiding the administration of high concentrations and rapid infusions.
8.8 T
RIMETHOPRIM /SULFAMETHOXAZOLE (TMP/SMX, C OTRIMOXAZOLE ,B ACTRIM ,
SEPTRA )
a) Supply: Commercially available as a single strength tablet containing trimethoprim 80mg 
and sulfamethoxazole 400mg and a double strength  (DS) tablet containing trimethoprim 
160mg and sulfamethoxaole 800mg. It is also  available in an oral suspension at a 
concentration of 40mg of trime thoprim and 200mg sulfamethoxazole per 5ml.  Parenteral 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
TMP/SMX is available in a solution for injecti on at a concentration of  80mg of trimethoprim 
and 400mg of sulfamethoxazole per 5ml. 
b) Preparation: For parenteral administration, the commercial so lution for injection must be 
diluted prior to administration.  It is recomme nded that each 5ml of the solution for injection 
be diluted with 100-125 ml or, if fluid restriction is required, in 75ml of dextrose 5% in 
water.  0.9% NaCl may be substituted as a diluent but the resulting solutions have reduced 
stability. Consult with pharmacy for questions  regarding diluent, volume, and expiration. 
c) Storage and Stability: Oral tablets and oral suspension should be stored at 15oto 30oC (59oto 
86oF) in a dry place and protected from light.  TMP/SMX for injection should be stored at 
room temperature between 15oto 30oC (59oto 86oF) and should not be refrigerated.  Stability 
of intravenous doses after final dilution is de pendent on concentration and diluent.  Consult 
with pharmacy for questions regarding stability and expiration dating. 
d) Administration – Oral and pare nteral.  Parenteral doses s hould be administered by an 
intravenous infusion over 60 to 90 minutes. 
e) Toxicities: 1) the most common adverse effects from TMP/SMX are gastrointestinal 
disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria).  2) Fatalities associ ated with the administration of sulfonamides, although rare, 
have occurred due to severe reactions, includi ng Stevens-Johnson syndrome, toxic epidermal 
necrolysis, fulminant hepatic necrosis, agranul ocytosis, aplastic anemia and other blood 
dyscrasias.  3) For TMP/SMX injection, local  reaction, pain and slight irritation upon IV 
administration are infrequent.  Thro mbophlebitis has rarely been observed.
8.9 U
RSODEOXYCHOLIC ACID (URSODIOL ,ACTIGALL®)
a) Supply – Commercially available as 300 mg capsules.b) Pharmacology - About 90% of a therapeutic dose of Ursodiol is absorbed in the small bowel 
after oral administration. After absorption, Ur sodiol enters the portal vein and undergoes 
efficient extraction from portal blood by the liver where it is conjugated with either glycine or taurine and is then secreted into the hepatic bile ducts. Only small quantities of Ursodiol appear in the systemic circulation and very small amounts are excreted into urine. The sites of the drug’s therapeutic actions are in the liver, bile, and gut lumen.
c) Storage and Stability – Oral capsules shoul d be stored at 15°C-30°C (59°F-86°F).
d) Administration – Oral.e) Toxicities – Nausea, vomiting, dyspepsia, me tallic taste, abdominal pain, biliary pain, 
cholecystitis, constipation, stomatitis, flatulence, di arrhea, pruritus, rash, dry skin, urticaria, 
headache, fatigue, anxiety, depression, sleep disorders. Less common side effects include 
sweating, thinning of hair, back pain, arthralgia, myalgia, rhinitis, cough.
f) Drug Interactions - Bile acid sequestering agents such as cholestyramine and colestipol may 
interfere with the action of Ursodiol by re ducing its absorption. Aluminum-based antacids 
have been shown to adsorb bile acids in vitro and may be expected to interfere with Ursodiol 
in the same manner as the bile acid sequestering agents. Estrogens, oral contraceptives, and clofibrate increase hepatic cholesterol se cretion, and encourage cholesterol gallstone 
formation and hence may counteract the effectiveness of Ursodiol.
8.10 C
EFTAZIDIME  (FORTAZ ®)
a) Supply: Supplied frozen, sterile, iso-osmotic non-pyrogenic solution in plastic containers.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
b) Preparation: For IV infusion, reconstitute the 1- or 2 Gm infusion pack with 100 mL sterile 
water. Consult with pharmacy for questions regarding diluent, volume, and expiration. 
c) Storage and Stability: Commercially available in dry state stored between 15 and 25  degrees 
C protected from light.  Also supplied frozen in  50-mL single dose plastic containers as a 
premixed solution of ceftazidime sodium  and should not be stored above - Û&
d) Administration: The usual dosage is 2 grams ad ministered intravenously every 8 to 12 hours. 
Parenteral doses should be administered by an  intravenous infusion over 20 to 30 minutes. 
e) Toxicities: 1) the most common adverse effects from ceftazidime are local reactions and 
allergic and gastrointestinal reactions. These reactions include: 1) phlebitis and inflammation 
at the site of injection, 2) pr uritis, rash, and fever, 3) naus ea, vomiting , and abdominal pain, 
4) headache, dizziness, and paresthesias, 
8.11 L EVOFLOXACIN  (LEVAQUIN ®)
a) Supply: Levofloxacin for injection is supplied in single-use vials with e ach vial containing a 
concentrated solution with the equivalent of 500 mg of levofloxacin in 20 mL vials and 750 
mg in 30 mL vials.  Levofloxacin is also supplied as a premix in 5% dextrose with each bag 
containing a dilute solution with the equi valent of 250, 500, or 750 mg respectively of 
levofloxacin. 
b) Preparation: For IV infusion, the single-use vi al must be diluted to 5 mg/mL with D5W or 
0.9% Sodium Chloride prior to administration. Fo r the levofloxacin in premixed, ready to use 
solution in D5W, no further preparation is necessary.
c) Storage and Stability:  Levofloxacin injection in Single-Use vials should be stored at 
controlled room temperature and protected for light.  Levofloxacin injection Premix should 
EHVWRUHGDWRUEHORZÛ&$ YRLGH[FHVVLYHKHDWDQGSURWHFW IURPOLJKW
d) Administration: Levofloxacin injection is 250 or 500 mg administered by slow infusion over 
60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 
24 hours.  
e) Toxicities: 1) Moderate to severe photoxicity reactions have been observed in patients 
exposed to direct sunlight while receiving le vofloxacin, 2) predispose to seizure, 3) 
disturbances in blood glucose,  4) peripheral neuropathies. 
8.12 C YCLOPHOSPHAMIDE  (CTX, C YTOXAN )
a) Supply – Cyclophosphamide will be purchased by the NIH Clinical Center Pharmacy 
Department from commercial sources and is supplied as a lyophilized powder in various vial sizes.
b) Preparation - will be reconstituted with sterile water for injection to yield a final 
concentration of 20 mg/ml as described in the package insert.
c) Storage and Stability - The vials are stored at room temperature. Followingd) reconstitutions as directed, solutions of cy clophosphamide are stable for 24 hours at room 
temperature, or 6 days when refrigerated at 2-8° C.
e) Route of Administration - The cyclophosphamide used in this regimen will be mixed in 100 
ml 0.9% sodium chloride, Inj., and given at a dose of 50 mg/kg as an IVPB over 2 hours on day -6. .e) Toxicities:1) Nausea and vomiting - variable; symptomatically improved with standard antiemetics 
and/or benzodiazepines [e.g., lorazepam].
2) Water retention – cyclophosphamide may rare ly provoke the syndrome of inappropriate 
antidiuretic hormone secretion and resultant hyponatremia, usually manifested 12-48 hrs 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
after IV administration, necessita ting frequent accurate assessm ent [q 1-2 hrs] of intake, 
urine output and urine specific gravity. This effect can be counteracted by furosemide. 
Fluid restriction is not feasible during administration of high dose cyclophosphamide.
3) Cardiomyopathy - cyclophosphamide may cause severe, sometimes le thal, hemorrhagic 
myocardial necrosis or congestive cardiomy opathy. Patients may present with congestive 
cardiomyopathy as late as 2 weeks after the last dose of cyclophosphamide. The clinical 
syndrome has been observed in patients receiving the dose of cyclophosphamide used in 
this protocol. In an attempt to minimize this complication, patie nts with significant 
cardiac dysfunction are excluded from this pr otocol [see patient eligibility]. Congestive 
failure is managed according to standard medical therapeutics.
4) Hemorrhagic cystitis – this is a serious, potentially life-threatening complication related 
to injury of the bladder epithe lium by cyclophosphamide metabolites.
5) Although sub-clinical hematuria is not uncommon at this dose level, clinically significant 
hematuria or serious hemorrhage can usually be avoided by maintaining a high urine 
volume and frequent voidings and the administra tion of Mesna. Diuresis is maintained 
for 24 hrs after completion of last dose by parenteral infusions of normal saline with potassium chloride. Careful monitoring of serum and urine electrolytes is mandated. 
Furosemide may be required to ensure this di uresis. Continuous bladder irrigation may be 
used for control of significant hematuria.
6) Sterility7) Less common but serious complications in clude pulmonary fibrosis and secondary 
malignancies. Less common but reversible toxicities include alopecia and skin rash.
8.13 E
QUINE ANTI-THYMOCYTE GLOBULIN (ATGAM )
a) Supply- Purified, concentrated sterile gamma  globulin, primarily monomeric IgG, from 
hyperimmune serum of horses immunized with human thymus lymphocytes. Each ml of 
ATGAM contains 50 mg of horse gamma globulin stabilized in 0.3 molar glycine to a PH of 
approximately 6.8.  
b) Preparation- ATGAM should be reconstituted at a concentration not to exceed 4 mg/ml on 
0.9% sodium chloride.  
c) Storage and Stability- $7*$0LVVWRUHGDVPODPSXOHVLQDUHIULIJHUDWRUDWÛWRÛ &'2
NOT FREEZE.  
d) Administration- Dose of 30 mg/kg IV every day on days -6, -5, and -4, for a total dose of 90 
mg/kg. Diluted ATGAM should be allowed to re ach room temperature before infusion.  The 
drug should be infused IV through an in-line filter with a pore size of 0.2 to 1.0 micron.  ATGAM should be infused over 4 hours.  
e) Toxicities- Because of risk of allergic reactio n to ATGAM, at least 24 hours before the first 
infusion of ATGAM, the manufacturer recomme nds that patients be tested with an 
intradermal injection of 0.1 ml of a 1:1000 dilution (5 μg horse ATG) of ATGAM in sodium 
chloride injection and a contra lateral sodium chloride injec tion control. The patient should 
be observed every 15 to 20 min over the first hou r of intradermal injection. A local reaction 
of 10 mm or more with a wheal or erythema or both should be considered a positive test. 
Additional toxicities include: leucopenia, thrombocytopenia, fever, chills, serum sickness like symptoms.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9 APPENDICES
9.1 A PPENDIX A: P REPARATIVE REGIMEN
Administration of Fludarabine and Total Body Irradiation (TBI) for 10/10 Matched 
Related and Unrelated Donor Transplantation 
Agent Dose Days
Fludarabine 30 mg/m2per day
IV infusion over 30 minutes,daily for 3 daysTransplant Days –4, -3, -2
TBI 200 cGy Transplant Day -1
Administration of Fludarabine and Total Body Irradiation (TBI) for 9/10 Matched Unrelated Donor Transplantation 
Agent Dose Days
Fludarabine 30 mg/m2per day
IV infusion over 30 minutes,daily for 3 daysTransplant Days –4, -3, -2
TBI 300 cGy Transplant Day -1
Administration of Fludarabine, Cyclophosphamide, Equine ATG and TBI for Umbilical Cord Blood Transplant
Agent Dose Days
Fludarabine40 mg/m2per day 
(25 mg/m2per day in 
patients < 50 kg)
IV infusion over 30 
min, daily for 5 daysTransplant Days -6, -5,    
-4, -3, -2
Equine ATG 30 mg/kg per dayTransplants Days -6, -5, -
4
Cyclophosphamide 50 mg/kg Transplant Day -6
Total body Irradiation 200 cGyTransplant Day -1
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Administration of Fludarabine, Cyclophosphamide, and TBI for Haploidentical 
Transplant
Agent Dose Days
Fludarabine30 mg/m2per day 
(25 mg/m2per day in 
patients < 50 kg)
IV infusion over 30 
min, daily for 5 daysTransplant Days -6, -5,    
-4, -3, -2
Cyclophosphamide 14.5 mg/kg per day Transplant Day -6,-5
Total body Irradiation 200 cGyTransplant Day -1
Total Body Irradiation
Patients receive irradiation given from a linear accelerator. Protocols specify the irradiation 
exposure and schedule of administration. TBI will be given at a dose of 200 cGy on day -1.
Fludarabine
Fludarabine is given as an IV infusion over 30 min.  Dosing is based on actual weight.
Cyclophosphamide dosing is based upon actual body weight. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9.2 A PPENDIX B: P ROTOCOL EVALUATION CHECKLIST
1. Recipient pre-transplant evaluation (perform 48 hours prior to the initiation of pre-
transplant  conditioning)  
a) CBC with differential
b) PT, PTTc) ABO Typingd) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
e) Urine ß-HCG if female of childbearing potential 
2. During hospitalization for transplant
a) CBC BID with differential in am b) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
c) Lipid panel weeklyd) Type and screen twice a week 
e) Sirolimus levels twice a week
f) Tacrolimus levels twice a weekg) Weekly CMV PCR Adenovirus, EBV, HHV6 PCR, toxoplasmosis
3. Post-transplant evaluation
a) CBC with diff twice weekly or weekly at the discretion of the PI. b) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum weekly or weekly at the discretion of the PI 
c) Lipid panel weekly or weekly at the discretion of the PI d) Type and screen twice weekly or weekly at the discretion of the PI e) Sirolimus levels twice weekly or weekly at the discretion of the PI f) Tacrolimus levels twice weekly or weekly at the discretion of the PI g) Weekly CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosis or weekly at the 
discretion of the PI 
4. Day + 14
a) CBC with differential, b) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
5. Day + 30
a) CBC with differential, b) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
c) Peripheral Blood Lymphocyte Phenotyping (T , B, NK). Send 5 cc blood in purple top 
tube to Clinical Center pathology. 
d) CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosise) Donor: Recipient Chimerism Studies to evaluate T-lymphoid, myeloid, and total 
blood chimerism. Send yellow top ACD tube to Clinical Center pathology, attn; Jody 
Keary.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
f) Leukocyte subset donor chimerism. Blood (Fiv e green CPT tubes) will be sent to Dr. 
Fran Hakim, ETIB, Bldg 10, Room 12-C-216. After lysis of RBC, flow sorting of T-
lymphocytes (CD3+), B-lymphocytes (CD 20+), NK cells (CD56+), and monocytes 
(CD14+) will be carried out.  If 10,000 to 100,000 cells can be obtained from the individual cell population, then chimerism w ill be carried out on the individual cell 
populations.  Sorted cell populations will be analyzed for donor chimerism by the 
Clinical Center pathology, attn: Dr. Roger Kurlander. 
g) If MDS is present pre-transplant, then a bone marrow aspirate with cytogenetics will 
be performed (5mLs will be sent to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-
216).
6. Day + 60 
a) CBC with differentialb) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
7. Day + 100
a) CBC with differentialb) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
c) Peripheral Blood Lymphocyte Phenotyping (T , B, NK). Send 5 cc blood in purple top 
tube to Clinical Center pathology. 
d) CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosise) Donor: Recipient Chimerism Studies to evaluate T-lymphoid, myeloid, and total 
blood chimerism. Send yellow top ACD tube to Clinical Center pathology, attn; Jody Keary. Leukocyte subset donor chimerism. Blood  (five green CPT t ubes) will be sent 
to Dr. Fran Hakim, ETIB, Bldg 10, Room 12- C-216.  After lysis of RBC, flow sorting 
of T-lymphocytes (CD3+), B-lymphocy tes (CD20+), NK cells (CD56+), and 
monocytes (CD14+) will be carried out.  If 10,000 to 100,000 cells can be obtained from the individual cell population, then chimerism will be carried out on the 
individual cell populations.  Sorted cell populations will be analyzed for donor 
chimerism by the Clinical Center pa thology, attn: Dr. Roger Kurlander. 
f) A bone marrow aspirate with cytogenetic s will be performed on all patients (5mLs 
will be sent to Dr. Fran Hak im, ETIB, Bldg 10, Room 12-C-216).
8. 6 Months Post-Transplant
a) CBC with differentialb) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
c) Peripheral Blood Lymphocyte Phenotyping (T , B, NK). Send 5 cc blood in purple top 
tube to Clinical Center pathology. 
d) CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosise) Donor: Recipient Chimerism Studies to evaluate T-lymphoid, myeloid, and total 
blood chimerism. Send yellow top ACD tube to Clinical Center pathology, attn; Jody 
Keary. Leukocyte subset donor chimerism. Blood (Five green CPT tubes) will be sent 
to Dr. Fran Hakim, ETIB, Bldg 10, Room 12- C-216.  After lysis of RBC, flow sorting 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
of T-lymphocytes (CD3+), B-lymphocy tes (CD20+), NK cells (CD56+), and 
monocytes (CD14+) will be carried out.  If 10,000 to 100,000 cells can be obtained 
from the individual cell population, then chimerism will be carried out on the 
individual cell populations.  Sorted cell populations will be analyzed for donor 
chimerism by the Clinical Center pa thology, attn: Dr. Roger Kurlander. 
f) If MDS is present pre-transplant, then a bone marrow aspirate with cytogenetics will 
be performed (5mLs will be sent to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-
216).
9. 12 Months Post –Transplant
a) CBC with differential
b) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum 
c) Peripheral Blood Lymphocyte Phenotyping (T , B, NK). Send 5 cc blood in purple top 
tube to Clinical Center pathology. 
d) CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosise) Donor: Recipient Chimerism Studies to evaluate T-lymphoid, myeloid, and total 
blood chimerism. Send yellow top ACD tube to Clinical Center pathology, attn; Jody 
Keary. Leukocyte subset donor chimerism. Bl ood (Five green CPT tubes) will be sent 
to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-216. After lysis of RBC, flow sorting 
of T-lymphocytes (CD3+), B-lymphocy tes (CD20+), NK cells (CD56+), and 
monocytes (CD14+) will be carried out.  If 10,000 to 100,000 cells can be obtained
from the individual cell population, then chimerism will be carried out on the 
individual cell populations.  Sorted cell populations will be analyzed for donor 
chimerism by the Clinical Center pathology, attn: Dr. Roger Kurlander.If MDS is present pre-transplant, then a bone marro w aspirate with cytogenetics will be 
performed (5mLs will be sent to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-216).
10. 18 Months Post –Transplant
a) CBC with differentialb) Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine kinase, 
Lactate Dehydrogenase, Uric acid-serum 
f) Peripheral Blood Lymphocyte Phenotyping (T , B, NK). Send 5 cc blood in purple top 
tube to Clinical Center pathology. 
c)CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosisd0 Donor: Recipient Chimerism Studies to evaluate T-lymphoid, myeloid, and total blood 
chimerism. Send yellow top ACD tube to C linical Center pathology, attn; Jody 
Keary. Leukocyte subset donor chimerism. Blood (Five green CPT tubes) will be sent 
to Dr. Fran Hakim, ETIB, Bldg 10, Room 12- C-216.. After lysis of RBC, flow sorting 
of T-lymphocytes (CD3+), B-lymphocy tes (CD20+), NK cells (CD56+), and 
monocytes (CD14+) will be carried out.  If 10,000 to 100,000 cells can be obtained from the individual cell population, then chimerism will be carried out on the 
individual cell populations.  Sorted cell populations will be analyzed for donor 
chimerism by the Clinical Center pa thology, attn: Dr. Roger Kurlander. 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
e) If MDS is present pre-transplant, then a bone marrow aspirate with cytogenetics will 
be performed (5mLs will be sent to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-
216).
11.  24 Month Post-Transplant
a)  CBC with differential
b)  Acute care panel, Hepatic panel, Mineral panel, Protein-total serum, Creatinine 
kinase, Lactate Dehydrogenase, Uric acid-serum  c) Peripheral Blood Lymphocyte Phenotyping (T, B, NK). Send 5 cc blood in purple top tube to Clinical Center pathology. 
d) CMV, Adenovirus, EBV, HHV6 PCR, Toxoplasmosis
e) Donor: Recipient Chimerism Studies to evaluate T-lymphoid, myeloid, and total 
blood chimerism. Send yellow top ACD tube to Clinical Center pathology, attn; Jody 
Keary. Leukocyte subset donor chimerism. Blood (Five green CPT tubes) will be sent 
to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-216. After lysis of RBC, flow sorting 
of T-lymphocytes (CD3+), B-lymphocy tes (CD20+), NK cells (CD56+), and 
monocytes (CD14+) will be carried out.  If 10,000 to 100,000 cells can be obtained from the individual cell population, then chimerism will be carried out on the 
individual cell populations.  Sorted cell populations will be analyzed for donor 
chimerism by the Clinical Center pa thology, attn: Dr. Roger Kurlander. 
f) If MDS is present pre-transplant, then a bone marrow aspirate with  cytogenetics will be 
performed (5mLs will be sent to Dr. Fran Hakim, ETIB, Bldg 10, Room 12-C-216).
9.3 A
PPENDIX C: I MMUNIZATIONS POST-TRANSPLANT
Immunizations:  All recipients will receive immunizations after transplant, according to the 
following table (http://intranet.cc.nih.gov/bmt/_pdf/table_II.pdf ):
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9.4 A PPENDIX D: G RADING AND MANAGEMENT OF ACUTE GRAFT -VERSUS -HOST DISEASE
Clinical Staging of Acute GVHD
Stage Skin Liver Gut
+ Rash < 25% BSA Total bilirubin 2-3 mg/dl Diarrhea 500-
1000ml/d
++ Rash 25-50% BSA Total bilirubin 3-6 mg/dl Diarrhea 1000-
1500ml/d
+++ Generalized 
erythodermaTotal bilirubin 6-15 mg/dl Diarrhea >1500ml/d
++++ Desquamation and 
bullaeTotal bilirubin > 15 mg/dl Pain +/- ileus
BSA = body surface area; use “rule of nines” or burn chart to determine extent of rash.
Clinical Grading of Acute GVHD 
Stage
Grade Skin Liver Gut PS
0 (none) 0000
I +  to ++ 000
II + to +++ + + +
III ++ to +++ ++ to +++ ++ to +++ ++
IV ++ to ++++ ++ to ++++ ++ to ++++ +++
Treatment of Acute GVHD
This schema is intended to se rve as a guideline and to promote consistency in our clinical 
practice; it may be modified for individual pa tients as clinical circumstances warrant.
Grade 0-I GVHD: 
1) Topical corticosteroids (usually 0.1% triamci nolone; 1% hydrocortisone to face) applied to 
rash BID.
Grade II-IV GVHD:1) Methylprednisolone (MP) 1 mg/kg per dose IV, BID for 4 consecutive days.2) If no response after 4 days, continue until response (7-day maximum trial); the dose may be 
doubled (4 mg/kg/day).
3) If response within 7 days, taper as follows:
a) 0.75 mg/kg per dose IV BID for 2 days.b) 0.5 mg/kg per dose IV BID for 2 days.c) 0.375 mg/kg per dose IV BID for 2 days.d) If clinically appropriate, change MP to oral prednisone to equivalent of IV dose) daily for 
2 days.  MP may be converted to prednisone  later in the taper at the investigators’ 
discretion.
e) After this, steroids will be reduced by 10% of  starting oral dose each week until a dose of 
10 mg/day is reached.  Subsequent reductions will be made at the investigators’ discretion.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
f) If GVHD worsens during taper, steroids should be increased to previous dose.
g) During steroid taper, maintain cyclos porine at therapeutic levels (Section 3.5.1).
4) If no response is observed within 7 days of MP treatment:
a) Increase Methylprednisolone to 10 mg/kg per dose IV, BID for 2 days.
b)If there is no improvement, consideration will be given to using second-line immunosuppressive therapy, e.g., tacrolimus,  mycophenolic acid, monoclonal antibodies, 
or studies of investigational agents for acute GVHD, if they are available.
5) Antifungal prophylaxis with agents effectiv e against mould will be started when it is 
anticipated that the patient will be receiving st eroids at > 1 mg/kg/day of methylprednisolone 
(or equivalent) for > 2 weeks. Voricona zole, caspofungin, liposomal amphotericin B 
(Ambisome), posaconazole or amphotericin B lipid  complex (Abelcet) are valid alternatives.  
During prophylaxis with any of the above ag ents, fluconazole should be discontinued.  In 
patients with therapeutic cyclosporine levels at the initiation of voriconazole therapy, the cyclosporine or tacrolimus dose should be decreas ed by approximately 50 %. In patients with 
therapeutic sirolimus levels at the initiation of voriconazole therapy, the sirolimus dose 
should be decreased by approximately 90%.
6) Determination of GVHD treatment response should be made  within 96 hours of starting the 
treatment.  The following are criteria to determine definitions of response to GVHD 
treatment:
a) Complete response:  Complete  resolution of all clinical signs and symptoms of acute 
GVHD.
b) Partial Response: 50% reduction in skin rash, stool volum e or frequency, and/or total 
bilirubin.  Maintenance of adequate performance status (Karnofsky Score > 70%).
c) Non-responder: < 50% reduction in skin rash , stool volume or frequency, and/or total 
bilirubin.  Failure to maintain adequate performance status (Karnofsky Score d70%).
d) Progressive disease:  Further progression of  signs and symptoms of acute GVHD, and/or 
decline in performance status after the initiation of therapy.
Treatment 
This schema is intended to serve as a guideline and to promote consistency in our clinical 
practice; it may be modified for individual patients as clinical circumstances warrant.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9.5 A PPENDIX E: M ANAGEMENT OF ENGRAFTMENT SYNDROME
Clinical Definition of Engraftment Syndrome
A constellation of clinical symptoms and signs has been observed during neutrophil recovery 
following HSCT, most commonly termed “engra ftment syndrome” (ES) , but interchangeably 
termed “capillary leak syndrome” and “autoa ggression syndrome”.  Engraftment syndromes 
have been observed after both autologous and allogeneic HSCT; in the latter setting, the clinical 
sequelae of neutrophil recovery were historically attributed to an early, sometimes “hyperacute” graft-versus-host reaction.  Our current understa nding of ES holds the overproduction of pro-
inflammatory cytokines at the time of neutrophil recovery to be the initiating event.  The study of 
ES has been somewhat hindered by the lack of uniform definition for this clinical entity; 
therefore, the following criteria have been propose (Spitzer 2001):
Major criteria: xFever > 38.3 qwith no identifiable infectious etiology
xErythrodermatous rash involving more than 25% of body 
surface area and not attributable to a medication
xNoncardiogenic pulmonary edem a, manifested by diffuse 
pulmonary infiltrates and hypoxia
Minor criteria xHepatic dysfunction with either total bilirubin > 2 mg/dl or 
transaminases levels > two times normalxRenal insufficiency (serum creatinine > two times baseline)
xWeight gain > 2.5% of baseline body weight
xTransient encephalopathy unexp lainable by other causes
A diagnosis of ES is established by the presence of all three major criteria, or two major criteria 
and one or more minor criteria; the clinical si gns and symptoms should appear within 96 hours of 
neutrophil recovery, according to the above proposed definition.
Neutrophil recovery after transplantation ma y result in “engraftment syndrome” (which 
may include fever, rash, edema, hypoxia)
The following criteria will be utilized to diagnose engraftment syndrome (must have 3 major criteria or 2 major + 1 minor criteria):
To promote consistency of our clinical prac tice, the following will be the recommended 
therapy for engraftment syndrome.  However, th is schedule may be modified (taper either 
accelerated or delayed) for individual pa tients as clinical circumstances warrant.
Treatment of Engraftment Syndrome
The mainstay of therapy for ES is high-dose co rticosteroids, based upon the literature on diffuse 
alveolar hemorrhage in the setting of bone marro w transplantation – a co mplication that many 
investigators now believe to be part of the spectrum of ES (M etcalf et al. 1994).  Our group has 
adopted the following treatment sc hema for patients diagnosed with  ES, with satisfactory results:
Day 1: Methylprednisolone 250 mg IV Q6 hours x 4 doses
Day 2: Methylprednisolone 250 mg IV Q8 hours x 3 dosesDay 3: Methylprednisolone 250 mg IV Q12 hours x 2 dosesDay 4: Methylprednisolone 125 mg IV Q12 hours x 2 doses
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Day 5: Methylprednisolone 60 mg IV Q12 hours x 2 doses
Day 6: Methylprednisolone 30 mg IV Q12 hours x 2 dosesDays 7-8: Prednisone 60 mg PO QD x 2 daysDays 9-10: Prednisone 50 mg PO QD x 2 daysDays 11-12: Prednisone 40 mg PO QD x 2 daysDays 13-14: Prednisone 30 mg PO QD x 2 daysDays 15-16: Prednisone 20 mg PO QD x 2 daysDays 17-18: Prednisone 10 mg PO QD x 2 daysDay 19: Discontinue prednisone
In the event that symptoms or clinical signs of  ES recur during the ster oid taper, patients should 
be retreated with methylprednisolone at a minimum dose of 60 mg IV QD.  This schema is 
intended to serve as a guideline and to promote c onsistency in our clinic al practice; it may be 
modified for individual patients as clinical circumstances warrant. In particular, steroid dosing 
for pediatric patients (< 18) will be determined on a case-by-case basis.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9.6 A PPENDIX F- NMDP C RITERIA FOR MATCHED UNRELATED DONOR
a) HLA-testing performed by high resolution typing, and donors matched at HLA (matched 
10/10) -A, B, C, and DRB1 and DQ lo ci  or 9/10 loci are acceptable donors.
b) An NMDP designated physician, in accordance with the most recent NMDP Standards 
and FDA Guidance, will perform unrelated donor  eligibility determina tion.  In general, 
the following inclusion criteria apply:
a. Age 18 – 60
b. Ability to give informed consent
c) Determination of Medical Suitability
a. Medical suitability will be determined as specified in the 19thEdition NMDP 
Standards, section 9.3000, and according to the NMDP standard operating procedure A00220.  The NMDP adheres to th e strictest interpretation of the FDA 
Guidance for Industry “Eligibility Deter mination for Donors of Human Cells, 
Tissue, and Cellular and Tissue-Based Products (HCT /P’s)”, February 2007. 
b. Per NMDP Standards, a physical exam is performed on all potential marrow and 
PBSC donors.  The assessment includes, but is not limited to:
i. Complete medical history and phys ical exam with special note of:
1. Deferral of voluntary blood donati on, prior experience or problems 
with anesthetic agents, or othe r possible contraindications to 
donation for the prospective donor
2. Vital signs, including height and weight3. List of medications4. Venous access for potential apheresis donors5. If information provided in the health history screening 
questionnaire or other relevant  medical records indicates a 
potential risk for transmission of a communicable disease, the donor may be deferred or a physical examination including specific assessment for signs or  symptoms of a communicable 
infection will be performed.
ii. Examinations including but not limited to:
1. Chest X-Ray2. Urinalysis3. Electrocardiogram4. Labs
a. Hemoglobin and Hematocrit b. CBC with differentialc. Platelet Countd. ABO and RHe. Screening for Hemoglobin Sf. Electrolytesg. Alkaline Phosphataseh. BUN and Creatininei. LDHj. Bilirubin
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
k. ALT,SBPT
l. Glucosem. Serum Total Protein plus albumin or serum protein 
electrophoresis
n. Serum Beta-HCG Pregnancy
c. Infectious Disease Testing
i. Donor Infectious Disease Markers are tested at the time of donor’s 
confirmatory typing, within 30 days of  collection, and again on the day of 
collection according to FDA regulations.  Interpretation of infectious disease markers is performed by the donor center physician according to NMDP Standard A00223 version 2.0 “IDM Eligibility and Labeling 
Guide” 
ii. The following markers are tested
1. Hepatitis B surface antigen (HBsAg)2. Hepatitis B core antibody (Anti HBc)
3. Hepatitis C antibody (Anti-HCV)
4. Anti-HTLV I/II5. Antibody to T.cruzi6. NAT testing for HIV-1/HCV7. Anti-HIV 1 and Anti-HIV 28. Syphilis serologic screening test (STS)9. Anti-CMV (IgG or total)10. WNV-NAT testing (only require d on day of collection during 
optional testing period)
iii. Any abnormal findings that may in crease the risk of transmitting a 
communicable disease or that could increase the risk of transplant for the recipient are disclosed to the transplant center.  The patient’s physician will be notified, and a determination will be made whether or not to proceed with the collection.  In the event the donation process continues a 
Letter of Urgent Medical Need will be generated.
d) Documentation of donor clearance and cons ent will be provided to NIH through the 
search-coordinating unit at the NMDP.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9.7 A PPENDIX G: E XPERIMENTAL TRANSPLANTATION AND IMMUNOLOGY BRANCH 
PRECLINICAL SERVICE POLICY FOR SAMPLE HANDLING  
Storage/Tracking in the Preclinical Development and Clinical Monitoring Facility 
(PDCMF)
xNormal patient blood and tissue samples, coll ected for the purpose of research under IRB 
approved protocols of the Ex perimental Transplantation and Immunology Branch (ETIB)
may be archived by the ETIB Preclinical Development and Clinical Monitoring Facility (PDCMF). All data associated with archived clinical research samples is entered into the ETIB PDCMF’s Microsoft Excel databases on frozen cells and plasma. These databases 
are stored on the NCI group drive in the ETIB ‘PRECLINSERVICE’ folder. Access to this folder is limited to PDCMF staff and ETIB clinical staff, requiring individual login and password. All staff in the PDCMF laboratory receives annually updated NIH/CIT 
training and maintains standa rds of computer security.
xThe data recorded for each sample includes the patient ID, trial name/protocol number, 
date drawn, treatment cycle/pos t-transplant time point, cell source (e. g. peripheral blood, 
lymphapheresis, mobilized peripheral blood stem  cells, marrow, urine, skin or oral biopsy
as well as box and freezer location. Patient  demographics that correlate treatment 
outcomes and therapies with the samples can  be obtained only through the NCI/ETIB 
clinical records. As of January 2007, all newly received samples receive a unique bar 
code number, which is included in the sample record in the PDCMF database. Only this 
bar code is recorded on the sample vial and th e vials will not be traceable back to patients 
without authorized access to the PDCMF data base. All non-coded samples previously 
archived will be stripped of identifiers prior to distribution for any use other than as a primary objective of the protocol under which they were collected.
xSamples are stored in locked freezers. All samples will be labeled solely with a bar code 
(which includes the date, and serially deter mined individual sample identifier). The key 
will be available to a restricted number of ETIB investigators and associate investigators 
on the protocol. Coded samples will be stored frozen at -20°, -80° or liquid nitrogen vapor phase to -180 C according to the stab ility requirements in a single location under 
the restricted control of the PDCMF of ETIB.
xAccess to samples from a protocol for research purposes will be by permission of the 
Principal Investigator of that protocol in or der to be used (1) for research purposes 
associated with protocol objectives for which the samples were collected, or (2) for a new 
research activity following submission and I RB approval of a new pr otocol and consent, 
or (3) for use only as unlinked or coded samples under the OHSRP Exemption Form 
guidelines stipulating that the activity is exempt from IRB review. Unused samples must be returned to the PDCMF laboratory.
xSamples and associated data will be stored permanently unless the patient withdraws 
consent. If researchers have samples remaining once they have completed all studies 
associated with the protocol, they must  be returned to the PDCMF laboratory.
xThese freezers are located onsite at the Pr eclinical Service laboratory (12C216) (-85° 
freezer) or in ETIB common equipment space (CRC/3-3273).
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Protocol Completion/Sample Destruction 
xOnce research objectives for the protocol are achieved, researchers can request access to 
remaining samples, providing th ey have both approval of the Pr incipal Investigator of the 
original protocol under which the samples or  data were collected and either an IRB 
approved protocol and patient consent or the OHSRP Exemption Form stipulating that 
the activity is exempt from IRB review.
xThe PDCMF staff will report to the Principal Investigators any destroyed samples, if samples become unsalvageable because of e nvironmental factors (ex. broken freezer or 
lack of dry ice in a shipping container), lost in transit between facilities or misplaced by a 
researcher. 
xThe PI will report destroyed samples to the IRB if samples become unsalvageable 
because of environmental factors (ex. broken freezer or lack of dry ice in a shipping 
container) or if a patient withdraws consent.  Samples will also be reported as lost if they are lost in transit between f acilities or misplaced by a researcher.  Freezer problems, lost 
samples or other problems associated with samples will also be reported to the IRB, the NCI Clinical Director, and the office of the CCR, NCI.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
9.8 Appendix H: Data Collection El ements Required By Protocol 
All of the following elements will be recorded in the C3D database.
A. Patient Enrollment 
Recipient
xDate of birth, age, gender, race, ethnicity
xPerformance Status
xDate of original diagnosis
xDate of Informed Consent signature, c onsent version and date of registration
xBaseline History/Physical
xBaseline Symptoms 
Donor
xDate of birth, age, gender, race, ethnicity
xHeight
xWeight
xBaseline History/Physical (Y/N)
B. Study Drug administration and response for each course of therapy given
xDates study drugs given
xDose level, actual dose, schedule and route given
xResponse assessment for each restaging performed
C. Laboratory and Diagnostic Test Data
xAll Clinical laboratory and diagnostic test results done at screening(recipient and 
donor) and until day 100 post transplant with the following exceptions:
xScreening labs that are not automatically loaded for example (HIV, anti hep B and C). 
xDiagnostic tests which are not specified in the protocol, and if the results are not needed to document the start or end of an adverse event that requires reporting (all 
CTs should be recorded).
xAll clinical laboratory and diagnostic tests done after day 100 that support a possible, 
probable or definite diagnosis of GVHD,  infection or secondary malignancy and 
those done to document a change in grade and the end of these adverse events.
xAll tests done to document resolution of advers e events that occurred in the first 100 
days post transplant
xHLA data (patient and donor).
xBlood, bone marrow, and tumor chimerism data 
D. Adverse Events Recorded per section 5.1
E. Concomitant Measures
xGVHD prophylaxis and treatme nt (start and stop dates)
xAll immunosuppressive  agents
F. Treatment of Persistent/Progressive Disease with Standard Therapy
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
xChemotherapy
xImmunotherapy
xRadiation therapy
xDonor Lymphocyte Infusion
G. Response 
Restaging studies performed at protocol specified time points and as clinically indicated.
H. Off study
xDate and reason for off study
xDate and cause of death
xAutopsy findings
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
10 REFERENCES
Anasetti, C., P. G. Beatty, et al. (1990). "Eff ect of HLA incompatibility on graft-versus-host 
disease, relapse, and survival after marrow transplantation for patients with leukemia or 
lymphoma." Hum Immunol 29(2): 79-91.
Anderlini, P., M. Korbling, et al. (1997). "Allogeneic blood stem cell transplantation: 
considerations for donors." Blood 90(3): 903-8.
Antin, J. H., H. T. Kim, et al. (2003). "Sirolimus, tacrolimus, and low-dose methotrexate for 
graft-versus-host disease prophylaxis in mismatched related donor  or unrelated donor 
transplantation." Blood 102(5): 1601-5.
Aoudjhane, M., M. Labopin, et al. (2005). "Com parative outcome of reduced intensity and 
myeloablative conditioning regimen in HLA id entical sibling allogeneic haematopoietic 
stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of 
the European group for Blood and Marrow Transplantation (EBMT)." Leukemia 19(12): 
2304-12.
Appelbaum, F. R. (2007). "Hematopoietic-c ell transplantation at 50." N Engl J Med 357(15): 
1472-5.
Ash, R. C., J. T. Casper, et al. (1990). "Successful  allogeneic transplantat ion of T-cell-depleted 
bone marrow from closely HLA-matched unrelated donors." N Engl J Med 322(8): 485-
94.
Bach, F. H., R. J. Albertini, et al. (1968). "B one-marrow transplantation in a patient with the 
Wiskott-Aldrich syndrome." Lancet 2(7583): 1364-6.
Barker, J. N., T. P. Krepski, et al. (2002). "S earching for unrelated donor hematopoietic stem 
cells: availability and speed of umbilical cord blood versus bone marrow." Biol Blood 
Marrow Transplant 8(5): 257-60.
Bearman, S. I., F. R. Appelbaum, et al. (1988) . "Regimen-related toxici ty in patients undergoing 
bone marrow transplantation." J Clin Oncol 6(10): 1562-8.
Beatty, P. G., R. A. Clift, et al. (1985). "Mar row transplantation from related donors other than 
HLA-identical siblings." N Engl J Med 313(13): 765-71.
Bernstein, H. M., D. A. Calhoun, et al. (2002). "Use of myeloid colony-stimulating factors in 
neonates with septicemia ." Curr Opin Pediatr 14(1): 91-4.
Bray, R. A., C. K. Hurley, et al. (2008). "National marrow donor pr ogram HLA matching 
guidelines for unrelated adult donor hemat opoietic cell transplants." Biol Blood Marrow 
Transplant 14(9 Suppl): 45-53.
Brunstein, C. G., J. N. Barker, et al. (2007).  "Umbilical cord blood transplantation after 
nonmyeloablative conditioning: impact on transp lantation outcomes in 110 adults with 
hematologic disease." Blood 110(8): 3064-70.
Buchali, A., P. Feyer, et al. (2000). "Immediate toxicity during fractionate d total body irradiation 
as conditioning for bone marrow tr ansplantation." Radiother Oncol 54(2): 157-62.
Buckley, R. H. (2003). "Treatment options for genetically determined immunodeficiency." 
Lancet 361(9357): 541-2.
Buckley, R. H., S. E. Schiff, et al. (1999). "Hematopoietic stem-cell transplantation for the 
treatment of severe combined immunodeficiency." N Engl J Med 340(7): 508-16.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Burroughs, L. M., R. Storb, et al. (2007). "Intensive postgrafting immune suppression combined 
with nonmyeloablative conditioning for transp lantation of HLA-iden tical hematopoietic 
cell grafts: results of a pilot study for trea tment of primary immunodeficiency disorders." 
Bone Marrow Transplant 40(7): 633-42.
Carvallo, C., N. Geller, et al. (2004). "Prior  chemotherapy and all ograft CD34+ dose impact 
donor engraftment following nonmyeloablative a llogeneic stem cell transplantation in 
patients with solid tumors." Blood 103(4): 1560-3.
Chakraverty, R., K. Peggs, et al. (2002). "Limitin g transplantation-related mortality following 
unrelated donor stem cell transplantation by using a nonmyeloablative conditioning 
regimen." Blood 99(3): 1071-8.
Champlin, R. E. (1990). "T-cell depletion for bone marrow transplanta tion: effects on graft 
rejection, graft-versus-host disease, graft-ve rsus-leukemia, and survival." Cancer Treat 
Res50: 99-111.
Childs, R., A. Chernoff, et al. (2000). "Regress ion of metastatic rena l-cell carcinoma after 
nonmyeloablative allogeneic peripheral-blood st em-cell transplantation." N Engl J Med
343(11): 750-8.
Childs, R., E. Clave, et al. (1999). "Engraf tment kinetics after nonmye loablative allogeneic 
peripheral blood stem cell tr ansplantation: full donor T-cell chimerism precedes 
alloimmune responses." Blood 94(9): 3234-41.
Copelan, E. A. (2006). "Hematopoietic st em-cell transplantation." N Engl J Med 354(17): 1813-
26.
Curtis, R. E., P. A. Rowlings, et al. (1997). "So lid cancers after bone marrow transplantation." N
Engl J Med 336(13): 897-904.
de Witte, T., S. Suciu, et al. (2001). "Intensi ve chemotherapy followed by allogeneic or 
autologous stem cell transplantation for patients with myelodysplastic syndromes 
(MDSs) and acute myeloid leukemia following MDS." Blood 98(8): 2326-31.
Deeg, H. J., R. Prentice, et al. (1983). "Increas ed incidence of malignant tumors in dogs after 
total body irradiation and marrow transplantation." Int J Radiat Oncol Biol Phys 9(10): 
1505-11.
Dufour, C., R. Rondelli, et al. (2001). "Stem cell transplantation from HLA-matched related 
donor for Fanconi's anaemia: a retrospective revi ew of the multicentric Italian experience 
on behalf of AIEOP-GITMO." Br J Haematol 112(3): 796-805.
Engel, M. E., D. D. Hickstein, et al. (2006). "Matched unrelated bone marrow transplantation 
with reduced-intensity conditioning for le ukocyte adhesion deficiency." Bone Marrow 
Transplant 37(7): 717-8.
Fay, J. W., J. R. Wingard, et al. (1996). "FK506 (Tacrolimus) monotherapy for prevention of 
graft-versus-host disease after histocom patible sibling allogenic bone marrow 
transplantation." Blood 87(8): 3514-9.
Filipovich, A. H., R. S. Shapiro, et al. (1992). "Unrelated donor bone marrow transplantation for 
correction of lethal congenital immunodeficiencies." Blood 80(1): 270-6.
Filipovich, A. H., D. Weisdorf, et al. (2005).  "National Institutes of Health consensus 
development project on criteria fo r clinical trials in chronic graft-versus-host disease: I. 
Diagnosis and staging working group report." Biol Blood Marrow Transplant 11(12): 
945-56.
Flomenberg, N., L. A. Baxter-Lowe, et al. (200 4). "Impact of HLA class I and class II high-
resolution matching on outcomes of unrelated  donor bone marrow transplantation: HLA-
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
C mismatching is associated with a strong adverse effect on transplantation outcome." 
Blood 104(7): 1923-30.
Gatti, R. A., H. J. Meuwissen, et al. (1968) . "Immunological reconstitution of sex-linked 
lymphopenic immunological deficiency." Lancet 2(7583): 1366-9.
Giralt, S., E. Estey, et al. (1997). "Engraftment of  allogeneic hematopoietic progenitor cells with 
purine analog-containing chemotherapy: ha rnessing graft-versus-leukemia without 
myeloablative therapy." Blood 89(12): 4531-6.
Giralt, S., P. F. Thall, et al. (2001). "Melphalan and purine analog-containing preparative 
regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenito r cell transplantation." Blood 97(3): 631-7.
Gluckman, E. (2000). "Current status of um bilical cord blood hematopoietic stem cell 
transplantation." Exp Hematol 28(11): 1197-205.
Gluckman, E., V. Rocha, et al. (1997). "Outcome of cord-blood transplantation from related and 
unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group." N Engl J Med 337(6): 373-81.
Greenberg, P., C. Cox, et al. (1997). "International scoring system for evaluating prognosis in 
myelodysplastic syndromes." Blood 89(6): 2079-88.
Haase, D., U. Germing, et al. (2007). "New insights into the prognostic impact of the karyotype 
in MDS and correlation with subtypes: eviden ce from a core dataset of 2124 patients." 
Blood 110(13): 4385-95.
Hackstein, H., T. Taner, et al. (2003). "Rapam ycin inhibits IL-4--induced dendritic cell 
maturation in vitro and de ndritic cell mobilization a nd function in vivo." Blood 101(11): 
4457-63.
Hansen, J. A., T. A. Gooley, et al. (1998). "Bone marrow transplants from unrelated donors for 
patients with chronic myeloi d leukemia." N Engl J Med 338(14): 962-8.
Hegenbart, U., D. Niederwieser, et al. (2006). "Treatment for acute myelogenous leukemia by 
low-dose, total-body, irradiation-base d conditioning and hematopoietic cell 
transplantation from related and unrelated donors." J Clin Oncol 24(3): 444-53.
Hiraoka, A., Y. Ohashi, et al. (2001). "Phase III study comparing tacrolimus (FK506) with 
cyclosporine for graft-versus-host disease prophylaxis after a llogeneic bone marrow 
transplantation." Bone Marrow Transplant 28(2): 181-5.
Honig, M., M. H. Albert, et al. (2007). "Patient s with adenosine deaminase deficiency surviving 
after hematopoietic stem cell transplantation are at high risk of CNS complications." 
Blood 109(8): 3595-602.
Horwitz, M. E., A. J. Barrett, et al. (2001). "Tre atment of chronic gra nulomatous disease with 
nonmyeloablative conditioning and a T-cell-depleted hematopoietic a llograft." N Engl J 
Med 344(12): 881-8.
Hsieh, M. M., E. M. Kang, et al. (2009). "Alloge neic hematopoietic stem-c ell transplantation for 
sickle cell disease." N Engl J Med 361(24): 2309-17.
Hsu, A. P., E. P. Sampaio, et al. "Mutations in GATA2 are associated with the autosomal 
dominant and sporadic monocytopenia a nd mycobacterial infection (MonoMAC) 
syndrome." Blood.
Huhn, R. D., J. F. Tisdale, et al. (1999). "Ret roviral marking and tran splantation of rhesus 
hematopoietic cells by nonmyeloab lative conditioning." Hum Gene Ther 10(11): 1783-
90.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Kang, E. M., Y. Hanazano, et al. (2001). "Persist ent low-level engraftment  of rhesus peripheral 
blood progenitor cells transduced with the fanc oni anemia C gene after conditioning with 
low-dose irradiation." Mol Ther 3(6): 911-9.
Kapoor, N., D. Kirkpatrick, et al. (1981). "Reco nstitution of normal mega karyocytopoiesis and 
immunologic functions in Wi skott-Aldrich syndrome by  marrow transplantation 
following myeloablation and immunosuppressi on with busulfan and cyclophosphamide." 
Blood 57(4): 692-6.
Kato, T., I. Tsuge, et al. (1999). "Successful bo ne marrow transplantation in a child with X-
linked hyper-IgM syndrome." Bone Marrow Transplant 23(10): 1081-3.
Kernan, N. A., G. Bartsch, et al. (1993). "Analysi s of 462 transplantations from unrelated donors 
facilitated by the National Marrow Donor Program." N Engl J Med 328(9): 593-602.
Khouri, I. F., M. Keating, et al. (1998). "Tra nsplant-lite: induction of graft-versus-malignancy 
using fludarabine-based nonabl ative chemotherapy and allo geneic blood progenitor-cell 
transplantation as treatment for ly mphoid malignancies." J Clin Oncol 16(8): 2817-24.
Khouri, I. F., R. M. Saliba, et al. (2001). "Nona blative allogeneic hemato poietic transplantation 
as adoptive immunotherapy for indolent lymp homa: low incidence of toxicity, acute 
graft-versus-host disease, and treatment-related mortality." Blood 98(13): 3595-9.
Kolb, H. J., G. Socie, et al. (1999). "Malignant neoplasms in long-term survivors of bone marrow 
transplantation. Late Effects Working Part y of the European Cooperative Group for 
Blood and Marrow Transplantation and the Eu ropean Late Effect Project Group." Ann 
Intern Med 131(10): 738-44.
Kroger, N., H. G. Sayer, et al. (2002). "Unrelated  stem cell transplantati on in multiple myeloma 
after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is 
highly effective with low transplantation-related mortality." Blood 100(12): 3919-24.
Kurtzberg, J., M. Laughlin, et al. (1996). "Place ntal blood as a source of hematopoietic stem 
cells for transplantation into unrel ated recipients." N Engl J Med 335(3): 157-66.
Laport, G. G., B. M. Sandmaier, et al. (2008) . "Reduced-intensity conditioning followed by 
allogeneic hematopoietic cell transplantation for adult pa tients with myelodysplastic 
syndrome and myeloproliferative disorders." Biol Blood Marrow Transplant 14(2): 246-
55.
Laughlin, M. J., J. Barker, et al. (2001). "Hematopoietic engraftment and survival in adult
recipients of umbilical-cord blood from unrelated donors." N Engl J Med 344(24): 1815-
22.
Laughlin, M. J., M. Eapen, et al. (2004). "Outco mes after transplantation of cord blood or bone 
marrow from unrelated donors in adu lts with leukemia." N Engl J Med 351(22): 2265-75.
Le Deist, F., S. Blanche, et al. (1989) . "Successful HLA nonidentical bone marrow 
transplantation in three patients with the leukocyte adhesion deficiency." Blood 74(1): 
512-6.
Lee, S. J., J. Klein, et al. (2007). "High-reso lution donor-recipient HLA matching contributes to 
the success of unrelated donor marrow transplantation." Blood 110(13): 4576-83.
Longhurst, H. J., D. Taussig, et al. (2002). "N on-myeloablative bone marr ow transplantation in 
an adult with Wiskott-Aldrich syndrome." Br J Haematol 116(2): 497-9.
Luznik, L., L. W. Engstrom, et al. (2002). "Posttransplantation cy clophosphamide facilitates 
engraftment of major histocompatibility complex-identical allogeneic marrow in mice 
conditioned with low-dose total body irradiation." Biol Blood Marrow Transplant 8(3): 
131-8.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Luznik, L., P. V. O'Donnell, et al. (2008). "HLA -haploidentical bone marrow transplantation for 
hematologic malignancies using nonmyeloablative conditioning and high-dose, 
posttransplantation cyclophosphamide. " Biol Blood Marrow Transplant 14(6): 641-50.
Maciejewski, J. P., A. Risitano, et al. (2002) . "Distinct clinical outcomes for cytogenetic 
abnormalities evolving from aplastic anemia." Blood 99(9): 3129-35.
Mackinnon, S., L. Barnett, et al. (1994). "Minimal residual disease is more common in patients 
who have mixed T-cell chimerism after bone marrow transplantation for chronic 
myelogenous leukemia." Blood 83(11): 3409-16.
Maris, M. B., D. Niederwieser, et al. (2003). "H LA-matched unrelated d onor hematopoietic cell 
transplantation after nonmyeloablative conditioning for patients with hematologic malignancies." Blood 102(6): 2021-30.
Markus, P. M., X. Cai, et al. (1991). "Preve ntion of graft-versus-host disease following 
allogeneic bone marrow transplantation in rats using FK506." Transplantation 52(4): 590-
4.
Martin, P. J., J. A. Hansen, et al. (1988). "Gra ft failure in patients r eceiving T cell-depleted 
HLA-identical allogeneic marrow transplants." Bone Marrow Transplant 3(5): 445-56.
Martino, R., M. D. Caballero, et  al. (2002). "Evidence for a graft-versus-leukemia effect after 
allogeneic peripheral blood stem cell transpla ntation with reduced-intensity conditioning 
in acute myelogenous leukemia a nd myelodysplastic syndromes." Blood 100(6): 2243-5.
McSweeney, P. A., D. Niederwieser, et al. (200 1). "Hematopoietic cell tr ansplantation in older 
patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects." Blood 97(11): 3390-400.
Metcalf, J. P., S. I. Rennard, et al. (1994). "C orticosteroids as adjunctive therapy for diffuse 
alveolar hemorrhage associated with bone  marrow transplantation. University of 
Nebraska Medical Center Bone Ma rrow Transplant Group." Am J Med 96(4): 327-34.
Mielcarek, M., B. E. Storer, et al. (2007). "Out comes among patients with recurrent high-risk 
hematologic malignancies afte r allogeneic hemat opoietic cell transplantation." Biol 
Blood Marrow Transplant 13(10): 1160-8.
Munchel, A., C. Kesserwan, et al. "Nonmye loablative, HLA-haploidentical bone marrow
transplantation with high dose, post-tran splantation cyclophosphamide." Pediatr Rep 3
Suppl 2: e15.
Myburgh, J. A., J. A. Smit, et al. (1980). "Trans plantation tolerance in primates following total 
lymphoid irradiation and allogeneic bone marrow injection. II. Renal allografts." 
Transplantation 29(5): 405-8.
Myburgh, J. A., J. A. Smit, et al. (1984). "T otal lymphoid irradiatio n in kidney and liver 
transplantation in the baboon: prolonged graft survival and alterations in T cell subsets 
with low cumulative dose regimens." J Immunol 132(2): 1019-25.
Nash, R. A., J. H. Antin, et al. (2000). "Phase  3 study comparing met hotrexate and tacrolimus 
with methotrexate and cyclosporine for proph ylaxis of acute graft-versus-host disease 
after marrow transplantation from unrelated donors." Blood 96(6): 2062-8.
Nash, R. A., R. Etzioni, et al. (1995). "Tacrolimus (FK506) alone or in combination with 
methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease 
after marrow transplantation from HLA-matched siblings: a single-center study." Blood
85(12): 3746-53.
Niederwieser, D., M. Maris, et al. (2003). "Low-dose total body irradiation (TBI) and 
fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or 
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
mismatched unrelated donors and postgrafting immunosuppre ssion with cyclosporine and 
mycophenolate mofetil (MMF) can induce durab le complete chimerism and sustained 
remissions in patients with he matological diseases." Blood 101(4): 1620-9.
Nimer, S. D. (2008). "Myelo dysplastic syndromes." Blood 111(10): 4841-51.
O'Donnell, P. V., L. Luznik, et al. (2002). "Nonmyeloablative bone marrow transplantation from 
partially HLA-mismatched re lated donors using posttransplantation cyclophosphamide." 
Biol Blood Marrow Transplant 8(7): 377-86.
Orsini, E., E. P. Alyea, et al. (2000). "C onversion to full donor chimerism following donor 
lymphocyte infusion is associated with di sease response in patients with multiple 
myeloma." Biol Blood Marrow Transplant 6(4): 375-86.
Petersdorf, E. W. (2006). "Immunogenomics of unrelated hematopoietic cell transplantation." 
Curr Opin Immunol 18(5): 559-64.
Petrus, M. J., J. F. Williams, et al. (2000) . "An immunoablative regimen of fludarabine and 
cyclophosphamide prevents fully MHC-misma tched murine marro w graft rejection 
independent of GVHD." Biol Blood Marrow Transplant 6(2A): 182-9.
Przepiorka, D., D. Weisdorf, et al. ( 1995). "1994 Consensus Conference on Acute GVHD 
Grading." Bone Marrow Transplant 15(6): 825-8.
Rao, K., P. J. Amrolia, et al. (2005). "Impr oved survival after unrelated donor bone marrow 
transplantation in children with primary immunodeficiency using a reduced-intensity 
conditioning regimen." Blood 105(2): 879-85.
Rocha, V., M. Labopin, et al. (2004). "Transplan ts of umbilical-cord blood or bone marrow from 
unrelated donors in adults with acute leukemia." N Engl J Med 351(22): 2276-85.
Rocha, V., J. E. Wagner, Jr., et al. (2000). "G raft-versus-host disease in children who have 
received a cord-blood or bone marrow tran splant from an HLA-identical sibling. 
Eurocord and International Bone Marrow Transplant Registry Working Committee on 
Alternative Donor and Stem Cell Sources." N Engl J Med 342(25): 1846-54.
Rubinstein, P., C. Carrier, et al. (1998). "Out comes among 562 recipien ts of placental-blood
transplants from unrelated donors." N Engl J Med 339(22): 1565-77.
Sanz, G. F., S. Saavedra, et al. (2001). "Standardized, unrelated donor cord blood transplantation 
in adults with hematologic malignancies." Blood 98(8): 2332-8.
Sauer, M., C. Bettoni, et al. (2005). "Complete substitution of cyclophosphamide by fludarabine 
and ATG in a busulfan-based preparative reg imen for children and a dolescents with beta-
thalassemia." Bone Marrow Transplant 36(5): 383-7.
Schetelig, J., C. Thiede, et al. (2003). "Evidence of a graft-versus-leukemia effect in chronic 
lymphocytic leukemia after reduced-intensi ty conditioning and allogeneic stem-cell 
transplantation: the Cooperative German  Transplant Study Group." J Clin Oncol 21(14): 
2747-53.
Shulman, L. N., N. J. Tarbell, et al. (1998). "Low-dose total body irradi ation and G-CSF without 
hematopoietic stem cell suppor t in the treatment of relapsed or refractory acute 
myelogenous leukemia (AML), or AML in seco nd or subsequent remission." Int J Radiat 
Oncol Biol Phys 42(5): 1113-7.
Slavin, S., A. Nagler, et al. (1998). "Nonmyeloab lative stem cell transpla ntation and cell therapy 
as an alternative to conven tional bone marrow transplantati on with lethal cytoreduction 
for the treatment of malignant and nonm alignant hematologic diseases." Blood 91(3): 
756-63.
Abbreviated Title: HSCT for GATA2 Mutation
Version Date: 05/18/2016
Spitzer, T. R. (2001). "Engraftment sy ndrome following hematopoietic stem cell 
transplantation." Bone Marrow Transplant 27(9): 893-8.
Spitzer, T. R., S. McAfee, et al. (2000). "I ntentional induction of mixed chimerism and 
achievement of antitumor responses after nonmyeloablative conditioning therapy and 
HLA-matched donor bone marrow transpla ntation for refractory hematologic 
malignancies." Biol Blood Marrow Transplant 6(3A): 309-20.
Stepkowski, S. M., L. Tian, et al. (1997). "Synergistic mechanisms by which sirolimus and 
cyclosporin inhibit rat heart and kidney allograft rejection." Clin Exp Immunol 108(1): 
63-8.
Storb, R., R. F. Raff, et al. (1993). "FK-506 and methotrexate prevent gr aft-versus-host disease 
in dogs given 9.2 Gy total body irradiati on and marrow grafts from unrelated dog 
leukocyte antigen-nonidentical donors." Transplantation 56(4): 800-7.
Storb, R., C. Yu, et al. (1999). "Stable mixed he matopoietic chimerism in dog leukocyte antigen-
identical littermate dogs given lymph node irradiation before and pharmacologic 
immunosuppression after marrow transplantation." Blood 94(3): 1131-6.
Thomas, E. D., H. L. Lochte, Jr., et al. (1957) . "Intravenous infusion of  bone marrow in patients 
receiving radiation and chemotherapy." N Engl J Med 257(11): 491-6.
Thomas, O., M. Mahe, et al. (2001). "Long-term complications of total body irradiation in 
adults." Int J Radiat Oncol Biol Phys 49(1): 125-31.
Truitt, R. L. and A. A. Atasoylu (1991). "Impac t of pretransplant conditioning and donor T cells 
on chimerism, graft-versus-host disease, graf t-versus-leukemia reactivity, and tolerance 
after bone marrow transplantation." Blood 77(11): 2515-23.
Veys, P., K. Rao, et al. (2005). "Stem cell tr ansplantation for cong enital immunodeficiencies
using reduced-intensity conditioning." Bone Marrow Transplant 35 Suppl 1: S45-7.
Vinh, D. C., S. Y. Patel, et al. (2010). "Autosomal dominant and sporadic monocytopenia with 
susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia." Blood
115(8): 1519-29.
Wagner, J. E., J. N. Barker, et al. (2002). "T ransplantation of unrelated donor umbilical cord 
blood in 102 patients with malignant and nonma lignant diseases: influence of CD34 cell 
dose and HLA disparity on treatment-rel ated mortality and survival." Blood 100(5): 
1611-8.
Wagner, J. E. and J. Kurtzberg (1997). "Cord blood stem cells." Curr Opin Hematol 4(6): 413-8.
Wong, R., S. A. Giralt, et al. (2003). "Reduc ed-intensity conditioning for unrelated donor 
hematopoietic stem cell transp lantation as treatment for myeloid malignancies in patients 
older than 55 years." Blood 102(8): 3052-9.